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1.1 anaToMy of The VIsual sysTeM 
When light enters the eye, the photoreceptors in the retina transform the light into an electric 
signal. There are two types of photoreceptors: cones and rods. The three diff erent types of 
cones give us the ability to see colours, and they are mainly localized in the macula (Figure 1).
The central part of the macula, the fovea, consists of the highest concentration of cones 
and is responsible for sharp vision. In contrast, the rods dominate the (mid-)periphery of the 
retina and are used in peripheral vision.1 They are the primary source of visual information in 
the dark. The optic signal which the photoreceptors produce is transported via the bipolar 
cells to the retinal ganglion cells.
There are three main types of retinal ganglions cells; the midget ganglion cells (project 
to parvocellular neurons, P-system, which is the largest system), the parasol cells (project to 
magnocellular neurons, M-system) and the bistratifi ed cells (project to koniocellular neurons, 
K-system) (Figure 2).2,3 The axons of the retinal ganglion cells are the fi bres of the optic nerve, 
and mainly terminate at the lateral geniculate nucleus (LGN) of the thalamus (retino-occipital 
visual pathway). The LGN is highly organised: layer 1, 4 and 6 receive axons from the contra-
lateral nasal retina, whereas 2, 3, 5 receive axons from the ipsilateral temporal retina.3 The 
magnocellular neurons are present in layer 1 and 2, the parvocellular neurons in layer 3-6 
and the koniocellular neurons are present in between.3 The M-system is characterized by low 
spatial resolution with rapid transmission of nerve impulses, and is therefore important for 
movement processing.3 In contrast, the P-system is characterized by high spatial resolution 
but slow transmission of nerve impulses, and is mainly involved in object processing.3 The 
function of the K system is less clear, but might be involved in colour processing.2,3
In addition to the retino-occipital pathway, there are several other essential but less studied 
visual pathways including the retino-collicular pathway (important for refl exive eye move-
Light
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figure 1: a cross section of the human eye with a schematic enlargement of the retina
Figure derived and adapted from http://webvision.med.utah.edu/book/part-i-foundations/simple-anato-
my-of-the-retina/.
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ments, motion discrimination and non-conscious perception of emotional stimuli, mainly 
M-system), the retino-pretectal pathway (serve the pupillary reflex), the retino-hypothalamic 
visual pathway (circadian rhythms), and the accessory optic system (head and gaze orienta-
tion and slow eye movements) (Figure 3).4-7
Following the retino-occipital visual pathway, the LGN project via the optic radiations 
mainly towards layer IV of the primary visual cortex in the occipital lobe of the brain.8 The 
primary cortex is organised into ocular dominance columns (ODC), meaning that bands of 
cortical tissues alternately receive input from the left or the right eye (Figure 4).9 Because of 
the partial crossing of the optic nerve at the optic chiasm, the primary cortex receives visual 
information from both eyes of the same side, thus the right visual field is processed by the 
left hemisphere and vice versa.1
Retina
Koniocellular
Bistratied
Midget
Parasol
Parvocellular
Magnocellular
LGN
V1
Koniocellular
Parvocellular
Magnocellular
2/3
4A
4B
4Cα
4Cβ
5
6
figure 2: an overview of the P-, M- and K-system in the retino-occipital visual pathway
Midget, parasol and bistratified ganglion cells are well characterized and have been linked to parallel sys-
tems that remain anatomically separate through the lateral geniculate nucleus neurons (LGN) and into the 
primary visual cortex (V1). Midget ganglion cells project to parvocellular layers of the LGN (P-system), and 
parasol ganglion cells project to magnocellular layers (M-system). Subsequently, both project to layer 4 
of the primary visual cortex. Bistratified ganglion cells project to koniocellular layers of the LGN and on to 
layer 2/3 (K-system). Although these ganglion cell types are numerically dominant in the retina, many more 
types are known to exist and are likely to subserve important parallel systems that are yet to be identified. 
(Adapted and printed by permission from Macmillan Publishers Ltd: Nature Reviews Neuroscience,3 copy-
right 2009.)
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figure 3: an overview of the visual pathways, from the eye to the primary visual cortex
Figure derived and adapted from https://www.studyblue.com.
Temporal 
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figure 4: segregation of eye-specifi c information at the early stages of visual processing
In mammals with binocular vision, the nasal portion of one retina encodes the same part of the visual world 
as the temporal portion of the other retina. The axons of retinal ganglion cells from the nasal portion of 
each retina cross the optic chiasm and project to the same LGN as the axons from the temporal portion of 
the other eye. These projections form discrete, eye-specifi c LGN layers. The projection from the LGN to layer 
4 of the primary visual cortex maintains this eye-specifi c segregation by terminating in eye-specifi c patches 
that are the anatomical basis for ocular dominance columns. Ocular dominance columns can therefore be 
considered to correspond to an eye (left or right) or a retinal location (nasal or temporal). (Adapted and 
printed by permission from Macmillan Publishers Ltd: Nature Reviews Neuroscience,9 copyright 2002.)
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Within the primary cortex there are connections between the diff erent neurons and layers, 
suggesting that the input from the diff erent systems (P-, M- and K-system) is mixed, before 
the visual information is projected to other brain areas.3 About 50 years ago the concept of 
two main visual streams from the primary cortex was proposed.10-12 The dorsal (‘where/how’) 
pathway, from the primary visual area to the parietal lobe, is mainly responsible for processing 
spatial information necessary for planning and programming of motor actions. The ventral 
(‘what’) pathway, from the primary visual area to the temporal lobe, is mainly responsible for 
conscious visual perception, visual recognition and visual memory.13,14 Although this concept 
is widely used, it is probably an oversimplifi cation, because there are many cortico-cortical 
connections between the diff erent brain areas processing visual information.12.
This complex combination of the input of the diff erent visual pathways and systems, 
together with the cortico-cortical connections leads to the perception and interpretation of 
the visual input.
1.2 VIsual DeVeloPMenT 
Prenatal development of the visual system
The visual system develops from the forebrain, which is already recognizable in the third week 
after fertilization.15-17 The eye development starts with the formation of the optic vesicle at day 
A B C D
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Lens 
placode
Lens 
vesicle
Bilayered 
optic cup
Lens
Neural 
retina
Retinal pigmented 
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Interneurons
Photoreceptor cells
Optic stalk
figure 5: Development of the human eye
A and B) When the optic vesicle reaches the surface ectoderm, it invaginates and the adjacent surface 
ectoderm starts to develop into the lens. C and D) The inner and outer wall of the optic cup give rise to the 
neural retina and the retinal pigmented epithelium. The neural retina develops into an outer neuroblastic 
layer, from which the photoreceptors derive, and the inner neuroblastic layer, from which the bipolar and 
retinal ganglion cells arise. The axons of the retinal ganglions cells grow into the optic stalk. (Adapted and 
printed by permission from Macmillan Publishers Ltd: Nature,18 copyright 2011.)
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22.15 When the optic vesicles make contact with the surface ectoderm, they invaginate to form 
the optic cups. The stem of the optic vesicle narrows to form the optic stalks (Figure 5).15,16
Simultaneously, the adjacent surface ectoderm starts to develop into the lens.15 The in-
ner and outer wall of the optic cup give rise to the neural retina and the retinal pigmented 
epithelium.15 The neural retina further develops into an outer neuroblastic layer, from which 
photoreceptor cells derive, and the inner neuroblastic layer, from which the bipolar and 
retinal ganglion cells arise.15,16 From the sixth week of development the axons of the retinal 
ganglions cells grow into the optic stalks, which will transform into the optic nerves (Figure 
6).15,16 The axons from both eyes join and partly cross at the optic chiasm and subsequently 
synaps with the LGN in the thalamus.15 Of the 3.7 million axons that are initially present (16th 
week), only 1.1 million will achieve an established connection at birth; the other axons will 
degenerate.19
In the fi rst weeks after fertilization also the cortex starts to develop. From the ventricular 
zone, adjacent to the ventricles, neurons proliferate and migrate to the correct layer (sixth 
week). They migrate initially to the most inner layer and fi nally to the most outer layer (layer 
I).8,20 One transient layer during development is the subplate zone. The thalamocortical axons 
fi rst synaps with the subplate neurons (15th -24th week), which at their turn connect with the 
neurons of layer IV.21,22 After this ‘waiting period’ in the subplate the thalamocortical axons 
grow into layer IV themselves and the subplate neuron connection disappears.20,23
40 8 12 16 20 24 28 32 36
Birth
2 4 6 8
Postnatal monthsWeeks after fertilization
Optic nerve & tract
Cortex
Optic radiation
A
B
C
D
E
F
G
figure 6: Main periods in the development of the visual system
A) Between 6th – 14th weeks of development the axons of the retinal ganglion cells grow into the optic stalk 
towards the thalamus and synaps with the LGN in the thalamus.15,16 B) Around 16 weeks about 3,7 million 
axons are present, but about two thirds will degenerate and 1,1 million have an established connection 
at birth.19 C) From the 15th week onward the thalamocortical axons grow into the subplate and synapse 
with the subplate neurons.21,22 D) Between the 24th until the 32nd week the subplate connection disappears 
and the thalamocortical axons grow into layer IV of the cortex to establish synapses with the layer IV neu-
rons.21 E) Subsequently, the maturation and refi nement of the thalamo- and cortico-cortical connections 
will start.21 F) From the 30th week onwards the cortex starts to myelinate.24 G) Myelination of the optic nerve 
takes largely places between the 32nd week and 7 months postnatal.25
Chapter 1
14
Postnatal development of the visual system
Although at birth the main structures are present, the visual system is still immature. The 
major part of the postnatal development takes place in the first period after birth, however 
the visual system does not reach full maturity before adulthood. For example: the fovea 
reaches maturity at 4 years, whereas myelination has its peak in the first year after birth, but 
continues into the third decade of life.26-28 For further development visual input at the right 
moment is essential. This is illustrated most clearly by the disorder amblyopia: an unilateral 
or, less commonly, bilateral reduction of the best corrected visual acuity (VA) that cannot 
be attributed directly to the effect of any structural abnormality of the eye or the posterior 
visual pathways.29,30 When a child is a few months old equal and sufficient visual input of both 
eyes is necessary to obtain normal VA. This lasts until the age of eight and is called the critical 
period. When one eye is not or hardly used due to strabismus, unequal refractive errors or 
cataract, amblyopia occurs.29,31 Amblyopia can be recovered by eliminating the underlying 
cause and patching the (better seeing) eye. The earlier this intervention starts the better the 
outcome. However, partly improvement of the VA by using patching can still be achieved 
in adolescence.31,32 Recently, binocular dichoptic training and brain stimulation was used in 
amblyopic adults with promising results.33-36
As a result of the immature system, a newborn has limited vision. This improves rapidly; at 
birth VA is between 20/1200-20/400 (0.015-0.05) and fixation is intermittent present.37 From 
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figure 7: Development of visual acuity
Development of VA measured binocular by Teller acuity cards (grating acuity at 55 cm), and Snellen ‘equiva-
lent’ (optotype acuity at 6 meters). (Figure derived and adapted from Teller acuity cards™ II handbook, 2005)
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two to three months onwards a child fixates well on human faces or nearby toys, and can 
follow a moving object smoothly.37,38 When the brain and the fovea mature the VA improves. 
Because different tests assess different visual aspects, such as forced preferential looking and 
measurement of VA with optotypes, the VA depends on the test used.30,32,39,40 For the different 
methods for VA measurement age norms have been defined (Figure 7).30,39,40
The difference between single VA with optotypes and line VA is called crowding, defined 
as the impairment of the ability to recognize objects in clutter, and can persist until adoles-
cence.41,42 Nevertheless, a near crowding ratio >2 (single optotype acuity divided by linear 
acuity) at all ages or a distance crowding ratio >2 after the age of 6 years is a reason for further 
investigation.43 The visual fields expand rapidly after birth, starting from approximately 30% 
of adult values at 2 months, to 75%-80% at 8 months and 100% at 2 years.32,44
1.3 CereBral VIsual IMPaIrMenT
The disorder cerebral visual impairment
Vision loss due to pathology of the brain was first recognized in adults and was called cortical 
blindness, for reviews see Hoyt and Good et al.45,46 However, in children with brain pathol-
ogy it was noticed that the majority was not completely blind, so the term cortical visual 
impairment was introduced.45 This name, though, is still misleading, as in many children not 
only the cortex is involved. Therefore, the preferred name is cerebral visual impairment, but 
cortical visual impairment is still commonly used.45,47 For this thesis the term cerebral visual 
impairment abbreviated as CVI will be used. CVI was first defined as “a neurological disorder 
resulting in bilateral impairment of VA by damage to the central nervous system, meaning VA 
is reduced as a result of a non-ocular disease”.46,48 During the beginning of the 21st centuries it 
was noticed that CVI could also lead to other visual disorders without VA loss and the defini-
tion was modified: “CVI includes all visual dysfunctions caused by damage to, or malfunction-
ing of, the retrochiasmatic visual pathways in the absence of damage to the anterior visual 
pathways or any major ocular disease”.49,50 Problems with processing and integrating of visual 
information are also known as higher functioning CVI, visuoperceptual disorders or cognitive 
visual dysfunction.48,51,52 Although amblyopia is also a kind of CVI, in general amblyopia is not 
meant when speaking of CVI.29
CVI is a major and increasing cause of visual impairment in children in Western countries. 
This is probably the result of better care for curable eye disorders (e.g. cataract), more aware-
ness of CVI, and a higher survival rate for preterm born children and children with multiple 
congenital abnormalities and/or severe neurological disorders.53 CVI is responsible for almost 
one third of low vision in children, a VA of ≤0.3 and/or visual field <30.53,54. In a group of 
children with a VA ≤0.1 and/or visual field <20°, CVI accounted for 18%-48% of the impair-
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ment.55-57. The number of children with CVI without low vision is currently unknown. In this 
thesis, the focus will be on CVI with low vision (VA ≤0.3 and/or visual field <30°).
Ophthalmological investigation and findings
The most important ophthalmological examinations and the possible results for patients 
with CVI will be discussed. The majority of the studies of CVI are performed in individuals 
with perinatal damage. Whether the results can be extrapolated to CVI due to other causes 
is unknown.
Fixation, eye movements and eye alignment
An important aspect of the ophthalmological examination is observation: does the patient 
fixate at and follow the examiner and interesting objects. Fixation can be unstable in patients 
with CVI, such as frequent loss of fixation, the inability to sustain fixation or no fixation at 
all.58,59 The fast eye movements towards a stimulus, reflexive saccadic eye movements, can be 
impaired.59 In addition, the reaction time to fixation can be delayed.60 In CVI patients devia-
tions of conjugated gaze can be observed. These are moments of uncontrolled wandering 
eye movements mainly made upward or sideward.59,61 Furthermore, smooth pursuit can be 
saccadic or completely absent in CVI.52,59 Although CVI was previously only diagnosed in the 
absence of nystagmus, it is now commonly accepted that nystagmus can be one of the ocular 
features.47,59,61,62
Strabismus can be present in patients with CVI. In patients with cortical damage exotropia 
is more common, whereas in patients with subcortical damage esotropia is more common.61 
Fluctuating eso-, ortho-, and exotropia (dyskinetic strabismus) can also be observed in pa-
tients with CVI.61
During observation abnormal visual behaviour can be seen, including looking away from 
the target while reaching to it, looking next to the target, not watching when listening, and 
staring into lights.46,58
Visual acuity
VA measurement in children under the age of 2 years is often possible by using forced 
preferential looking or visual evoked potentials (VEP).30,37,63 In VEP measurement the electric 
potential in the visual cortex initiated by a brief visual stimulus is recorded. In CVI the VEP 
vernier acuity measurement correlates best with forced preferential looking at Teller acuity 
cards (TAC) based on grating acuity.64 However, the sweep VEP might be predictive for the 
future grating or recognition acuity.65 Grating acuity cards (e.g. TAC) are based on the reflex 
of people to look at contrasting patterns instead of a homogeneous target (Figure 8).38 Tests 
based on object recognition, such as the LH test or Landolt C test can be used in older chil-
dren.66 From 6 years onwards acuity can often be measured by Snellen acuity charts. For the 
LH, Landolt C and Snellen test it is possible to measure single VA or line VA (in a row), which 
17
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is useful to detect crowding. In crowding measurement there is an infl uence of test design: 
a chart with fi xed intersymbol spacing should be used, since charts with proportional inter-
symbol spacing do not reveal diff erences between normally sighted and visually impaired 
children.67 The acuity defi ned by VEP or TAC is a grating acuity and cannot be compared to 
a recognition acuity, as the tests are based on diff erent aspects of vision. For the purpose of 
communication often a Snellen ‘equivalent’ is mentioned.
In all children and in persons with intellectual disability (ID) the VA test should be related 
to the developmental level of the person. For example in an adult with CVI and a severe intel-
lectual disability the TAC can be the only method to assess the VA. However, in patients with 
impaired refl exive saccadic eye movements or vertical visual fi eld defects the TAC cannot 
always be used.
In patients with CVI the VA can range from blindness to normal, and can improve over 
time.50,68,69 There is a inverse correlation between the severity of perinatal damage and the 
degree of acuity impairment.70,71 Crowding is a feature of the immature visual system, low 
visual acuity and CVI.67 It is present in about half of the CVI patients.72-74
One other characteristic of CVI can be fl uctuating visual performances and attention, 
which could hamper the measurement of VA.46,58
Visual fi elds
Visual fi eld measurement by perimetry such as the Goldmann is often not possible under 
the age of 7 years.37 Nevertheless, it is possible to get information about the visual fi elds in 
younger persons by using a confrontational method with white Stycar balls on a stick (Figure 
9).75 A slightly modifi ed version of this method, the BEFIE test, was shown to give reliable 
results.76
A B
C
figure 8: Diff erent charts to measure the visual acuity
A) Teller acuity cards. B) LH test uncrowded. C) LH test crowded.
Chapter 1
18
In patients with CVI the visual fi elds are often impaired, which can consist of homonymous 
hemianopia, upper and lower visual fi eld, or constriction of the visual fi eld. Visual fi eld defects 
are more severe when the abnormalities in the posterior visual system are more extensive. 
Sometimes a clear correlation of the visual fi eld with the brain damage can be seen, for 
example an occlusion in the middle cerebral artery or anterior cerebral artery may lead to 
hemianopia.77,78
Slit lamp examination, funduscopy and refraction
Slit lamp examination sometimes reveals minimal nystagmoid eye movements. It is also 
important to investigate the anterior segment (e.g. to detect corneal damage or cataract). 
With funduscopy, after pupil dilation, it is possible to have a look at the retina and evaluate 
the fovea and the optic nerve. Young children can be diffi  cult to examine, as they only want 
to fi xate on the light or don’t want to look at the light at all. The latter can be caused by 
photophobia, which can be present in CVI patients.79 In patients with CVI a pale optic disc 
or a pale segment of the optic disc can be seen. A small optic disc or a more pronounced 
excavation is reported in patients with CVI due to perinatal problems.80,81
The presence of refraction errors needs to be evaluated. When the pupils are dilated 
refraction can be examined objectively with a hand-held autorefractor or by retinoscopy. 
figure 9: Two stycar balls on a stick for examining the visual fi eld
The patient is asked to fi xate at one stycar ball, that is held in front of the patient. Another person stands 
behind the patient and moves the second Stycar ball with a wide circle into the visual fi eld of the patient. A 
refl exive saccadic eye movement can be observed when the second Stycar ball is noticed.
19
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For this measurement steady fixation is necessary, which sometimes lacks in patients with 
CVI. Hypermetropia is a normal phenomenon during childhood, and can be corrected by 
accommodation. In CVI patients incomplete accommodation with persistent hypermetropia 
occurs.82 However, myopia and astigmatism can also be present in CVI patients.51,79 Just like 
normally sighted person, refraction errors are common and important to correct in CVI pa-
tients. However, it may be more difficult to get the child accustomed to glasses.52
Electroretinography and optical coherence tomography
Electroretinography (ERG) is used to investigate the function of the cells in the retina, among 
others the photoreceptors. An electrode is put on the forehead and wire or lens electrodes 
are placed on the anesthetized eye to measure the flash induced responses. An ERG is a 
demanding examination and can only be performed in cooperative older children or under 
anesthetics.30 ERG abnormalities can be found in retinopathies. In individuals with CVI with-
out other ocular deficits the ERG can be normal. However, in optic atrophy, which can be seen 
in CVI as a result of retrograde degeneration of optic nerve fibres, the ERG may be abnormal.
Optical coherence tomography (OCT) produces a cross sectional image of the retina, 
macula and optic disc by using infra-red light. Patients should be able to fixate and willing to 
put their head in the standard. Aberrant OCT images may be present in CVI, because the optic 
disc can be abnormal. However, to our knowledge, no OCT studies have been performed in 
a CVI cohort.
Higher visual functioning
Disorders in higher visual functioning are sometimes the only features of CVI.50 For example, 
a patient can have problems with the detection of movements, difficulties in recognition of 
faces, expressions or objects or inability to differentiate a floor boundary. Inability to select 
relevant visual information in a busy scene, crowding, can also be a deficit of higher visual 
functioning. For a first screening of higher perceptual deficits several questionnaires have 
been developed that can be filled in by parents or caretakers.72,83,84 More detailed neuropsy-
chological tests, such as the L94 visual perceptual battery, can be helpful to gain more insight 
in specific higher perceptual deficits in the individual.85,86 However, not all questionnaires and 
batteries are validated in toddlers, persons with intellectually disability and/or in patients 
with a VA ≤0.3, so these questionnaires may not be suitable for these persons.87
Comorbidities of CVI
The malfunctioning or damage of the brain is mostly not limited to the visual system. There-
fore, additional features like epilepsy, delayed development and intellectual disability can be 
present.53 Sometimes CVI can also be accompanied by abnormalities of other organ systems. 
Thus CVI can occur in isolation or be part of a syndrome.
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Diagnosing CVI
CVI is an umbrella diagnosis of any kind of malfunctioning of (parts of ) the visual system 
behind the eye, leading to many different presentations.88 This makes it difficult to formulate 
clear criteria for the diagnosis. CVI is often diagnosed when no ocular disorder can explain 
the visual impairment, so called diagnosis per exclusionem. The diagnosis evolved over time, 
and additional conditions were proposed to be required, such as recognizable brain damage 
on imaging, low VA, absence of nystagmus, or abnormalities at detailed neuropsychological 
investigations (personal experience).46,62,89 Probably the most comprehensive criteria nowa-
days are published by C. Roman and others: “(1) an eye examination that cannot fully explain 
the child’s use of vision; (2) a history or presence of neurological problems, even when the 
child’s brain-imaging studies may appear normal; and (3) the presence of the behavioural or 
visual responses that are collectively associated with CVI.”90
Differential diagnosis
If an infant or young child presents with a bilaterally impaired visual acuity, the most impor-
tant diagnoses to exclude are cataract, uncorrected refraction errors, retinopathies, albinism, 
and delayed visual maturation.39,53 Most of them can be excluded by thorough ophthalmo-
logical examination. The most important and more challenging differential diagnoses are 
discussed below.
Leber congenital amaurosis
Children with Leber congenital amaurosis (LCA) often push or rub their eyes with a finger 
or fist, the oculodigital sign. The VA range from 0.1 (rare) to no light perception, and the 
eye movements can be wandering. In addition, patients can have nystagmus, high hyperme-
tropia, photophobia and poor or absent pupil responses. The fundus can appear normal in 
the first year after birth, but later pigmentary changes, vascular narrowing and/or optic disc 
pallor can be observed. Pattern and flash VEP are mostly absent, but diagnostic is the ERG, 
which shows extremely attenuated or absent responses.39,91.
Delayed visual maturation
Delayed visual maturation (DVM) is a disorder in which the infant shows poor visual func-
tioning for his/her age, without any ocular disorder. It shows strong resemblances with CVI, 
however in DVM the vision improves to normal, generally within 6-12 months, but longer 
periods have been reported.39,92,93 Although the vision fully recovers, these children have 
a higher risk on developmental disorders, and vice versa DVM can occur in children with 
developmental delay.89,91,94,95 Some authors see DVM as a mild form of CVI.91 Nevertheless, 
the boundary between CVI and DVM still needs to be determined. Some suggested criteria 
for DVM are a normal brain MRI, normal flash VEP for age and full recovery of vision.91,93,94 
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However, this is challenged by reports in which children with DVM have persistent deficits or 
VEP abnormalities.94,95
Nystagmus and other motility disorders of the eye
Infantile nystagmus is often a feature of an underlying disorder, such as albinism or congeni-
tal stationary night blindness.91,96 In infantile ‘idiopathic’ nystagmus, thus without an underly-
ing ocular or neurological disorder, the VA can be impaired but is in general above 0.3.96 In 
addition, there are no co-morbidities and frequently there is a family history of nystagmus.
Congenital oculomotor apraxia can be difficult to distinguish from CVI.47 The condition is 
featured by the inability to fix and follow moving targets, which could give the impression 
that the child is blind. However, an optokinetic nystagmus, induced by rotation, is intermit-
tent or absent in congenital oculomotor apraxia and older children use head movements and 
head thrusting to fixate and follow.97
Optic nerve abnormalities
The VA in patients with optic nerve abnormalities can vary from normal vision to blindness. 
Other features like visual field defects, nystagmus or strabismus can be present.92,98 Two 
optic nerve abnormalities relevant for the differential diagnosis of CVI are optic atrophy and 
optic hypoplasia.47,99 It can be difficult to define whether it is a developmental disorder of 
the optic nerve (optic hypoplasia), an endogenous defect resulting in increased apoptosis of 
optic nerve fibres (primary optic atrophy), or transsynaptic retrograde degeneration of the 
optic nerve fibres (secondary optic atrophy, which can be present in CVI). First of all there is 
a discrepancy between the ophthalmological and pathological definition of hypoplasia and 
atrophy. Optic hypoplasia is defined by pathologists as an underdevelopment, which means 
less fibres in the optic nerve.100 Optic atrophy is defined as degeneration, which means loss 
of fibres.101 Ophthalmologist base the terminology on the characteristics of the optic disc, 
a small optic disc is called hypoplasia and a pale optic disc is called is atrophy.39 In patients 
with early gestational injury optic hypoplasia has been reported by ophthalmologists.61,102 
However, in these patients the smaller optic nerves are probably due to an increase of 
the normal apoptosis of axons in an early stage of development, thus atrophy might be a 
more appropriate term.99,103 Optic nerve hypoplasia is also seen in combination with other 
abnormalities such as anterior eye defects and midline defects, including corpus callosum 
agenesis, hypothalamic or pituitary dysfunction.98 The pathophysiology underlying the small 
optic discs in these disorders is largely unknown. It may be a primary failure of the retinal 
ganglion cell to develop or, as now more commonly believed, due to a secondary apoptosis of 
the axons as a result of interference of normal axonal migration within the visual pathways.92
Secondly, it can be difficult to define whether the optic atrophy is primary or secondary. 
Secondary optic atrophy develops due to transsynaptic retrograde degeneration, which 
can occur when the retrochiasmal parts of the visual system are malfunctioning, for ex-
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ample in gestational injury or other brain abnormalities.92,104,105 The aspect of the optic disc 
in transsynaptic retrograde degeneration is indistinguishable from primary optic atrophy. 
Therefore, discriminating between (pre-) chiasmal (primary optic atrophy) and retrochiasmal 
disorders (secondary optic atrophy, which can be present in CVI) can be challenging and 
this implicates that a commonly used definition for CVI is not always applicable in clinical 
practice: ‘CVI includes all visual dysfunctions caused by damage to, or malfunctioning of, the 
retrochiasmatic visual pathways in the absence of damage to the anterior visual pathways or 
any major ocular disease’.49 Nevertheless, the absence or presence of other ophthalmological 
features (e.g. normal eye movements) and the history (e.g. late onset with detoriation) can 
often discriminate between CVI and other forms of optic nerve abnormalities.99
Therapy in CVI
It is important to make the patient, his family, and caretakers aware of CVI, in order to make 
them understand the sometimes strange visual behaviour, e.g. not noticing objects in a busy 
environment. Depending on the level of impairment, this can require specific adjustments 
as pointed out in Table 1. For instance, it can be better to use pictograms instead of photo-
graphs as communication aid. In general, it is important to structure and simplify the visual 
environment. To train the patient, the situation can slowly become more complex, guided 
on the level of the patient. Furthermore, it can be necessary to teach the patient about the 
meaning of visual information. For instance, let the patient feel with hands and feet what the 
differences in height are between the carpet and parquet. Furthermore, vision strategies can 
be used. Persons with lower visual field defects for example, can be learned to scan the whole 
ground by head and eye movements. In addition, trainings have been developed to stimulate 
Table 1: examples of impairments, strategies and trainings for CVI
Impairment examples of strategies examples of training
Auditory stimuli predominate Structured acoustic circumstances (e.g. put 
of the radio)
Motility disorder of the eyes Structured visual input Guided search training
Visual impairment in general Optimize lightning circumstances 
Low vision aids
Crowding Structured visual input (e.g. plain place 
mats or agree upon a specific place on the 
school yard) 
Gradually make the situation more 
complex
Visual field defects Present objects in the remaining visual field Teach to use head movements
Difficulties with abstract figures Use photographs Training in which line drawings 
become a real object
Difficulties with estimating height on 
different coloured grounds 
Remove colour differences on a flat ground 
and highlight stairs with coloured rims
Experience and gradually make the 
situation more complex
Facial expressions Support the expression with more emotion 
in the voice. 
From exaggerated expressions 
or emoticons to more subtle 
expressions 
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fixation, following, and visual recognition, and to reduce crowding.42,106,107 Although, it is 
plausible that these trainings will improve vision, just like physiotherapy improves motor 
development, it is hardly been formally investigated in CVI.42
Aetiology of CVI
Acquired causes
In brief, all events that cause brain injury prenatal, perinatal or postnatal can lead to CVI. The 
disorders with a high risk on CVI and several illustrative examples will be discussed below 
from prenatal to postnatal events.
Prenatal infections, such as congenital CMV infections, could lead to CVI. About 0.6% of 
the newborns are infected by CMV, of which 10% is symptomatic at birth.108 Especially these 
symptomatic newborns are at risk to develop visual impairment due to CVI.109 Other prenatal 
events can be maternal drug abuse or twin-twin transfusion syndrome.52,110
A well recognized cause of CVI are perinatal problems. The risk on perinatal problems 
increases with a decrease of the gestational age at birth and a lower birth weight.111,112 In two 
studies the risk on CVI with low vision was 1-2% in premature born children (birth weight 
<1500g or gestational age <27 weeks).113,114 The perinatal problems underlying CVI may 
consist of periventricular leukomalacia, brain haemorrhages, sepsis, and neonatal hypogly-
caemia.
Postnatal risk factors include severe head trauma, infections of the brain, severe uncon-
trolled epilepsy or hydrocephalus.52,115-118
Genetic causes
Till recently, in the larger CVI aetiology studies, varying from 100 to 170 persons with CVI, 
minimal attention is paid to the genetic disorders involved.51,79,119 For some genetic syndromes 
the affected individuals are systematically investigated for deficits in higher visual function-
ing by neuropsychological test. For example in Noonan syndrome, Williams syndrome, and 
Prader-Willi syndrome; higher visual disorders are diagnosed, but impairment of VA has not 
been reported.120-122 However, many reports of genetic syndromes and CVI are case studies 
in which the ophthalmological examination (especially VA), the perinatal condition, or the 
molecular diagnosis are not reported in detail. Therefore, it is difficult to come up with a 
complete and reliable list of genetic disorders in which CVI with low vision is part of the 
phenotype.
Nevertheless, based on the sporadic literature, the genetic causes underlying CVI can be 
divided into three groups. In the first group CVI is indirectly caused by the genetic defects, 
such as disorders that increase the risk of stroke or brain tumours; for instance mitochondrial 
encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), protein C deficiency, 
tuberous sclerosis.62,123-125 The second group consists of progressive neurodegenerative 
disorders, such as Leigh syndrome or X-linked adrenoleukodystrophy.62 The third group is 
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the group of the non-progressive disorders. CVI is for example reported in chromosomal 
disorders, such as Down syndrome and 1p36 deletions, and monogenetic disorders, such as 
congenital disorders of glycosylation.126-132
1.4 InTroDuCTIon InTo GeneTICs 
Genetics
The fi rst large contribution to our understanding of inherited disease nowadays was made 
by G. Mendel (1822-1884) who reported dominant and recessive inheritance in 1865.133 
Forty years later it was proposed that the chromosomes in the nucleus were the bearers of 
this heredity,134,135 and it was thought that a human being had 48 chromosomes. In 1956 
the correct number of 46 was established (Figure 10).136 Only a few years later, in 1959, the 
fi rst numeric chromosomal disorder was identifi ed, trisomy 21 or Down syndrome,137, and 
when G-banding karyotyping was introduced the resolution to detect aberrations became 
5-10 Mb.138 In the years that followed other techniques to investigate our chromosomes 
were developed and it was shown that also submicroscopic aberrations (<5 Mb) could lead 
to neurodevelopmental disorders.138 After targeted techniques, such as fl uorescence in situ 
hybridization (FISH) or unbiased techniques such as multiplex ligation-dependent probe am-
plifi cation (MLPA) telomere screening, the genome-wide microarrays were introduced.139,140 
The resolution improved over time up to the detection of aberrations as small as 20 kb cur-
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figure 10: Diff erent methods to perform genetic investigations
A) Schematic presentation of the genetic material. B) Karyogram revealing trisomy 21. C) Microarray led to 
the identifi cation of a de novo deletion on 4q28.3q31.1 of 2.73 Mb. D) Sanger sequencing reveals a de novo 
c.755T>C variant in NR2F1. E) Whole exome sequencing identifying a de novo c.3646G>A variant in GABRB2.
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rently. Copy number variants (CNVs) are present in healthy and affected persons. On group 
level, patients with intellectual disability (ID) and autism have more and larger CNVs, which 
arise more often de novo and are less frequent in the global population compared to healthy 
individuals.141-143 However, these statistics are not useful on individual level, because they are 
not discriminative. For the interpretation whether a CNV is pathogenic, workflows have been 
developed.144-146 These workflows include the following aspects: comparing the phenotype of 
persons with a similar CNV by using control and patient datasets (e.g. Database of genomic 
variants (DGV), DECIPHER and ECARUCA (https:// http://dgv.tcag.ca/, https://decipher.sanger.
ac.uk/ and http://umcecaruca01.extern.umcn.nl:8080/ecaruca/),147-149 establishing the origin 
of the CNV (de novo or inherited from a healthy or affected parent), and investigating the 
genes involved. With the use of these microarrays a causal chromosomal aberration could be 
detected in 10-20% of the patients with developmental delay/ID, autism spectrum disorders, 
and/or multiple congenital anomalies.150-152 This had led to the identification of many new 
microdeletion and microduplication syndromes reviewed by Van Bon and Watson et al.153,154
In the fifties not only the exact number of chromosomes was identified, but also the double 
helix structure of DNA was discovered.155 In the following 10 years the relation between the 
sequence of the bases (adenine, cytosine, guanine, and thymine) and encoded proteins became 
clear, which made it possible to predict the effect of a nucleotide variant.156 The first disorder in 
which a pathogenic amino acid change could be proven was sickle cell anaemia in 1956.157 The 
next major step was the development of a method to investigate the sequence of nucleotides by 
F. Sanger in 1977, called Sanger sequencing.158 This initiated a project to sequence the entire ge-
nome: the Human Genome Project, which was a collaborative effort of 20 institutes and started 
in 1990 and was declared finished in 2003.159,160 It turned out that the sequence of DNA between 
humans is 99% identical,161 implicating that there are millions of variations in the nucleotides. 
The majority of these variants are situated in the non-coding part of the DNA, but thousands 
of variants are present in genes. Most variants have no or only a mild effect on the phenotype 
and contribute to the fact that everybody is a bit different. However, some variants do have 
severe phenotypic consequences. For example, in ophthalmological disorders, mutations in 
NDP lead to Norrie disease, characterized by a specific early onset retinopathy, hearing loss, ID, 
and behavioural abnormalities.162 Based on the phenotype it is now known which gene has to 
be sequenced, but for other disorders, such as non-syndromic retinitis pigmentosa many genes 
(>75) can be mutated (https://sph.uth.edu/Retnet/sum-dis.htm accessed on July 2015). To test 
all genes one by one by Sanger sequencing is very laborious, time consuming and expensive.163 
In the last decade next generation sequencing (NGS) techniques made it possible to investigate 
the DNA faster. With this novel technique a targeted region of the genome can be sequenced, 
such as a number of known disease genes, a certain (part of a) chromosome, or (almost) all 
coding parts, called whole exome sequencing (WES). Sequencing of the exons of known disease 
genes by using NGS was proven to be useful to detect the underlying pathogenic variant in het-
erogeneous diseases, such as retinopathies.164,165 WES, however, opens the possibility to identify 
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causal variants in genes not yet known to be associated with the disorder. Because many variants 
are identified by WES, several approaches are used to pinpoint the underlying causative variant, 
depending on the phenotype, the (expected) inheritance pattern, and molecular knowledge of 
the disorder.166 Five more commonly used approaches which have led to the identification of 
new associations between genes and disorders are depicted in Figure 11.
Sometimes it is possible to define a candidate region, for example by using homozygos-
ity mapping in consanguineous families or by using linkage analysis in large families with 
B CA D
E F G
figure 11: several approaches to prioritize the variants identified by Wes
Examples of the approaches discussed in the text. The arrows indicate the persons in which WES is per-
formed. Filled symbols in the pedigrees represent affected individuals, empty symbols represent presum-
ably healthy individuals, and obligate carriers are depicted by a symbol with a dot. Circles below each 
pedigree symbolize the genetic variants identified, and the grey areas the most promising variants. A) 
Candidate region approach: disorder with a suspected X-linked inheritance, the shared variants between 
the probands on the X chromosome are the most promising candidates. B) Candidate region approach: 
disorder with a suspected autosomal dominant inheritance. The shared variants between the probands in 
the linkage area are the most promising candidates. C) Candidate region approach: consanguineous family 
with suspected autosomal recessive disorder in which the homozygous variants are the most promising 
candidates. D) Sib-pair approach: The overlapping variants following an autosomal recessive and X-linked 
inheritance are the most promising candidates. E) Phenotype first approach: variants in overlapping genes 
are the most promising candidates. F) Gene list approach: the variants in genes present on the list are the 
most promising candidates. F) De novo approach: the de novo variants and the variants following an auto-
somal recessive or X-linked inheritance are the most promising candidates.
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multiple affected. The variants identified in the defined region can be further analyzed to find 
the underlying gene defect (Figure 11A-C).167-169
Secondly, in two affected sibs of non-consanguineous parents it is also possible to perform 
sib-pair WES to identify the pathogenic variant (Figure 11D).170,171 In many patients, however, 
there are no other affected family members. When there is a distinct clinical phenotype, 
sequencing of several probands can lead to the underlying gene defect, the phenotype first 
approach (Figure 11E).172-176
The fourth approach is to prioritize the variants by using molecular knowledge about the 
genes and mechanisms involved in the phenotype (Figure 11F). The application of gene lists 
based on the involved pathway or binding site of a specific transcription factor was success-
ful in identifying the causal mutation.177,178 Because our molecular knowledge is far from 
complete, this strategy might lead to the exclusion of the pathogenic variant and therefore 
this approach is not often solely used.
For CVI, however, none of these approaches are suitable: little is known about genes and 
pathways underlying CVI, the patients are often the only affected in the family, and the par-
ents are mainly non-related. In addition, CVI is an umbrella diagnosis and therefore probably 
clinically and genetically heterogeneous, excluding a phenotype-based approach.
In other heterogenic sporadic disorders, such as non-syndromic ID, epilepsy or autism, the 
trio approach was shown to be a useful strategy.179-182 By sequencing not only the patient but 
also the parents, de novo events can be detected and these de novo mutations appeared to be 
causal in 10-15% of the patients with a developmental disorder (Figure 11G).183,184 Moreover, 
this approach can also be used to search for pathogenic variants following an autosomal 
recessive or X-linked inheritance. In about 25% of individuals with developmental disorders 
a diagnosis can be established by using WES, and a possible diagnosis can be identified in up 
to 50% of the individuals.182-186
At the moment chromosomal investigations by using microarray is often performed before 
WES, but the methods to detect copy number variants, encompassing at least three exons, in 
WES data improve.187-189
Advantages to know the underlying pathology
The knowledge about the underlying defect and a name for the disorder is already a relieve 
for parents. This allows the patient and/or parents to get in contact with other patients and 
parents with the same disorder and support each other on (non-)medical problems. Fur-
thermore, information about the phenotypic spectrum and the long term prognosis can be 
beneficial for the patient. In disorders with a risk on CVI for example, early ophthalmological 
investigation and support can be given. Moreover, because of the critical period in visual 
development it is probably important to stimulate the vision as early as possible to achieve 
the best possible vision. Another question that often arises is whether there is a chance of 
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recurrence; for themselves, a healthy brother or sister or other family members. Based on the 
inheritance pattern of the identified disorder a clear answer can be given.
Furthermore, investigation of genes underlying CVI will improve our understanding of 
their function in the visual system and the molecular pathways involved, and this may give 
insight in the normal and pathological development and functioning of vision. Finally, this 
knowledge may lead to improved therapy, such as stimulation programs.
1.5 sCoPe, MeThoDs anD ouTlIne of The ThesIs
The genetics underlying CVI has hardly been investigated. Therefore, we decided to study 
which genetic disorders were involved in the aetiology of CVI patients with low vision. We 
focussed on persons with low vision because of several reasons. First CVI can be difficult 
to diagnose. Therefore, we choose for patients with a quantifiable impairment: low visual 
acuity. Furthermore, CVI is a major cause of low vision in children, but the aetiology is only 
partly known.53 In addition, by including only patients with low vision a representative co-
hort (n=828) could be obtained, because it has been estimated that about half of all visually 
impaired children in the Netherlands are investigated in Bartiméus, institute for the visually 
impaired in Zeist, the Netherlands.53 The patient inclusion was based on the database in 
Bartiméus, in which the diagnosis and level of visual impairment was recorded by paediatric 
ophthalmologists.53 To search for patients with CVI the search terms listed in Box 1 were used, 
and only patients with low vision (VA ≤0.3 or <1.6 cycles/cm or visual field of ≤30°) were 
included.53
Box 1: search terms
Cerebral visual impairment
Corpus callosum agenesia
Cerebral anomaly
Central nervous system anomaly unspecified
Encephalopathy unspecified
Motility disorder not leading to strabismus
Neurological disorder unspecified
Partial optic nerve atrophy
Of the 1144 patients obtained from this database (1975-2013) the medical files have been 
studied and patients with an additional major ocular disorder (e.g. cataract, retinitis pigmen-
tosa, or retinopathy of prematurity) were excluded for further study. After applying these 
broad criteria 828 patients remained, which have been used for the studies in chapter 2 and 
chapter 3.
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As a proof of principle the medical files were studied for the presence of genetic disorders 
in patients with CVI with low vision (chapter 2). For the first study a recent 10-year period 
was used, because the awareness of genetic causes and the possibilities to diagnose genetic 
disorders has improved rapidly (chapter 2.1, Figure 12). The aetiology, co-morbidities and 
ophthalmological findings are reported for 309 CVI patients. In addition, it was investigated 
whether there were differences in the ophthalmological features between patients with an 
acquired cause versus those with a genetic aetiology.
In chapter 2.2 the chromosomal aberrations identified in patients with CVI are evaluated 
in more detail. Because karyotyping is performed since 1970 a 20-year period was chosen 
to investigate the chromosomal aberrations.138 The aberrations identified were classified to 
investigate which chromosomal aberrations could lead to CVI.
For the studies described in chapter 3 and 4, we used more stringent criteria applied to 
the initial cohort of 828 patients. Based on the medical information in the files all patients 
with possible a risk factor for CVI (Box 2) or an identified genetic disorder were excluded. 
Subsequently, the selected patients and their parents were invited to participate in the study 
in Bartiméus (Figure 13). In one session the history was taken, and clinical examination was 
performed, which comprised the evaluation of the presence of dysmorphisms and ophthal-
mological investigation (Table 2). Blood was taken to perform DNA investigations, including 
targeted gene analyses, microarray and WES, in 56 patients and in most of the parents.
1975 1985 1995 2005 2015
Chapter 2.1, n=309
Chapter 2.2, n=607
Initial cohort, n=828
figure 12: overview of the patients selected for the different cohorts used in this thesis
Years represent the first ophthalmological examination in Bartiméus of the patient included in the study.
Box 2: Possible risk factors for CVI
Intrauterine CMV infection
Maternal drug or alcohol abuse
Perinatal problems
Periventricular leukomalacia
Brain haemorrhage
Neonatal hypoglycemia
Meningitis/encephalitis
Severe brain trauma
Hydrocephalus
West syndrome
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In chapter 3.1 we investigate whether WES can be used to detect the underlying genetic 
defects in CVI. Moreover, this unbiased approach can lead to new associations between genes 
and CVI. Therefore, WES was performed in 25 patients and their parents.
In chapter 3.2 the identification of compound heterozygous mutations in PGAP1 are 
discussed. PGAP1 is important in the GPI-anchoring pathway and was a candidate gene for 
intellectual disability. Further functional investigations were performed to strengtend the 
causal relation. In chapter 3.3 we report on the identification of heterozygous mutations in 
NR2F1 that lead to CVI, optic atrophy and intellectual disability. Whether the identified mis-
sense mutations lead to an aberrant protein function was investigated by a functional study. 
The overall results of the 56 CVI patients and a short discussion of these results are presented 
in chapter 4. In chapter 5 a general discussion is given. This chapter outlines the challenges 
in the interpretation of genetic variants in the light of CVI. Furthermore, the entity CVI and 
future perspectives are discussed.
- Risk factor and/or known    
genetic disorder (n=631)
- Deceased (n=58)
Initial cohort 
(n=828)
Eligible
(n=139)
Included for study described 
in chapter 3 and 4
(n=56)
- Declined (n=53)
- Unreachable (n=30)
figure 13: flow diagram of the patient inclusion for the study described in chapter 3
Table 2: aspects of the ophthalmological examination
aspect Method used
Fixation, eye movements and alignment Observation, little toys, covering of one eye
VA TAC, LH, Landolt C, Snellen chart
Visual fields Confrontative with Stycar balls or toy on a stick, Goldmann
Anterior segment Slit lamp
Retina, optic disc and fovea Funduscopy, OCT
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aBsTraCT
Background To gain more insight into genetic causes of cerebral visual impairment (CVI) in 
children and to compare ophthalmological findings between genetic and acquired forms of 
CVI.
Methods The clinical data of 309 individuals (mainly children) with CVI, and a visual acuity 
≤0.3 were analysed for aetiology and ocular variables. A differentiation was made between 
acquired and genetic causes. However, in persons with West syndrome or hydrocephalus, it 
might be impossible to unravel whether CVI is caused by the seizure disorder or increased 
intracranial pressure or by the underlying disorder (that in itself can be acquired or genetic). 
In two subgroups, individuals with ‘purely’ acquired CVI and with ‘purely’ genetic CVI, the 
ocular variables (such as strabismus, pale optic disc and visual field defects) were compared.
Results It was possible to identify a putative cause for CVI in 60% (184/309) of the cohort. In 
the remaining 40% the aetiology could not be determined. A ‘purely’ acquired cause was 
identified in 80 of the patients (26%). West syndrome and/or hydrocephalus was identified 
in 21 patients (7%), and in 17 patients (6%) both an acquired cause and West syndrome and/
or hydrocephalus was present. In 66 patients (21%) a genetic diagnosis was obtained, of 
which 38 (12%) had other possible risk factor (acquired, preterm birth, West syndrome or 
hydrocephalus), making differentiation between acquired and genetic not possible. In the 
remaining 28 patients (9%) a ‘purely’ genetic cause was identified.
CVI was identified for the first time in several genetic syndromes, such as ATR-X, Mowat-
Wilson, and Pitt Hopkins syndrome. In the subgroup with ‘purely’ acquired causes (N=80) 
strabismus (88% versus 64%), pale optic discs (65% versus 27%) and visual field defects (72% 
versus 30%) could be observed more frequent than in the subgroup with ‘purely’ genetic 
disorders (N=28).
Conclusions We conclude that CVI can be part of a genetic syndrome and that abnormal 
ocular findings are present more frequently in acquired forms of CVI.
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BaCKGrounD
Cerebral visual impairment (CVI) is one of the major causes of low vision in the developed 
world and accounts for 27% of the visually impaired children.53 Visual impairment in CVI is 
due to a disorder in projection and/or interpretation of the visual input in the brain.47 In the 
absence of absolute criteria for the diagnosis, the following definition is commonly used: 
CVI includes all visual dysfunctions caused by damage to, or malfunctioning of, the retrochi-
asmatic pathways in the absence of any major ocular disease.51 A more practical definition 
includes an impairment of vision with normal function of the ocular structures and anterior 
visual pathways.62,79,119 The main features of CVI during ophthalmological investigation are: 
impaired visual acuity, visual field defects, and abnormal visual behaviour, while obvious 
ocular abnormalities are not found. This visual behaviour consists of looking away from the 
target while reaching to it, looking past the target, staring into lights, and fluctuating visual 
performances. Fixation abnormalities can be observed, such as a prolonged time before fixat-
ing on a stimulus and intermittent fixation towards a stimulus.58,190 The visual acuity can range 
from blindness to normal, and is in CVI due to perinatal causes correlated to the severity of 
the brain damage.50,70,72 Crowding, the impairment of the ability to recognize objects in clut-
ter, is present in more than 40% of the normally sighted CVI individuals, however, in individu-
als with CVI and low vision the percentage of crowding is unknown.41,72,74 The occurrence of 
strabismus (37-73%) and nystagmus (12-73%) varies highly among previous reports.51,79,119 In 
funduscopy a (segmental) pale optic disc can be seen (25-44%), whereas in premature born 
individuals a small optic disc or a more pronounced excavation can be found.112 Remarkably, 
the latter could also be observed in individuals with mutations in NR2F1, which were recently 
identified.191 Visual fields can be impaired, varying from partial visual field defects, to severe 
constriction of visual fields.77 It has been demonstrated that visual evoked responses do not 
differ between individuals with and without CVI, although the responses can be abnormal.192 
In addition, fixation is often severely impaired in CVI and minimal fixation is necessary for 
visual evoked responses. Therefore, visual evoked responses cannot be used to diagnose CVI. 
Furthermore, difficulties with object or face recognition and visiospatial disorders can be ob-
served.46,58 Neuropsychological testing can be helpful to gain more insight in specific higher 
perceptual deficits in the individual, but are only applicable to children with a developmental 
age above two years and 9 months.85 For a first screening of higher perceptual functions 
several questionnaires have been developed.72,83
In general, the causes of CVI can be divided into acquired and genetic forms. The acquired 
forms can be derived prenatally (e.g. intrauterine infections), perinatally (e.g. ischaemic brain 
injury), and postnatally (e.g. hypoglycemia or meningitis). Perinatal problems, often due to 
premature birth, are the most frequent causes of acquired CVI, occurring in up to two-thirds 
of the cases, whereas neonatal meningitis and/or encephalitis has been reported as impor-
tant causes in the postnatal period (2.5-12%).47,51,79,112,119 Other acquired causes of CVI, such as 
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head trauma and brain tumours are less common.51,62,79 In complex cases, like children with 
severe epilepsy or hydrocephalus, it might be impossible to unravel whether CVI is caused by 
the seizure disorder or increased intracranial pressure or by the underlying disorder (that in 
itself can be acquired or genetic).115,116 CVI, either acquired or genetic, is often part of a more 
complex phenotype, and co-occurrence of non-ophthalmic impairments and disorders, such 
as intellectual disability or epilepsy, are common.51,79
Knowledge about the occurrence of CVI in persons with or without intellectual disability 
can alter the way of approaching the person. For example, it is important to offer objects one 
by one or for a longer period of time, in case of crowding or fixation abnormalities. Moreover, 
rehabilitation of children with CVI can improve their overall function.193
Although few studies reported on large series of 100 to 170 individuals with CVI, little at-
tention is paid to whether genetic disorders are involved.51,79,119 Several studies have been 
performed on higher perceptual deficits in more common genetic syndromes, such as 
Williams syndrome and Prader-Willi syndrome.121,194 However, in the description of these 
patients in those reports a reduced visual acuity is not mentioned. Our goal was to get more 
insight into the genetic causes of CVI with low vision. Because in acquired forms of CVI the 
mechanism and the moment of disruption are different compared to CVI due to genetic 
causes, we also aimed to investigate whether different ocular phenotypes could be observed 
for genetic versus acquired forms.
MeThoDs
All individuals with CVI included in this study were seen in Bartiméus, an institute for diag-
nostics, rehabilitation and schooling of the visually impaired in the Netherlands, in the period 
2002-2012. Assuming that the incidence of visual impairment in 3.1 million Dutch children 
aged 0–15 years is similar to the 8 / 100 000 per year reported in Scandinavia, approximately 
half of the annually recorded children with low vision in the Netherlands are seen at Bar-
timéus.53 All children were referred to Bartiméus by medical specialists, i.e. paediatricians, 
rehabilitation physicians, ophthalmologists, general physicians and orthoptists. The children 
were referred for different reasons, mostly because of suspected visual impairment. A mi-
nority was referred for further diagnosis such as electrophysiology. The majority of children 
lived at home with their parents and were seen in the outpatient facilities of the Institute. All 
investigations were performed by a paediatric ophthalmologist with assistance of a technical 
ophthalmological assistant and/or orthoptist. Visual acuity was measured mono- and bin-
ocularly with correction of the refraction error under controlled light conditions. Monocular 
vision was measured by covering one eye by a special device for occlusion which could be 
added to the glasses worn by the patient. Visual acuity in young children or in individuals 
with a young developmental age was measured by forced preferential looking (Teller Acuity 
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Cards, 55 cm), or with “LH Symbols” (3 m).66 The confrontational method with white Stycar 
balls, 5 cm, was used to estimate the visual fields. The balls on a stick were presented in 
all quadrants by a person behind the individual investigated. A person in front looked for 
response to the presented object: eye movements, pointing or a verbal response. Eye align-
ment, fixation, following, and visual behaviour were observed. A handheld slit lamp was used 
to assess the anterior segment. In mydriasis, funduscopy and retinoscopy were performed, 
whenever the patient and parents agreed. But in case of lack of cooperation funduscopy and 
retinoscopy were not always possible. Electroretinography was rarely performed, because of 
developmental age or behavioural problems. CVI was diagnosed when there was no other 
ocular diagnosis which could explain the visual impairment or visual field defect, and/or 
typical features such as poor fixation or crowding were present, and/or CVI was found at 
neuropsychological investigation. Neuropsychological investigation of the visual functions 
was, however, not possible in a majority of the individuals, because of their developmental 
age. Although, there are tests available from 2+9 years onwards, the tests used in Bartiméus in 
the past 10 years were only applicable in patients with a developmental age above six years. 
Crowding was measured with the C-test at 5m or with a LH Symbols version of the C-test on 
40 cm as described in Huurneman et al. and was defined increased when the crowded ratio 
was ≥2.67,74,195 Additional inclusion criteria were a first visit over a 10 years period between 
1-1-2002 and 1-1-2012 and low vision, defined as a visual acuity of ≤0.3 or <1.6 cycles/cm at 
55 cm or a visual field radius of ≤30° degrees.53 Under the age of three the visual acuity was 
measured by Teller Acuity Cards and defined as decreased, when the acuity in cycles/degree 
was below the normal range for their age reported by Courage and Adams.196 Exclusion 
criterion was a second ocular diagnosis causing low vision, such as cataract or retinopathy 
of prematurity. Optic nerve atrophy was not an exclusion criteria, because it can occur as a 
result of retrograde transsynaptic degeneration in CVI.105 Primary (hereditary) optic atrophy 
or congenital idiopathic nystagmus were excluded based on the history and results during 
ocular examination by the ophthalmologist. Bilateral amblyopia was excluded as refraction 
was measured and corrected if necessary.
The most recent ophthalmologic examination was used for further analyses, including 
binocular visual acuity, visual fields, strabismus, nystagmus, refraction error and the aspect 
of the optic disc. The use of vigabatrin was registered because of the risk of constriction of 
visual field.197 To identify potential causes of CVI we evaluated the genetic investigations, 
risk factors during pregnancy, birth, and neonatal/childhood period, and reports on cerebral 
imaging.
For the comparison of the ophthalmological findings the data of the individuals with 
acquired causes and with a genetic diagnosis were used. To avoid confounding factors, 
which may contribute to CVI, additional criteria were used to select the subgroups for this 
comparison. Individuals with West syndrome and hydrocephalus as well as individuals with 
a genetic diagnosis in combination with a gestational age <37 weeks, unknown gestational 
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age or acquired causes (e.g. perinatal problems) were excluded. For the statistical analysis 
the Mann-Whitney U test and the Fisher’s Exact test were used. A p-value below 0.05 was 
considered to be significant. To control for the false discovery rate at 0.05 we used the 
Benjamini-Hochberg method.198 This study was approved by the Ethics Committee of the 
Radboud university medical center (Commissie Mensgebonden Onderzoek, regio Arnhem-
Nijmegen). According to the Committee informed consent was not necessary, because all 
data were processed anonymously. Local approval of the institute was obtained. The study 
was conducted according to the tenets of the Declaration of Helsinki.
resulTs
309 individuals with low vision fulfilled the criteria for CVI. The general information about 
the cohort is presented in Table 1 and in more detail in Additional file 1. Almost half of the 
patients (151/309) had their first ophthalmological examination before the age of three 
years, whereas five individuals were over 18 years of age. 152 persons had more than one 
examination, and there was a median interval of 28 months between the first and the most 
recent examination. The persons without a second examination (n=157) had a median age 
of 46 months (5 months -45 years). In 20% (62/309) of the cohort there was a vision below 
0.05 or 1.6 cycles/cm at 55 cm (Teller acuity cards) (Table 2). High refraction errors, myopia 
<-4 or hypermetropia >+4, were present in 25% (42/172) of the persons. In 77% (226/295) a 
strabismus and in 42% (113/270) a nystagmus was present. Visual field defects were found 
in 60% (149/249), consisting of constricted visual fields in half of the individuals. (Partial) 
pale optic discs were present in 44% (128/293). Fixation problems were present in 45% and 
fluctuating visual performances 31%.
Co-morbidities were found in a high percentage, such as intellectual disability (96%, 
298/309, IQ<70 or developmental delay) and hearing impairment (12%, 24/196, hearing 
threshold above 25 dB) (ICD-10, http://www.who.int/classifications/icd/en/) (Table 1). In 32% 
(71/221) the gestational age was below 37 weeks, of which two-thirds were born before 35 
weeks. In 67% of the cohort a MRI-scan was performed, which was reported normal in only 
14% (28/206). Brain anomalies were either caused by a disturbance in the developmental pro-
cess (e.g. lissencephaly, cortical dysplasia) and white matter disease (e.g. hypomyelination) 
or acquired (e.g. periventricular leukomalacia (PVL), stroke). We subdivided the patients in a 
normal MRI group and an abnormal MRI group and searched for the difference in ophthal-
mologic features. In the patients with an abnormal MRI scan more pale optic disc were seen 
(49% versus 14%, p=0.001) (Additional file 2).
It was possible to identify one or more possible causes for CVI in 60% of the cohort. In 
23% there was evidence of severe perinatal problems, such as haemorrhage or infarctions, 
PVL or post-partum reanimation. In 11% exogenous factors led to brain damage and CVI, 
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such as meningitis or encephalitis, a diabetic coma, or a complication during an operation. 
Hydrocephalus was present in 6% and West syndrome in 9% of the cohort.
A genetic diagnosis was reported in 21% (Table 3), of which 50% had a proven chromo-
somal aberration. In half of the persons with a genetic syndrome other factors, such as West 
syndrome or stroke, may have contributed to the CVI. In the other half the CVI might be 
associated with the genetic syndrome.
After excluding individuals who had multiple factors that could have contributed to CVI 
a subgroup (N=108) remained, which allowed for the comparison of the ocular findings be-
Table 1: General information, co-morbidities, aetiology of the cohort
General information  Median (range)
Age first examination (months) 36 (4 months- 45 years)
Age most recent examination (months) 53 (5 months – 45 years)
Birth weight (gram) 2980 (760-4750)
Gestational age (weeks) 39 (27-42)
regarding n/ available n (%)
Men 170/309 (55%)
Mortality 15/309 (5%)
Twins 20/309 (6%)
Gestational age <37 weeks 71/222 (32%)
Vigabatrin use 44/309 (14%)
Anomalies MRI-cerebrum 178/206 (86%)
Co-morbidities affected n/ available n (%)
Intellectual disability 298/309 (96%)
Motor impairment 288/294 (98%)
Hearing impairment 24/196 (12%)
aetiology number (%)
Perinatal problems* 70 (23%)
PVL* 35
Stroke* 32
Exogenic* 33 (11%)
Meningitis/encephalitis * 13
Congenital CMV infection* 6
Head trauma* 6
Complication of operation/co-morbidity* 8
Genetic diagnosis* 66 (21%)
Hydrocephalus* 20 (6%)
West syndrome* 28 (9%)
Unknown 125 (40%)
*Can coexist.
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tween individuals with a ‘purely’ acquired form of CVI (N=80) and those with a ‘purely’ genetic 
form (N=28). There were no significant differences between the groups according to the age 
at the ophthalmological examination (72 months versus 54 months, p=0.333) or the use of 
vigabatrin (9% versus 7%, p=1.00), of which a known side effect is visual field constriction 
defects (Table 4).197 The occurrence of blindness (16% versus 25%, p=0.396), nystagmus (46% 
versus 35%, p=0.357) or high refraction errors (myopia: 4% versus 0%, p=0.567; hypermetro-
pia; 6% versus 11%, p=0.425) did not differ significantly between the groups. In the ‘purely’ 
acquired group, however, strabismus (88% versus 64%, p=0.009), visual field defects (72% 
versus 30%, p=0.001) and (partial) pale optic discs (65% versus 27%, p=0.001) were observed 
more often than in the ‘purely’ genetic group. The type of visual field defects, concentric, 
hemianopia, or upper or lower visual field defects, did not seem to differ between the two 
groups, but the numbers were too small to make definite conclusions.
Table 2: findings of ophthalmological examinations
ocular findings affected n/ available n (%)
Myopia < -4 13/171 (8%)
Hypermetropia > +4 29/171 (17%)
Visual acuity < 0.05 or <1.6 cycles/cm at 55 cm 62/309 (20%)
Strabismus 226/295 (76%)
Nystagmus 113/270 (42%)
Eye movement disorders 100/283 (35%)
Visual field defect 149/249 (60%)
Hemianopia  28/149 (19%)
Upper or lower visual field defect  37/149 (25%)
Constriction of visual field  84/149 (56%)
(Partial) pale optic disc 128/293 (44%)
Visual behaviour/
higher visual disorders
Percentage
Fluctuating visual performances 31%
Fixation abnormalities 45%
Looking away from the target 19%
Crowding 8%
Problems with object/face recognition 7%
Staring at lights 15%
Auditive stimuli dominates 9%
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Table 3: syndromic diagnosis in patients with CVI
ID Diagnosis* Ga Contributing 
factors
age at 
examination 
(months)
CVI 
previously 
reported
evidence
for genetic
diagnosis
Gene
269 Aicardi syndrome 36 W 50
199
C
316 Aicardi syndrome 42 W 108 C
173 Aromatic decarboxylase deficiency 32 38 200 C,M
319 ATR-X 38 70 C,G ATRX
55 CDG type 1a 41 22
126,127
C,M
305 CDG type 1a NA 25 C,M
223 Citrullinaemia NA 81 C,M
128 Coffin-Siris syndrome 41 84 C
43 Cohen syndrome 38 53 C
433 Complex I deficiency NA 15
201,202
C,M
378** Complex I deficiency 40 35 C,M
403 Complex II deficiency 41 46
202
C,M
5 Complex III deficiency 41 W 73 C,M
266 Complex I and III deficiency NA 50 C,M
29 Complex II and III deficiency 42 S 48 C,M
175 D2-hydroxyglutaaraciduria NA 20 203-205 C,M
425 Incontinentia Pigmenti 40 S, W 67 206,207 C
184 Infantile neuroaxonal dystrophy 39 45 208,209 C
325 Copper storage disorder 41 27 210 C,M
263 Lissencephaly NA 38 211 C,G DCX
231 Marden-Walker syndrome 35 79 C
17 Mowat-Wilson syndrome 41 34 C,G ZEB2
215 Opitz C syndrome NA 199 C
216 Pelizaeus-Merzbacher syndrome 38 27 62 C,G PLP1
192 Pitt-Hopkins syndrome 40 35 C,G TCF4
85
Pontocerebellar hypoplasia type 2
Triple X
36 30 212
C
C,G
238 Propion acidemia 36 117 213 C,M
78 Rett syndrome 36 23 C,G MECP2
99 Rett syndrome 38 20
214
C,G CDKL5
172 Rett syndrome NA 14 C,G CDKL5
364 Rett syndrome NA 197 215 216 C
341 Tubereus sclerosis NA Compression 
from tubers
179
62
C
41 Tubereus sclerosis NA Compression 
from tubers
165 C
348 Vanishing white matter NA 28 217 C
*in an additional 33 individuals chromosomal aberrations were identified. **previously described in Mora-
va et al.218 ATR-X syndrome= Alpha-Thalassemia X-linked intellectual disability syndrome, CDG = congenital 
disorder of glycosylation, C= clinical diagnosis, GA= gestational age, G=gene mutation, M= metabolic diag-
nosis, NA= not available, P= perinatal problems, S= stroke, W= West syndrome. The syndromes in the bold 
formatted rows are for the first time associated with CVI.
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DIsCussIon
We analysed causes of CVI in a large cohort of 309 individuals with low vision in the Nether-
lands. Although CVI has also been described in individuals with a (sub-)normal visual acuity 
and higher perceptual deficits, within this study only patients were selected with a vision 
≤0.3 or a visual field below 30 degrees.46,50,72 For the purpose of this study, we excluded per-
sons with major anterior ocular diseases, although CVI can also be present in those patients. 
In some persons only grating acuity (Teller Acuity Cards) could be measured. In general using 
grating acuity initially may lead to higher scores than the optotype acuity that can be ap-
plied later in development.219 Although some children were investigated at a very young 
age, which might hamper the differentiation between CVI and delayed visual maturation 
(DVM), about half of the individuals had more than one ophthalmological examination, with 
a median interval of 28 months between the first and the most recent examination, whereas 
another quart of the persons were over 48 months allowing for an accurate clinical diagnosis. 
We hypothesized that in children with DVM there is a concordant delay in visual functions. 
In CVI, on the contrary, there may be discrepancies in the developmental stage of different 
visual functions. When this hypothesis is correct, it might be possible to differentiate earlier 
between CVI and DVM by signalling discrepancies in the profile of visual functions.
Table 4: ocular findings in individuals with a ‘purely acquired’ or a ‘purely genetic’ cause
acquired (n=80) Genetic (n=28) Raw
p-value
Mean age most recent examination 
(months)
70 (SD 58) 54 (SD 39) 0.333
affected n/ available n affected n/ available n
Men 48/80 (60%) 17/28 (61%) 1.00
Vigabatrin use 7/80 (9%) 2/28 (7%) 1.00
Abnormal MRI 55/56 (98%) 11/14 (79%) 0.023
Myopia <-4 3/80 (4%) 0/28 (0%) 0.567
Hypermetropia >+4 5/80 (6%) 3/28 (11%) 0.425
Visual acuity <0.05 or <1.6 cycles/cm 
at 55 cm
13/80 (16%) 7/28 (25%) 0.396
Strabismus 68/77 (88%) 18/28 (64%) 0.009*
Nystagmus 31/67 (46%) 9/26 (35%) 0.357
Visual field defect 47/65 (72%) 7/23 (30%) 0.001*
Hemianopia  10/47  1/7 -
Upper or lower visual field defect  19/47  3/7 -
Constriction of visual field  18/47  3/7 -
(Partial) pale optic disc 51/78 (65%) 7/26 (27%) 0.001*
 *p-Values represent differences that passed the Benjamini–Hochberg criterion (false discovery rate at 0.05).
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This study was based on the medical files, in which sometimes information is missing, 
for example on ERG, ophthalmological results or MRI scan. In addition, for some features 
(e.g. fixation) only abnormalities were reported, although this was probably assessed in all 
patients but not always recorded. However, we were able to collect a large group of patients 
and in the majority of these patients extended investigations were performed. The ocular 
findings in our cohort were comparable to previous reports, except for the visual field de-
fects, of which a higher percentage was found in our study (60% versus 9%).51,79 In two-thirds 
of the patients an MRI scan was performed. In only 14% of the individuals with an MRI scan 
of the brain, the images were reported to be normal (28/206), which is comparable with a 
previous study by Khetpal et al.79 The spectrum of MRI abnormalities in our cohort was broad: 
from structural abnormalities, such as corpus callosum dysplasia, holoprosencephaly or lis-
sencephaly, to white matter abnormalities, such as hypomyelination and PVL. This shows that 
many different mechanism that lead to brain disease may cause CVI. In individuals with a nor-
mal MRI scan or only a thin corpus callosum, the pathogenesis was less clear. Pale optic discs 
were seen more frequently in the patients with reported anomalies on MRI scan. However, as 
the MRI scans were assessed by many radiologists with different expertise we are reluctant 
to draw firm conclusions.
In 60% of the individuals, we were able to identify the cause of the CVI, of which 32 persons 
were classified in more than one group. In 34% evidence of acquired problems, mainly peri-
natal, were found which is lower than the 42% - 67% previously reported.51,79,119 This might 
be due to more stringent criteria used in our study, as only individuals with known brain 
damage on cerebral imaging, twin-twin transfusion syndrome or postpartum resuscitation 
were classified as perinatal problems.
In 40% of the patients we could not identify a cause for CVI. This can be due to missing in-
formation in the medical file, a not recognized acquired cause (for example an unrecognized 
CMV infection during pregnancy), a not identified genetic cause or a combination of several 
minor acquired and genetic risk factors.
In 21% of the individuals a genetic diagnosis was obtained, of which 50% had proven 
chromosomal aberrations (Table 3). As the techniques to identify underlying genetic causes 
are improving rapidly, this 21% is probably an underestimation.
We observed various genetic syndromes for which an association with CVI has previously 
been reported: trisomy 21, congenital disorder of glycosylation (CDG) type 1A, complex II 
deficiency, copper storage diseases, infantile neuroaxonal dystrophy, Pelizaeus-Merzbacher 
syndrome and Rett syndrome.62,126,127,130-132,202,208-210,214-216 However, for the following genetic 
syndromes such association was not reported so far: Alpha-Thalassemia X-linked intellectual 
disability syndrome, Coffin-Siris syndrome, Pitt-Hopkins syndrome, Mowat-Wilson syndrome 
and Cohen syndrome.
In some of these syndromes retinal diseases have been described, for example in Cohen 
syndrome or CDG type 1A.126,220 In our cohort an electroretinography was often not available. 
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However, as funduscopy did not reveal any retinal abnormalities, retinopathy was unlikely to 
cause visual impairment. In neurodegenerative diseases, such as complex II deficiency, optic 
atrophy can occur as a result of mitochondrial dysfunction, but these disorders affect the 
brain equally.202 Moreover, retrograde transsynaptic atrophy may occur, making differentia-
tion between CVI and visual impairment due to optic atrophy in these disorders difficult.
Although CVI might still be a coincidental finding in the above mentioned genetic syn-
dromes, most individuals with these or other syndromes have not systematically been tested 
for CVI. For example, visual acuity, visual behaviour, and the findings at funduscopy are sel-
dom reported in the clinical reports and children with an intellectual disability are not always 
seen by a paediatric ophthalmologist. Therefore, it is likely that CVI might be a consistent part 
of these syndromes, but a thorough assessment of the visual functions in more individuals 
with these syndromes is necessary to establish this association.
We were able to establish a diagnosis in the majority of CVI in our study population, 
consisting of genetic disorders and acquired causes. After exclusion of possible confounders 
a ‘purely’ genetic and a ‘purely’ acquired subgroup remained. Between those two different 
aetiologies the ophthalmological examination revealed significant differences (Table 4). 
Strabismus, visual field defects and (partial) pale optic disc were significantly less common in 
the genetic group compared to the acquired group. This might be explained by the localiza-
tion of the defect as in the acquired group, the most important cerebral damage was PVL 
and stroke, both mainly localized in the optic radiations. Damage to the optic radiations can 
cause visual field defects and retrograde optic disc pallor.61,105,112 In the genetic group the 
optic radiations are probably less severely affected and a more overall dysfunction of the 
brain and/or cortical anomalies might have resulted in the visual impairment. This theory is 
supported by the observation that normal optic discs are seen more often in individuals with 
cortical lesions compared to subcortical lesions.61 A comparable mechanism might result in 
the higher frequency of strabismus in the acquired group. To guide the alignment of the 
visual axes the binocular connections in the striate cortex play an important role.221 When the 
input to the striate cortex is disturbed by prism-glasses, strabismus develops in primates.222 
So it can be expected that injury to the optic radiations by stroke or PVL, which also disrupts 
the input to the striate cortex, leads to strabismus. Although there are more mechanisms 
that cause strabismus, the above mentioned probably accounts for the difference between 
the two groups.
ConClusIons
In conclusion, we presented a large cohort of mainly children with CVI and impaired vision. 
Genetic disorders were present in 21% of patients and an association between the disorder 
and CVI is considered. CVI patients with genetic disorders showed an overall different and 
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milder ocular phenotype: less frequently strabismus, visual field defects and pale optic discs. 
Moreover, we observed CVI for the first time in several known genetic syndromes making 
the screening of visual functions in those syndromes recommendable, to ensure the best 
approach and clinical care to the often multiple disabled persons. Also clinical genetic inves-
tigation should be considered in persons with CVI without evidence of an acquired cause. 
Awareness of CVI as part of a genetic disorder is currently increasing, and the techniques to 
identify the underlying genetic defect are improving rapidly. Therefore, it is likely that more 
genetic defects will be identified to be associated with CVI in the near future.
48
a
dd
it
io
na
l fi
le
 1
: P
he
no
ty
pe
 in
fo
rm
at
io
n 
of
 a
ll 
pa
ti
en
ts
 in
vo
lv
ed
, p
ar
t 1
ID
M
al
e/
 fe
m
al
e
Bi
rt
h 
we
ig
ht
 
(g
ra
m
)
Ge
st
at
io
na
l 
ag
e
In
te
lle
ct
ua
l 
di
sa
bi
lit
y
De
ve
lo
pm
en
ta
l 
ag
e a
t c
al
en
de
r 
ag
e
he
ar
in
g 
im
pa
irm
en
t
Cl
as
sifi
ca
tio
n
Ge
ne
tic
 
di
ag
no
sis
ri
sk
 
fa
ct
or
M
rI
 ce
re
br
um
 ab
no
rm
al
iti
es
 
(b
as
ed
 o
n 
re
po
rt
s)
Vi
ga
ba
tri
n
1
M
al
e
34
80
39
+
-
Hy
dr
oc
ep
ha
lu
s a
nd
/
or
 W
es
t s
yn
dr
om
e
W
No
rm
al
2
M
al
e
37
20
39
+
-
Un
kn
ow
n
Co
rp
us
 ca
llo
su
m
 ag
en
es
is
3
M
al
e
27
50
40
+
6 
m
on
th
s a
t 6
 
ye
ar
s
Ge
ne
tic
De
le
tio
n 
2q
W
Hy
pe
rd
en
se
 ab
no
rm
al
iti
es
 d
or
sa
l 
th
al
am
us
Ye
s
4
Fe
m
al
e
32
00
40
+
-
Un
kn
ow
n
No
rm
al
5
Fe
m
al
e
34
15
41
+
3-
4 
m
on
th
s a
t 
1+
10
 ye
ar
s
Ge
ne
tic
Co
m
pl
ex
 III
 
de
fic
ie
nc
y
W
No
rm
al
Ye
s
6
Fe
m
al
e
43
50
38
+
-
‘P
ur
el
y’ 
ac
qu
ire
d
PV
L, 
S
NR
Ye
s
7
M
al
e
44
90
41
+
-
Un
kn
ow
n
At
ro
ph
y o
f c
er
eb
el
la
r h
em
isp
he
re
s, 
pe
du
nc
le
s a
nd
 ve
rm
is.
9
Fe
m
al
e
28
40
40
+
11
-1
5 
m
on
th
s 
at
 4
2 
m
on
th
s
-
Un
kn
ow
n
Th
in
 co
rp
us
 ca
llo
su
m
, 
pe
riv
en
tri
cu
la
r w
hi
te
 m
at
te
r 
ab
no
rm
al
iti
es
11
M
al
e
26
00
39
+
-
Hy
dr
oc
ep
ha
lu
s a
nd
/
or
 W
es
t s
yn
dr
om
e
W
NR
12
Fe
m
al
e
35
00
38
+
Un
kn
ow
n
Br
ai
n 
dy
sg
en
es
is
15
Fe
m
al
e
35
25
38
+
IQ
 5
5
-
Un
kn
ow
n
NR
Ye
s
16
Fe
m
al
e
38
55
41
+
9 
m
on
th
s a
t 3
0 
m
on
th
s
-
Un
kn
ow
n
Hy
po
m
ye
lin
at
io
n 
of
 th
e 
ce
nt
ra
l 
w
hi
te
 m
at
te
r a
nd
 o
cc
ip
ita
l
17
M
al
e
38
10
41
+
-
‘P
ur
el
y’ 
ge
ne
tic
M
ow
at
-W
ils
on
 
sy
nd
ro
m
e
Sm
al
l c
or
pu
s c
al
lo
su
m
, a
ge
ne
sis
 
ge
nu
 an
d 
ro
st
ru
m
18
Fe
m
al
e
31
05
40
+
8 
m
on
th
s a
t 
1+
4 
ye
ar
s
-
Un
kn
ow
n
Hy
po
m
ye
lin
at
io
n
aDDITIonal fIles
49
Low vision due to CVI: differentiating between acquired and genetic causes
Ch
ap
te
r 2
.1
a
dd
it
io
na
l fi
le
 1
: P
he
no
ty
pe
 in
fo
rm
at
io
n 
of
 a
ll 
pa
ti
en
ts
 in
vo
lv
ed
, p
ar
t 1
 (c
on
ti
nu
ed
)
ID
M
al
e/
 fe
m
al
e
Bi
rt
h 
we
ig
ht
 
(g
ra
m
)
Ge
st
at
io
na
l 
ag
e
In
te
lle
ct
ua
l 
di
sa
bi
lit
y
De
ve
lo
pm
en
ta
l 
ag
e a
t c
al
en
de
r 
ag
e
he
ar
in
g 
im
pa
irm
en
t
Cl
as
sifi
ca
tio
n
Ge
ne
tic
 
di
ag
no
sis
ri
sk
 
fa
ct
or
M
rI
 ce
re
br
um
 ab
no
rm
al
iti
es
 
(b
as
ed
 o
n 
re
po
rt
s)
Vi
ga
ba
tri
n
19
Fe
m
al
e
24
60
36
+
28
 m
on
th
s a
t 
42
 m
on
th
s
Un
kn
ow
n
Hy
po
m
ye
lin
at
io
n
20
Fe
m
al
e
42
10
41
+
2 
ye
ar
s a
t 2
+6
 
ye
ar
s
Ac
qu
ire
d
H,
 P
VL
, S
Pe
riv
en
tri
cu
la
r l
eu
ko
m
al
ac
ia
 
pa
rie
to
-o
cc
ip
ita
l, h
yd
ro
ce
ph
al
us
22
M
al
e
37
25
40
+
Hy
dr
oc
ep
ha
lu
s a
nd
/
or
 W
es
t s
yn
dr
om
e
W
Hy
po
pl
as
ia
 an
d 
de
la
ye
d 
m
ye
lin
at
io
n 
of
 co
rp
us
 ca
llo
su
m
Ye
s
25
Fe
m
al
e
36
05
+
Un
kn
ow
n
Al
m
os
t c
om
pl
et
e 
ag
en
es
is 
of
 
ve
rm
is.
27
M
al
e
29
15
40
+
6 
m
on
th
s a
t 9
 
m
on
th
s
-
Ac
qu
ire
d
H,
 S
M
aj
or
 in
tra
ve
nt
ric
ul
ai
r b
le
ed
in
gs
28
M
al
e
36
10
41
+
-
Un
kn
ow
n
M
eg
a c
ist
er
na
 m
ag
na
, c
or
pu
s 
ca
llo
su
m
 ag
en
es
is,
 co
lp
oc
ep
ha
ly,
 
ce
re
br
al
 at
ro
ph
y, 
de
la
ye
d 
m
ye
lin
at
io
n
29
Fe
m
al
e
42
75
42
+
-
Ge
ne
tic
 an
d 
ac
qu
ire
d
Co
m
pl
ex
 II 
an
d 
III
 
de
fic
ie
nc
y
S
Al
m
os
t a
bs
en
ce
 o
f c
er
eb
el
la
r 
he
m
isp
he
re
s. 
Po
ss
ib
le
 re
m
ai
ni
ng
s 
of
 h
ae
m
or
rh
ag
es
. P
os
sib
le
 
an
te
rio
r t
em
po
ra
l w
hi
te
 m
at
te
r 
ab
no
rm
al
iti
es
31
Fe
m
al
e
+
-
Un
kn
ow
n
Su
pr
at
en
to
ria
l c
en
tra
l a
tro
ph
y a
nd
 
pe
rip
he
ra
l f
ro
nt
ot
em
po
ra
l a
tro
ph
y. 
En
la
rg
ed
 ve
nt
ric
le
s.
32
Fe
m
al
e
30
75
39
+
Un
kn
ow
n
NR
33
M
al
e
28
20
38
+
9-
11
 m
on
th
s a
t 
2+
11
 ye
ar
s
-
Un
kn
ow
n
No
rm
al
50
Chapter 2.1
a
dd
it
io
na
l fi
le
 1
: P
he
no
ty
pe
 in
fo
rm
at
io
n 
of
 a
ll 
pa
ti
en
ts
 in
vo
lv
ed
, p
ar
t 1
 (c
on
ti
nu
ed
)
ID
M
al
e/
 fe
m
al
e
Bi
rt
h 
we
ig
ht
 
(g
ra
m
)
Ge
st
at
io
na
l 
ag
e
In
te
lle
ct
ua
l 
di
sa
bi
lit
y
De
ve
lo
pm
en
ta
l 
ag
e a
t c
al
en
de
r 
ag
e
he
ar
in
g 
im
pa
irm
en
t
Cl
as
sifi
ca
tio
n
Ge
ne
tic
 
di
ag
no
sis
ri
sk
 
fa
ct
or
M
rI
 ce
re
br
um
 ab
no
rm
al
iti
es
 
(b
as
ed
 o
n 
re
po
rt
s)
Vi
ga
ba
tri
n
34
Fe
m
al
e
28
00
+
1+
4 
ye
ar
s a
t 
3+
2 
ye
ar
s
Ge
ne
tic
De
le
tio
n 
6q
15
-q
16
.1
No
rm
al
36
Fe
m
al
e
41
+
15
-1
7 
m
on
th
s 
at
 2
+9
 ye
ar
s
-
Un
kn
ow
n
Di
ffu
se
 d
im
in
ish
ed
 b
ra
in
vo
lu
m
e. 
Gl
io
sis
 al
on
g 
ve
nt
ric
le
s, 
m
ai
nl
y 
oc
cip
ita
l.
37
M
al
e
39
80
42
+
11
 m
on
th
s a
t 
2+
6 
ye
ar
s
-
Un
kn
ow
n
De
la
ye
d 
m
ye
lin
at
io
n.
39
M
al
e
40
00
40
+
9-
10
 m
on
th
s a
t 
22
 m
on
th
s
-
Un
kn
ow
n
W
id
e 
ve
nt
ric
le
s, 
th
in
 co
rp
us
 
ca
llo
su
m
, t
hi
n 
pi
tu
ita
ry
 st
al
k
40
M
al
e
38
00
38
+
1,
5-
3 
m
on
th
s a
t 
33
 m
on
th
s
-
Un
kn
ow
n
NR
41
M
al
e
+
-
Ge
ne
tic
 an
d 
ac
qu
ire
d
Tu
be
re
us
 
sc
le
ro
sis
CO
M
In
tra
ce
re
br
al
 tu
be
rs
Ye
s
42
M
al
e
37
+
+
‘P
ur
el
y’ 
ge
ne
tic
Du
pl
ica
tio
n 
4q
32
.2
De
la
ye
d 
m
ye
lin
isa
tio
n,
 e
nl
ar
ge
d 
ve
nt
ric
le
s, 
sm
al
l c
er
eb
el
lu
m
, m
eg
a 
cis
te
rn
a m
ag
na
.
43
M
al
e
27
10
38
+
-
‘P
ur
el
y’ 
ge
ne
tic
Co
he
n 
sy
nd
ro
m
e
NR
45
Fe
m
al
e
+
4 
ye
ar
s a
t 1
0 
ye
ar
s
-
Ge
ne
tic
De
le
tio
n 
6p
25
.3
-
pt
er
, D
up
lic
at
io
n 
20
q1
3.
33
-q
te
r
Sm
al
l c
er
eb
el
lu
m
46
Fe
m
al
e
+
-
Un
kn
ow
n
Po
lym
icr
og
yr
ia
, t
em
po
ra
l lo
be
 an
d 
al
on
g 
Sy
lv
ia
n 
fis
su
re
 ab
no
rm
al
 
sig
na
l o
f w
hi
te
 m
at
te
r
47
M
al
e
41
10
41
+
Un
kn
ow
n
W
id
e 
pe
rip
he
re
 liq
uo
r a
re
as
48
Fe
m
al
e
20
25
34
+
-
‘P
ur
el
y’ 
ac
qu
ire
d
PV
L
De
la
ye
d 
m
ye
lin
at
io
n,
 
pe
riv
en
tri
cu
la
r l
eu
ko
m
al
ac
ia
51
Low vision due to CVI: differentiating between acquired and genetic causes
Ch
ap
te
r 2
.1
a
dd
it
io
na
l fi
le
 1
: P
he
no
ty
pe
 in
fo
rm
at
io
n 
of
 a
ll 
pa
ti
en
ts
 in
vo
lv
ed
, p
ar
t 1
 (c
on
ti
nu
ed
)
ID
M
al
e/
 fe
m
al
e
Bi
rt
h 
we
ig
ht
 
(g
ra
m
)
Ge
st
at
io
na
l 
ag
e
In
te
lle
ct
ua
l 
di
sa
bi
lit
y
De
ve
lo
pm
en
ta
l 
ag
e a
t c
al
en
de
r 
ag
e
he
ar
in
g 
im
pa
irm
en
t
Cl
as
sifi
ca
tio
n
Ge
ne
tic
 
di
ag
no
sis
ri
sk
 
fa
ct
or
M
rI
 ce
re
br
um
 ab
no
rm
al
iti
es
 
(b
as
ed
 o
n 
re
po
rt
s)
Vi
ga
ba
tri
n
49
M
al
e
15
10
31
+
-
‘P
ur
el
y’ 
ac
qu
ire
d
PV
L
Pe
riv
en
tri
cu
la
r l
eu
ko
m
al
ac
ia
50
M
al
e
+
-
‘P
ur
el
y’ 
ac
qu
ire
d
S
Ti
ss
ue
 lo
ss
, a
sy
m
m
et
ric
 ve
nt
ric
le
 
sy
st
em
51
M
al
e
+
Un
kn
ow
n
Sm
al
l c
er
eb
el
lu
m
 an
d 
ve
rm
is,
 
de
la
ye
d 
m
ye
lin
at
io
n.
Ye
s
54
M
al
e
34
60
40
-
-
‘P
ur
el
y’ 
ac
qu
ire
d
P
Ab
no
rm
al
55
Fe
m
al
e
32
90
41
+
‘P
ur
el
y’ 
ge
ne
tic
CD
G 
ty
pe
 1
a
No
rm
al
56
Fe
m
al
e
13
55
32
+
-
‘P
ur
el
y’ 
ac
qu
ire
d
PV
L
Pe
riv
en
tri
cu
la
r l
eu
ko
m
al
ac
ia
, h
ar
dl
y 
an
y m
ye
lin
at
io
n
57
M
al
e
21
90
39
+
6-
10
 m
on
th
s a
t 
3 
ye
ar
s
-
‘P
ur
el
y’ 
ac
qu
ire
d
S, 
T
Co
rti
ca
l n
ec
ro
sis
 w
ith
 lo
ss
 o
f 
co
rti
ca
l a
nd
 su
bc
or
tic
al
 w
hi
te
 an
d 
gr
ay
 m
at
te
r. R
em
ai
ni
ng
s o
f o
ld
 
bl
ee
di
ng
 w
ith
 g
lio
sis
.
64
M
al
e
31
86
37
+
-
‘P
ur
el
y’ 
ac
qu
ire
d
PV
L
En
la
rg
ed
 ve
nt
ric
le
s a
nd
 
pe
riv
en
tri
cu
la
r l
eu
ko
m
al
ac
ia
.
66
Fe
m
al
e
10
90
27
-
IQ
 7
2
-
‘P
ur
el
y’ 
ac
qu
ire
d
PV
L, 
S
Pe
riv
en
tri
cu
la
r l
eu
ko
m
al
ac
ia
67
M
al
e
+
-
Un
kn
ow
n
M
ild
 p
er
ive
nt
ric
ul
ar
 w
hi
te
 m
at
te
r 
ab
no
rm
al
iti
es
, d
ys
pl
as
ia
 ce
re
be
lla
r 
ve
rm
is
68
M
al
e
+
Ge
ne
tic
Tr
iso
m
y 2
1
NR
70
M
al
e
20
50
35
+
5-
8m
on
th
s a
t 
2+
8 
ye
ar
s
Un
kn
ow
n
M
uc
h 
liq
uo
r, t
w
ist
ed
 o
pt
ic 
ne
rv
es
72
M
al
e
19
50
31
+
-
‘P
ur
el
y’ 
ac
qu
ire
d
PV
L
Pe
riv
en
tri
cu
la
r l
eu
ko
m
al
ac
ia
73
Fe
m
al
e
10
00
29
-
IQ
 7
6
-
Un
kn
ow
n
NR
74
M
al
e
+
-
Ge
ne
tic
Tr
iso
m
y 2
1
NR
52
Chapter 2.1
a
dd
it
io
na
l fi
le
 1
: P
he
no
ty
pe
 in
fo
rm
at
io
n 
of
 a
ll 
pa
ti
en
ts
 in
vo
lv
ed
, p
ar
t 1
 (c
on
ti
nu
ed
)
ID
M
al
e/
 fe
m
al
e
Bi
rt
h 
we
ig
ht
 
(g
ra
m
)
Ge
st
at
io
na
l 
ag
e
In
te
lle
ct
ua
l 
di
sa
bi
lit
y
De
ve
lo
pm
en
ta
l 
ag
e a
t c
al
en
de
r 
ag
e
he
ar
in
g 
im
pa
irm
en
t
Cl
as
sifi
ca
tio
n
Ge
ne
tic
 
di
ag
no
sis
ri
sk
 
fa
ct
or
M
rI
 ce
re
br
um
 ab
no
rm
al
iti
es
 
(b
as
ed
 o
n 
re
po
rt
s)
Vi
ga
ba
tri
n
75
M
al
e
+
-
Un
kn
ow
n
NR
77
Fe
m
al
e
27
50
36
+
4,
5 
m
on
th
s a
t 
19
 m
on
th
s
Un
kn
ow
n
NR
78
Fe
m
al
e
27
10
36
+
-
Ge
ne
tic
Re
tt 
sy
nd
ro
m
e
No
rm
al
79
M
al
e
+
-
Hy
dr
oc
ep
ha
lu
s a
nd
/
or
 W
es
t s
yn
dr
om
e
W
NR
Ye
s
81
Fe
m
al
e
+
-
Un
kn
ow
n
NR
83
M
al
e
19
00
36
+
23
-2
6 
m
on
th
s 
at
 2
+1
0 
ye
ar
s
-
Un
kn
ow
n
W
hi
te
 m
at
te
r a
bn
or
m
al
iti
es
 
pe
riv
en
tri
cu
la
r
84
Fe
m
al
e
30
30
39
+
-
Ac
qu
ire
d
P, 
W
Ab
no
rm
al
iti
es
 fr
on
ta
l a
nd
 in
 th
e 
ba
sa
l g
an
gl
ia
, t
ha
la
m
us
.
85
Fe
m
al
e
18
10
36
+
-
Ge
ne
tic
Po
nt
oc
er
eb
el
la
r 
hy
po
pl
as
ia
 ty
pe
 2
Po
nt
oc
er
eb
el
la
r h
yp
op
la
sia
 ty
pe
 2
87
M
al
e
35
00
36
+
-
Hy
dr
oc
ep
ha
lu
s a
nd
/
or
 W
es
t s
yn
dr
om
e
H
NR
88
Fe
m
al
e
+
-
Un
kn
ow
n
Th
in
 co
rp
us
 ca
llo
su
m
, im
m
at
ur
e 
br
ai
n
89
M
al
e
33
-
-
‘P
ur
el
y’ 
ac
qu
ire
d
PV
L
NR
92
Fe
m
al
e
24
80
37
+
+
‘P
ur
el
y’ 
ac
qu
ire
d
S
Co
ng
en
ita
l m
ed
ia
 st
ro
ke
 le
ft.
93
Fe
m
al
e
37
+
Hy
dr
oc
ep
ha
lu
s a
nd
/
or
 W
es
t s
yn
dr
om
e
W
De
la
ye
d 
m
ye
lin
at
io
n
Ye
s
95
M
al
e
+
-
‘P
ur
el
y’ 
ac
qu
ire
d
I
Ne
cr
os
is 
of
 ce
re
br
al
 ti
ss
ue
. D
ee
p 
w
hi
te
 m
at
te
r a
nd
 b
as
al
 g
an
gl
ia
 
sh
ow
ed
 h
ig
h 
sig
na
l.
53
Low vision due to CVI: differentiating between acquired and genetic causes
Ch
ap
te
r 2
.1
a
dd
it
io
na
l fi
le
 1
: P
he
no
ty
pe
 in
fo
rm
at
io
n 
of
 a
ll 
pa
ti
en
ts
 in
vo
lv
ed
, p
ar
t 1
 (c
on
ti
nu
ed
)
ID
M
al
e/
 fe
m
al
e
Bi
rt
h 
we
ig
ht
 
(g
ra
m
)
Ge
st
at
io
na
l 
ag
e
In
te
lle
ct
ua
l 
di
sa
bi
lit
y
De
ve
lo
pm
en
ta
l 
ag
e a
t c
al
en
de
r 
ag
e
he
ar
in
g 
im
pa
irm
en
t
Cl
as
sifi
ca
tio
n
Ge
ne
tic
 
di
ag
no
sis
ri
sk
 
fa
ct
or
M
rI
 ce
re
br
um
 ab
no
rm
al
iti
es
 
(b
as
ed
 o
n 
re
po
rt
s)
Vi
ga
ba
tri
n
96
Fe
m
al
e
+
20
 m
on
th
s a
t 
33
 m
on
th
s
-
‘P
ur
el
y’ 
ac
qu
ire
d
CO
M
NR
97
Fe
m
al
e
35
00
42
+
‘P
ur
el
y’ 
ac
qu
ire
d
I
M
ul
tic
ys
tic
 e
nc
ep
ha
lo
pa
th
y, 
en
la
rg
ed
 th
ird
 an
d 
la
te
ra
l v
en
tic
le
s.
Ye
s
99
Fe
m
al
e
38
+
‘P
ur
el
y’ 
ge
ne
tic
Re
tt 
sy
nd
ro
m
e
Hy
po
pl
as
ia
 o
f t
he
 fr
on
to
te
m
po
ra
l 
ar
ea
s t
ill 
th
e 
po
st
er
io
r f
os
sa
Ye
s
10
1
Fe
m
al
e
37
60
41
+
-
‘P
ur
el
y’ 
ac
qu
ire
d
PV
L
M
ul
tic
ys
tic
 e
nc
ep
ha
lo
pa
th
y w
ith
 
ve
nt
ric
le
 d
ila
ta
tio
n
Ye
s
10
2
M
al
e
40
+
-
‘P
ur
el
y’ 
ge
ne
tic
Du
pl
ica
tio
n 
11
q2
3.
3-
qt
er
, 
De
le
tio
n 
12
q2
4.
3-
qt
er
NR
10
3
Fe
m
al
e
35
15
38
+
-
Ge
ne
tic
 an
d 
ac
qu
ire
d
De
le
tio
n 
21
q2
2.
13
-q
22
.3
, 
Du
pl
ica
tio
n 
18
p1
1.
32
-p
11
.2
1
I,S
Isc
ha
em
ic 
da
m
ag
e 
th
al
am
us
 
an
d 
le
ft 
oc
cip
ita
l d
am
ag
e 
du
e 
to
 
ab
ce
ss
.
10
4
M
al
e
36
40
39
+
14
 m
on
th
s a
t 2
 
ye
ar
s
-
Un
kn
ow
n
NR
10
5
Fe
m
al
e
21
70
40
+
9 
m
on
th
s a
t 
2+
3 
ye
ar
s
-
‘P
ur
el
y’ 
ge
ne
tic
De
le
tio
n 
5q
35
Sm
al
l c
ho
ro
id
 p
le
xu
s c
ys
t
10
7
Fe
m
al
e
15
90
31
+
-
‘P
ur
el
y’ 
ac
qu
ire
d
PV
L, 
S
As
ym
m
et
ric
 d
ila
ta
tio
n 
of
 ve
nt
ric
le
s. 
Pe
riv
en
tri
cu
la
r w
hi
te
 m
at
te
r 
ab
no
rm
al
iti
es
 w
ith
 p
un
ct
at
e 
hy
po
in
te
ns
ity
. S
lig
ht
ly 
de
la
ye
d 
m
ye
lin
at
io
n.
10
8
M
al
e
+
Ge
ne
tic
Tr
iso
m
y 2
1
NR
54
Chapter 2.1
a
dd
it
io
na
l fi
le
 1
: P
he
no
ty
pe
 in
fo
rm
at
io
n 
of
 a
ll 
pa
ti
en
ts
 in
vo
lv
ed
, p
ar
t 1
 (c
on
ti
nu
ed
)
ID
M
al
e/
 fe
m
al
e
Bi
rt
h 
we
ig
ht
 
(g
ra
m
)
Ge
st
at
io
na
l 
ag
e
In
te
lle
ct
ua
l 
di
sa
bi
lit
y
De
ve
lo
pm
en
ta
l 
ag
e a
t c
al
en
de
r 
ag
e
he
ar
in
g 
im
pa
irm
en
t
Cl
as
sifi
ca
tio
n
Ge
ne
tic
 
di
ag
no
sis
ri
sk
 
fa
ct
or
M
rI
 ce
re
br
um
 ab
no
rm
al
iti
es
 
(b
as
ed
 o
n 
re
po
rt
s)
Vi
ga
ba
tri
n
10
9
M
al
e
23
25
36
+
‘P
ur
el
y’ 
ac
qu
ire
d
S, 
T
Pr
og
re
ss
ive
 co
rti
ca
l d
eg
en
er
at
io
n.
 
In
tra
ce
re
br
al
 h
em
or
ha
ge
s
11
0
M
al
e
42
+
-
Un
kn
ow
n
NR
11
1
M
al
e
38
+
-
‘P
ur
el
y’ 
ac
qu
ire
d
S, 
T
W
id
e 
liq
uo
r a
re
as
, c
er
eb
ra
l a
tro
ph
y, 
lit
tle
 w
hi
te
 m
at
te
r, s
m
al
l c
or
pu
s 
ca
llo
su
m
.
11
2
M
al
e
+
6 
m
on
th
s a
t 
9+
8 
ye
ar
s
-
Un
kn
ow
n
Gy
ra
tio
n 
di
so
rd
er
 al
on
g 
th
e 
Sy
lv
ia
n 
fis
su
re
Ye
s
11
3
M
al
e
15
25
34
+
-
‘P
ur
el
y’ 
ac
qu
ire
d
PV
L
Gl
io
sis
 p
er
ive
nt
ric
ul
ar
11
5
Fe
m
al
e
40
00
40
+
-
Un
kn
ow
n
NR
11
6
M
al
e
19
80
35
+
-
‘P
ur
el
y’ 
ac
qu
ire
d
PV
L
Pe
riv
en
tri
cu
la
r l
eu
ko
m
al
ac
ia
11
7
M
al
e
+
-
‘P
ur
el
y’ 
ac
qu
ire
d
I
Cy
st
ic 
ab
no
rm
al
iti
es
, m
ai
nl
y i
n 
po
st
er
io
r f
os
sa
, a
nd
 le
ft 
ba
sa
l 
ga
ng
lia
.
11
8
M
al
e
+
-
Ac
qu
ire
d
H,
 I
NR
11
9
M
al
e
+
-
Un
kn
ow
n
Co
rti
ca
l d
ys
pl
as
ia
 fr
on
ta
l le
ft
12
0
Fe
m
al
e
25
00
38
+
-
‘P
ur
el
y’ 
ge
ne
tic
De
le
tio
n 
15
NR
12
2
M
al
e
27
35
39
+
‘P
ur
el
y’ 
ge
ne
tic
Du
pl
ica
tio
n 
14
 
an
d 
8
Dy
sg
en
es
ia
 o
f c
or
pu
s c
al
lo
su
m
 an
d 
in
tra
ve
nt
ric
ul
ar
 cy
st
12
4
Fe
m
al
e
+
-
Un
kn
ow
n
In
co
m
pl
et
e 
m
ye
lin
at
io
n
12
6
M
al
e
33
+
-
‘P
ur
el
y’ 
ac
qu
ire
d
P
NR
12
7
M
al
e
34
50
31
+
+
‘P
ur
el
y’ 
ac
qu
ire
d
S
NR
12
8
Fe
m
al
e
37
40
41
+
‘P
ur
el
y’ 
ge
ne
tic
Co
ffi
n-
Si
ris
 
sy
nd
ro
m
e
Co
rp
us
 ca
llo
su
m
 ag
en
es
is 
w
ith
 
co
lp
oc
ep
ha
ly
55
Low vision due to CVI: differentiating between acquired and genetic causes
Ch
ap
te
r 2
.1
a
dd
it
io
na
l fi
le
 1
: P
he
no
ty
pe
 in
fo
rm
at
io
n 
of
 a
ll 
pa
ti
en
ts
 in
vo
lv
ed
, p
ar
t 1
 (c
on
ti
nu
ed
)
ID
M
al
e/
 fe
m
al
e
Bi
rt
h 
we
ig
ht
 
(g
ra
m
)
Ge
st
at
io
na
l 
ag
e
In
te
lle
ct
ua
l 
di
sa
bi
lit
y
De
ve
lo
pm
en
ta
l 
ag
e a
t c
al
en
de
r 
ag
e
he
ar
in
g 
im
pa
irm
en
t
Cl
as
sifi
ca
tio
n
Ge
ne
tic
 
di
ag
no
sis
ri
sk
 
fa
ct
or
M
rI
 ce
re
br
um
 ab
no
rm
al
iti
es
 
(b
as
ed
 o
n 
re
po
rt
s)
Vi
ga
ba
tri
n
13
1
M
al
e
15
03
31
+
-
‘P
ur
el
y’ 
ac
qu
ire
d
PV
L, 
S
In
tra
ve
nt
ric
ul
ai
r h
ae
m
or
rh
ag
e, 
pe
riv
en
tri
cu
la
r l
eu
ko
m
al
ac
ia
13
3
Fe
m
al
e
+
IQ
 6
7
-
Un
kn
ow
n
En
la
rg
ed
 su
pr
at
en
to
ria
l v
en
tri
cle
 
sy
st
em
 an
d 
w
id
e 
pe
rip
he
ra
l li
qu
or
 
ar
ea
. A
re
as
 o
f h
ig
h 
sig
na
l in
te
ns
ity
: 
no
rm
al
 o
r s
ig
n 
of
 p
er
ive
nt
ric
ul
ar
 
le
uk
om
al
ac
ia
.
13
4
M
al
e
+
+
Ge
ne
tic
Ch
ro
m
os
om
al
 
ab
er
ra
tio
n 
on
 1
0 
an
d 
12
H
NR
13
5
M
al
e
+
Un
kn
ow
n
Po
lym
icr
og
yr
ia
, lo
ss
 o
f w
hi
te
 
m
at
te
r w
ith
 ve
nt
ric
le
 d
ila
ta
tio
n.
 
Hy
po
m
yle
lin
isa
tio
n
13
6
Fe
m
al
e
+
Un
kn
ow
n
Gl
io
sis
 p
er
ive
nt
ric
ul
ar
, w
hi
te
 an
d 
gr
ey
 m
at
te
r l
os
s
13
8
M
al
e
20
00
36
+
2+
6 
ye
ar
s a
t 
3+
8 
ye
ar
s
Un
kn
ow
n
NR
13
9
M
al
e
21
00
32
+
21
 m
on
th
s a
t 
40
 m
on
th
s
‘P
ur
el
y’ 
ac
qu
ire
d
PV
L
Pe
riv
en
tri
cu
la
r l
eu
ko
m
al
ac
ia
14
2
Fe
m
al
e
34
70
40
+
8-
9 
m
on
th
s a
t 
2+
3 
ye
ar
s
-
Un
kn
ow
n
No
rm
al
14
3
Fe
m
al
e
16
40
30
+
-
‘P
ur
el
y’ 
ac
qu
ire
d
PV
L
Pe
riv
en
tri
cu
la
r l
eu
ko
m
al
ac
ia
14
5
M
al
e
39
50
+
Un
kn
ow
n
No
rm
al
14
6
M
al
e
11
05
31
+
16
-3
3 
m
on
th
s 
at
 3
+6
 ye
ar
s
-
‘P
ur
el
y’ 
ac
qu
ire
d
PV
L
Ve
nt
ric
ul
om
eg
al
y
14
7
M
al
e
+
Un
kn
ow
n
NR
56
Chapter 2.1
a
dd
it
io
na
l fi
le
 1
: P
he
no
ty
pe
 in
fo
rm
at
io
n 
of
 a
ll 
pa
ti
en
ts
 in
vo
lv
ed
, p
ar
t 1
 (c
on
ti
nu
ed
)
ID
M
al
e/
 fe
m
al
e
Bi
rt
h 
we
ig
ht
 
(g
ra
m
)
Ge
st
at
io
na
l 
ag
e
In
te
lle
ct
ua
l 
di
sa
bi
lit
y
De
ve
lo
pm
en
ta
l 
ag
e a
t c
al
en
de
r 
ag
e
he
ar
in
g 
im
pa
irm
en
t
Cl
as
sifi
ca
tio
n
Ge
ne
tic
 
di
ag
no
sis
ri
sk
 
fa
ct
or
M
rI
 ce
re
br
um
 ab
no
rm
al
iti
es
 
(b
as
ed
 o
n 
re
po
rt
s)
Vi
ga
ba
tri
n
14
9
M
al
e
35
00
40
+
-
Hy
dr
oc
ep
ha
lu
s a
nd
/
or
 W
es
t s
yn
dr
om
e
W
Dy
sg
en
es
is,
 p
os
sib
ly 
lis
se
nc
ep
ha
ly
Ye
s
15
2
Fe
m
al
e
13
75
33
+
-
‘P
ur
el
y’ 
ac
qu
ire
d
PV
L, 
S
Pe
riv
en
tri
cu
la
r l
eu
ko
m
al
ac
ia
 an
d 
th
in
 co
rp
us
 ca
llo
su
m
15
6
M
al
e
+
22
 m
on
th
s a
t 
3+
1 
ye
ar
s
-
‘P
ur
el
y’ 
ac
qu
ire
d
T
NR
15
7
Fe
m
al
e
21
95
37
+
11
 m
on
th
s a
t 2
 
ye
ar
s
-
Un
kn
ow
n
De
la
ye
d 
m
ye
lin
at
io
n,
 w
id
e 
ve
nt
ric
le
s
15
8
M
al
e
16
50
38
+
Ac
qu
ire
d
PV
L, 
W
Cy
st
s p
er
ive
nt
ric
ul
ar
Ye
s
15
9
Fe
m
al
e
35
00
37
+
Un
kn
ow
n
No
rm
al
16
1
M
al
e
25
90
39
+
13
 m
on
th
s a
t 
18
 m
on
th
s
+
‘P
ur
el
y’ 
ac
qu
ire
d
P
NR
16
3
Fe
m
al
e
31
00
40
+
IQ
 <
60
-
Un
kn
ow
n
Pr
og
re
ss
ive
 at
ro
ph
y o
f c
er
eb
el
lu
m
16
6
Fe
m
al
e
21
20
34
+
-
‘P
ur
el
y’ 
ac
qu
ire
d
PV
L
Pe
riv
en
tri
cle
s h
ig
h 
sig
na
ls 
in
 
w
hi
te
 m
at
te
r. H
yp
op
la
st
ic 
co
rp
us
 
ca
llo
su
m
17
0
Fe
m
al
e
+
13
-2
0 
m
on
th
s 
at
 6
+4
 ye
ar
s
-
Un
kn
ow
n
Ch
ia
ri 
on
e 
m
al
fo
rm
at
io
n,
 
w
hi
te
 m
at
te
r l
os
s e
n 
w
hi
te
 
m
at
te
r a
bn
or
m
al
iti
es
. D
el
ay
ed
 
m
ye
lin
at
io
n.
17
1
Fe
m
al
e
+
-
Ge
ne
tic
Tr
iso
m
y 2
1
NR
17
2
Fe
m
al
e
29
00
+
-
Ge
ne
tic
Re
tt 
sy
nd
ro
m
e
NR
17
3
Fe
m
al
e
16
60
32
+
3-
4 
m
on
th
s a
t 
2+
5 
ye
ar
s
Ge
ne
tic
Ar
om
at
ic 
de
ca
rb
ox
yla
se
 
de
fic
ie
nc
y
NR
57
Low vision due to CVI: differentiating between acquired and genetic causes
Ch
ap
te
r 2
.1
a
dd
it
io
na
l fi
le
 1
: P
he
no
ty
pe
 in
fo
rm
at
io
n 
of
 a
ll 
pa
ti
en
ts
 in
vo
lv
ed
, p
ar
t 1
 (c
on
ti
nu
ed
)
ID
M
al
e/
 fe
m
al
e
Bi
rt
h 
we
ig
ht
 
(g
ra
m
)
Ge
st
at
io
na
l 
ag
e
In
te
lle
ct
ua
l 
di
sa
bi
lit
y
De
ve
lo
pm
en
ta
l 
ag
e a
t c
al
en
de
r 
ag
e
he
ar
in
g 
im
pa
irm
en
t
Cl
as
sifi
ca
tio
n
Ge
ne
tic
 
di
ag
no
sis
ri
sk
 
fa
ct
or
M
rI
 ce
re
br
um
 ab
no
rm
al
iti
es
 
(b
as
ed
 o
n 
re
po
rt
s)
Vi
ga
ba
tri
n
17
4
Fe
m
al
e
32
+
10
-1
2 
m
on
th
s 
at
 5
+1
0 
ye
ar
s
Hy
dr
oc
ep
ha
lu
s a
nd
/
or
 W
es
t s
yn
dr
om
e
H
NR
17
5
Fe
m
al
e
+
-
Ge
ne
tic
D2
-h
yd
ro
xy
gl
ut
a-
ar
ac
id
ur
ia
NR
17
6
M
al
e
+
IQ
 4
8
-
Un
kn
ow
n
No
rm
al
17
8
M
al
e
+
Un
kn
ow
n
No
rm
al
17
9
Fe
m
al
e
25
75
41
+
7 
m
on
th
s a
t 
3+
4 
ye
ar
s
+
‘P
ur
el
y’ 
ge
ne
tic
Tr
iso
m
y 2
1
NR
18
0
Fe
m
al
e
29
00
42
+
1+
3 
ye
ar
s a
t 1
1 
ye
ar
s
-
Un
kn
ow
n
Pa
ch
yg
yr
ia
 an
d 
w
hi
te
 m
at
te
r 
ab
no
rm
al
iti
es
18
1
Fe
m
al
e
30
25
39
+
-
Un
kn
ow
n
Le
ss
 m
ye
lin
at
io
n,
 co
rp
us
 ca
llo
su
m
 
ag
en
es
is,
 w
id
e 
po
st
er
io
r h
or
ns
18
4
Fe
m
al
e
30
00
39
+
-
‘P
ur
el
y’ 
ge
ne
tic
In
fa
nt
ile
 
ne
ur
oa
xo
na
l 
dy
st
ro
ph
y
NR
18
5
M
al
e
+
13
 m
on
th
s a
t 
4+
3 
ye
ar
s
-
Un
kn
ow
n
Ho
lo
pr
os
en
ce
ph
al
y
18
7
M
al
e
41
+
Un
kn
ow
n
Ce
re
br
al
 n
ec
ro
sis
, w
ith
 su
bc
or
tic
al
 
cy
st
ic 
le
uk
om
al
ac
ia
, n
ec
ro
sis
 an
d 
at
ro
ph
y i
n 
th
al
am
us
 an
d 
st
ria
tu
m
.
18
8
M
al
e
+
2 
ye
ar
s a
t 3
 
ye
ar
s
-
‘P
ur
el
y’ 
ac
qu
ire
d
S
Bi
la
te
ra
l h
em
or
ra
gh
es
, c
ys
tic
 
le
uc
oe
nc
ep
ha
lo
pa
th
y
18
9
Fe
m
al
e
+
-
Ac
qu
ire
d
H,
 I
NR
58
Chapter 2.1
a
dd
it
io
na
l fi
le
 1
: P
he
no
ty
pe
 in
fo
rm
at
io
n 
of
 a
ll 
pa
ti
en
ts
 in
vo
lv
ed
, p
ar
t 1
 (c
on
ti
nu
ed
)
ID
M
al
e/
 fe
m
al
e
Bi
rt
h 
we
ig
ht
 
(g
ra
m
)
Ge
st
at
io
na
l 
ag
e
In
te
lle
ct
ua
l 
di
sa
bi
lit
y
De
ve
lo
pm
en
ta
l 
ag
e a
t c
al
en
de
r 
ag
e
he
ar
in
g 
im
pa
irm
en
t
Cl
as
sifi
ca
tio
n
Ge
ne
tic
 
di
ag
no
sis
ri
sk
 
fa
ct
or
M
rI
 ce
re
br
um
 ab
no
rm
al
iti
es
 
(b
as
ed
 o
n 
re
po
rt
s)
Vi
ga
ba
tri
n
19
2
Fe
m
al
e
32
50
40
+
-
‘P
ur
el
y’ 
ge
ne
tic
Pi
tt-
Ho
pk
in
s 
sy
nd
ro
m
e
W
id
e 
pe
rip
he
ra
l li
qu
or
 ar
ea
s a
nd
 
Vi
rc
ho
w
-R
ob
in
 sp
ac
es
 in
 th
e 
ba
sa
l 
ga
ng
lia
, m
in
im
al
 ce
re
br
al
 at
ro
ph
y
19
4
M
al
e
29
80
38
+
-
Un
kn
ow
n
No
rm
al
Ye
s
19
9
Fe
m
al
e
+
‘P
ur
el
y’ 
ac
qu
ire
d
CO
M
Po
ss
ib
le
 p
os
te
rio
r i
nf
ar
ct
io
n 
le
ft,
 
hy
pe
rin
te
ns
ity
 o
f l
en
tif
or
m
 n
uc
le
us
20
0
M
al
e
35
55
40
+
Un
kn
ow
n
Hy
pe
rtr
op
hi
c l
ef
t h
em
isp
he
re
, 
se
co
nd
ar
y a
tro
ph
y
20
2
Fe
m
al
e
+
-
Un
kn
ow
n
NR
20
3
M
al
e
35
20
40
+
Un
kn
ow
n
NR
20
5
M
al
e
32
00
35
+
-
Un
kn
ow
n
Hy
pe
rin
te
ns
e 
le
as
io
ns
 
pe
riv
en
tri
cu
la
r o
cc
ip
ita
l w
hi
te
 
m
at
te
r, m
ild
 ce
re
be
lla
r a
tro
ph
y
20
7
Fe
m
al
e
19
80
32
+
-
Un
kn
ow
n
NR
20
8
M
al
e
28
95
40
+
12
 m
on
th
s a
t 
3+
3 
ye
ar
s
Un
kn
ow
n
Co
rp
u 
ca
llo
su
m
 ag
en
es
is,
 
hy
po
pl
as
tic
 ce
re
be
lla
r v
er
m
is
21
0
M
al
e
+
‘P
ur
el
y’ 
ac
qu
ire
d
T
NR
21
1
Fe
m
al
e
+
5 
ye
ar
s a
t 6
 
ye
ar
s
Un
kn
ow
n
Gl
io
sis
, m
ai
nl
y o
cc
ip
ita
l in
 cl
ac
ar
in
’s 
fis
su
re
 ti
ll c
en
tra
l fi
ss
ur
e 
an
d 
fro
nt
al
 
gy
ru
s. 
Al
so
 g
lio
sis
 in
 cr
an
ia
l v
er
m
is 
an
d 
ce
re
be
lla
r c
or
te
x. 
Ul
eg
yr
ia
21
2
Fe
m
al
e
24
40
36
+
Un
kn
ow
n
Dy
sp
la
st
ic 
co
rp
us
 ca
llo
su
m
, w
id
e 
ve
nt
ric
le
s, 
ab
no
rm
al
 ce
re
be
lla
r 
pe
du
nc
le
s.
59
Low vision due to CVI: differentiating between acquired and genetic causes
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additional file 2: ocular findings in individuals with a normal or abnormal MrI scan of the brain
normal MrI (n=28) abnormal MrI (n=178)
raw
p-value
Mean age most recent examination 
(months)
76 (SD 70) 61 (SD 48) 0.364
affected n/ available n affected n/ available n
Men 17/28 (61%) 94/178 (53%) 0.542
Vigabatrin use 4/28 (14%) 30/178 (17%) 1.000
Myopia <-4 0/28 (0%) 5/178 (3%) 1.000
Hypermetropia >+4 3/28 (11%) 16/178 (9%) 0.728
Visual acuity <0.05 or <1.6 cycles/
cm at 55 cm
5/28 (18%) 41/178 (23%) 0.663
Strabismus 18/27 (67%) 136/171 (80%) 0.141
Nystagmus 6/26 (23%) 73/155 (47%) 0.031
Visual field defect 11/22 (50%) 91/146 (62%) 0.349
Hemianopia  3/11  16/91 -
Upper or lower visual field defect  4/11  20/91 -
Constriction of visual field  4/11  55/91 -
(Partial) pale optic disc 4/28 (14%) 82/169 (49%) 0.001*
*p-Values in bold represent differences that passed the Benjamini–Hochberg criterion.

2.2
Chromosomal aberrations in cerebral visual 
impairment
Daniëlle G.M. Bosch, F. Nienke Boonstra, Margot R.F. Reijnders, Rolph Pfundt, 
Frans P.M. Cremers, Bert B.A. de Vries.
Eur J Paediatr Neurol 2014; 18: 677-684.
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Background Cerebral visual impairment (CVI) is a disorder in projection and/or interpretation 
of the visual input in the brain and accounts for 27% of the visually impaired children.
Aim A large cohort of patients with CVI was investigated in order to ascertain the relevance of 
chromosomal aberrations in the aetiology of this disorder.
Methods 607 patients with CVI and a visual acuity ≤0.3 were assessed for the presence of 
a chromosomal aberration retrospectively. The observed aberrations were classified for 
pathogenicity.
Results A total of 98 chromosomal aberrations were found in 79 persons (13%) of the cohort.
In nine persons it was not possible to classify the clinical implication of the aberration, due 
to lack of detailed information. In 70 persons it was possible to classify the aberration for 
causality: in 41 patients the aberration was associated with CVI, in 16 it was unknown and in 
13 the aberration was unlikely to be associated with CVI. For four aberrations, present in 26 
patients, the association with CVI has been reported before: trisomy 21, 1p36 deletion syn-
drome, 17p13.3 deletion syndrome (Miller-Dieker syndrome) and 22q13.3 deletion syndrome 
(Phelan-McDermid syndrome). The chromosomal aberrations in another 15 patients were for 
the first time associated with CVI.
Conclusions Chromosomal aberrations associated with CVI were found in 7% (41/607) of pa-
tients, of which 37% (15/41) have not been reported before in association with CVI. Therefore, 
in patients with CVI chromosomal investigations should be routinely performed to warrant a 
good clinical diagnosis and counselling.
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InTroDuCTIon
Cerebral visual impairment (CVI) is one of the major causes of visual impairment in the 
developed world, as it accounts for 27% of low vision in childhood.53,55 It includes all visual 
dysfunctions caused by damage to, or malfunctioning of, the retrochiasmatic pathways in the 
absence of damage to the anterior visual pathways or any major ocular disease.49,51 CVI is di-
agnosed when no ocular abnormality can explain the impairment in vision. This impairment 
can consist of a reduced visual acuity, and/or visual field defects.47 Furthermore, there can be 
an abnormal visual behaviour, such as staring into light or delayed fixation. Deficits in higher 
perceptual functions, for example difficulties with recognition of objects and faces, or visio-
spatial disorders can occur, and are sometimes the only features of CVI.46,50,85 The prevalence 
of persons with CVI without a severe visual acuity loss or visual field defects is unknown.
An important cause of CVI is acquired damage to the brain, mainly the result of perinatal 
problems, such as cerebral haemorrhage or periventricular leukomalacia. Cerebral damage 
during the prenatal (e.g. congenital CMV infection), neonatal (e.g. hypoglycaemia) and child-
hood (e.g. meningitis or head trauma) period are less frequent causes of CVI.47 Furthermore, 
West syndrome and hydrocephalus can result in CVI.115,116,223 So far, less attention has been 
paid to genetic causes of CVI, although several neurodegenerative causes have been de-
scribed.62
CVI is often part of a more complex phenotype, consisting of intellectual disability, 
epilepsy and/or deafness.51,79,224 Recently, the awareness is growing that CVI is common in 
intellectual disability and in a large cohort of 923 patients with intellectual disability visual 
impairment due to CVI was present in 5%.225 In patients with intellectual disability a causative 
chromosomal aberration can be found in about 5-30%, depending on the resolution of the 
technique used and the cohort selected.138,144,152,226,227 Since 1970 karyotype analysis has 
been used to detect chromosomal aberrations larger than 5 Mb, but since the introduction 
of array-based comparative genomic hybridization (array CGH) techniques around ten years 
ago, the resolution increased significantly allowing the detection of causative aberrations 
as small as 20 kb. Besides intellectual disability also other neurocognitive disorders, such as 
autism and schizophrenia, can be caused by chromosomal aberrations.228 Moreover, recently, 
deletions of 5q15 including the NR2F1-gene were described to cause CVI.191 This initiated our 
study to ascertain to what extend chromosomal aberrations can be the underlying cause 
of CVI. Here we provide an overview of the chromosomal aberrations found in the largest 
cohort of patients with CVI described so far.
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All patients diagnosed with CVI were seen and tested in Bartiméus, an institute for diagnostics, 
rehabilitation and schooling of the visually impaired in the Netherlands. CVI was diagnosed 
by a paediatric ophthalmologist under the following criteria: no other ocular diagnosis which 
could explain the visual impairment or visual field defect, and/or typical features such as poor 
fixation or crowding, and/or CVI found at neuropsychological investigation. Neuropsycho-
logical investigation was, however, not possible in a majority of the individuals, because of 
their developmental age. The individuals with CVI included in this study underwent their first 
ophthalmological examinations between 1-1-1993 and 1-1-2013. Additional inclusion crite-
ria were low vision, defined as a visual acuity of ≤0.3 or <9.8 cycles/cm at 55 cm or a visual 
field of 30° or below.53 Under the age of three the visual acuity was measured by Teller Acuity 
Cards and defined as decreased, when the cycles/degree were below the standard deviation 
reported by Courage and Adams.196 Visual acuity in young children or in individuals with a 
young developmental age was measured by preferential looking (Teller Acuity Cards, 55 cm), 
Cardiff cards (1 m), picture optotypes (mainly LH Symbols at 3 m), or number optotypes (6 m). 
The confrontational method with white Stycar balls, 5 cm in diameter, was used to estimate 
the visual field. Exclusion criterion was a second ocular diagnosis causing low vision, such 
as cataract, retinopathy of prematurity, congenital nystagmus, or primary (hereditary) optic 
atrophy. All medical correspondence of the patients with CVI was screened for chromosomal 
investigations. For all patients with a chromosomal aberration the available clinical data were 
screened for risk factors for CVI, which are perinatal problems, periventricular leukomalacia, 
stroke, West syndrome, hydrocephalus, hypoglycaemia or a gestational age <37 weeks. In ad-
dition, the results of the most recent ophthalmologic examination were collected, including 
binocular visual acuity, visual fields, strabismus, nystagmus, refraction error and the appear-
ance of the optic disc. All chromosomal aberrations were classified for pathogenicity for CVI 
according to an adapted workflow of Koolen et al. (Figure 1).144 The database of genomic 
variants (http://dgv.tcag.ca/dgv/app/home) was used to filter against common variants. 
When no cerebral damage or other risk factor was found to explain CVI it was assumed that 
the chromosomal aberration was possibly associated with CVI.
resulTs
Of the 607 individuals with CVI and a visual acuity of ≤0.3, 197 (32%) had undergone chromo-
somal investigations, either karyotype analysis (n=109 ) or array CGH (n=75). In 13 patients 
the method was not specified. In 79 patients (79/607, 13%) 98 aberrations were found 
(Supplementary Table 1). The phenotype of these patients is described in Supplementary 
Table 2. Three patients (patients 12, 41 and 45) have been reported previously.229-231 For ten 
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aberrations it was not possible to obtain the exact breakpoints of the aberration. In addition, 
the clinical interpretation proved to be difficult for four aberrations. First, a del(22)(p11.1) 
deletion, patient 1, this region contains no genes and was therefore not classified. Secondly, 
a small duplication dup(6)(p25.3p25.2) in patient 47 was of unknown inheritance. This gain 
contains partly the GMDS-gene, GDP-mannose 4,6-dehydratase. It is unknown whether this 
duplication disrupts the GMDS-gene, therefore the duplication could not be classified. Lastly, 
two duplications on chromosome X in two girls, patient 59 and 60, were not classified, be-
cause detailed phenotype information and the X-inactivation profile was lacking.
The remaining 84 aberrations, consisting of three structural aberrations without evidence 
for aneuploidy, 23 whole chromosome aberrations, and 58 partial chromosomal aberrations, 
were classified for causality according to the workflow (Figures 1 and 2).
CVI previously reported? 
Unlikely to be associated 
n=16
Unknown whether 
n=22
Associated with CVI
n=46
Common chromosomal aberration?
1) Internal dataset of normal controls
2) Publically available datasets of normal controls
Segregates with the phenotype?
Risk factors for CVI* or unknown birth term?
Yes 
n=1
No
n=20
Yes 
n=26
Yes/ unknown
n=42
No
n=15
Yes
n=22
Chromosomal aberration
n=84
No
n=57
No 
n=83
with CVIassociated with CVI
figure 1: Workflow for the decision making of chromosomal aberrations in individuals with cerebral 
visual impairment.
 *These risk factors are a gestational age <37 weeks, hypoglycaemia, hydrocephalus, meningitis/encephali-
tis, perinatal problems, periventricular leukomalacia, stroke and West syndrome.
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Unlikely to be associated with CVI
16 chromosomal aberrations were classified as unlikely to be associated with CVI (Figure 1). 
One aberration (patient 61) was reported several times in normal controls in the database of 
genomic variants. The other 15 aberrations did not segregate with the CVI phenotype, either 
inherited from an unaffected parent (n=11), not present in a similarly affected sib (n=2), or 
was not fitting with the phenotype reported in literature (n=2, patient 72 and 73). Patient 72 
had a trisomy X. However, she was known with a pontocerebellar hypoplasia type 2, leading 
Associated with CVI
Unknown whether associated with CVI 
Unlikely to be associated with CVI
4
1 2 3 4 5 6 7 8
13 14 15 16 17
49
65
9
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1 433 542
62
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63*
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50
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52
64 7
54
55
66
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55
8
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11*
13
2 2
7
50
2
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16
18
48
N
14
40
68
69
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70
69
72 73
6
46
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61*
44
9 10 11 12
22 X Y
12
18 19 20 21
figure 2: overview of the chromosomal aberrations reported in patients with CVI.
Copy number losses are depicted on the left-hand side and copy number gains on the right-hand side of 
the chromosomes by coloured bars. Underlined numbers indicate that more than one aberration was pres-
ent in the patient. 11* mosaic triplication, 45* mosaic triplication, 61* triplication, 63* partially duplicated 
and partially triplicated. N: patients 19, 20, 21, 22, 23, 24, 25, 26, 27, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, and 
39 had a trisomy 21, and 28 mosaic trisomy 21.
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to the conclusion that the triple X was a coincidental finding and probably not associated 
with CVI. In patient 73 a duplication of Y was present, which results in no or only a mild 
phenotype not related to CVI, and was therefore also considered as a coincidental finding, 
unlikely to be associated with CVI. Those 16 aberrations were present in 14 patients. However, 
patient 46 had three aberrations, of which one, a deletion del(6)(q14.1), was inherited and 
classified as unlikely to be associated, but the two other deletions del(5)(q14.3) and del(6)
(q25.3), proved to be de novo and classified as unknown. In total, in 13 individuals all the 
aberrations found, were classified as unlikely to be associated with CVI.
Unknown whether associated with CVI
22 chromosomal aberrations were classified as unknown (Figure 1). The chromosomal aberra-
tions were not present in a dataset of normal controls and did segregate with the phenotype, 
but there were other factors present that might have caused the CVI. These other factors con-
sist of West syndrome, hydrocephalus, perinatal problems, stroke, meningitis/encephalitis, 
and hypoglycaemia (n=13). In addition, when the gestational age was unknown (n=7) or <37 
weeks (n=2) the aberration was classified as unknown. Those 22 aberrations were present in 
17 patients. However, patient 14 had a duplication dup(15)(q15) of unknown causality and a 
deletion del(22)(q13.3), which is associated with CVI, resulting in 16 patients in which it was 
unknown whether the aberration found caused CVI.
Associated with CVI
46 chromosomal aberrations in 41 patients were associated with CVI (Figure 1, Table 1). CVI 
was previously reported in 26 patients and CVI was associated with the chromosomal aberra-
tion in another 15 patients. These aberrations were not present in a dataset of normal controls 
and segregated with the phenotype. Moreover, no other factors that could have caused CVI 
were present and the patients had a normal gestational age, rendering the chromosomal 
aberrations likely to be associated with CVI.
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Table 1: Description of persons with a chromosomal aberration associated with CVI
Pt Chromosomal aberration Male/ 
female
Ga
(weeks)
ID MrI brain report epilepsy other 
factor
1 del(1)(p36.3)* F 40 + + P
2 del(15)(q24.3q25)
dup(2)(q37.3)
del(2)(q37.3)
M 37 + Minor aspecific abnormalities 
occipital
-
3 del(4)(p15) F 40 +
4 del(4)(q28.3q31.1) M AT + Small area with low signal 
density left temporal in optic 
radiation, probably cavernous 
haemangioma.
5 del(5)(p13) M 37 + Normal -
6 del(5)(q35) F 40 + Small choroid plexus cyst -
7 del(9)(p),
dup(13)(q)
M 41 + +
8 dup(9)(q34), dup(15)(q13) M 42 + -
9 del(10)(p12.33p12) F 40 - Normal -
10 dup(11)(q23.3)
del(12)(q24.3)
M 40 + -
11 Tetrasomy 12p M 37 + +
12 dup(12)(p13.1q11) F 38 + Normal -
13 dup(12)(q21.1q21.2) M 40 +
14 dup(15)(q15)
del(22)(q13)
F + -
15 del(17)(p13.3)* F 43 + Lissencephaly +
16 del(17)(p13.3)* M 40 + Lissencephaly +
17 dup(17)(q) M 39 +
18 del(18)(q) M 38 + -
40 del(22)(q13.3)* F + Normal - G
41 Ring X,45X/46,X F 39 + -
19 Trisomy 21* M + -
20 Trisomy 21* M + -
21 Trisomy 21* M +
22 Trisomy 21* F + -
23 Trisomy 21* F 41 + +
24 Trisomy 21* M 39 + Normal +
25 Trisomy 21* M 40 +
26 Trisomy 21* M + -
27 Trisomy 21* M 39 + -
28 Trisomy 21*, mosaic M 39 + -
29 Trisomy 21* F 39 +
30 Trisomy 21* M 39 + - P
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DIsCussIon
In our cohort of 607 patients with CVI only 32% had a reported chromosome testing, which 
probably reflects an underestimation as normal results may not always have been registered 
properly. In 13% a chromosomal aberration was found, mainly by classical karyotyping 
which has a lower resolution than novel array CGH techniques (5 Mb versus down to 20 kb). 
After classification, the chromosomal aberrations were considered associated with CVI in 7% 
(41/607), unknown in 3% (16/607), and unlikely to be associated with CVI in 2% (13/607) of 
the patients. All patients with a chromosomal aberration in this cohort were intellectually 
disabled. The association between the severity of the intellectual disability and a higher risk 
for low vision has been reported before, however, the majority of individuals with intellectual 
disability do have normal visual acuity.225
Aberrations with known associations with CVI
In four of the aberrations, CVI has been reported previously, even though in medical literature 
results of ophthalmological examination, especially visual acuity measurement or assessment 
for CVI, are sparsely reported. The most often found aberration in our CVI cohort was trisomy 
21 in 21 patients, which has a known association with CVI.130-132 A lower visual acuity in Down 
syndrome might be explained by accommodation problems, which is present in a majority 
of individuals with Down syndrome.131 Bifocals improve the near visual acuity (15-40 cm), but 
not the distance visual acuity (3 m).232,233 Whether poor accommodation played a role in the 
visual acuity measurement at 55cm in our cohort is unknown. Nevertheless, the low vision in 
Down syndrome patients cannot be completely attributed to poor accommodation or other 
ophthalmological abnormalities.130-132,234 Supporting evidence for visual cortex malfunction 
Table 1: Description of persons with a chromosomal aberration associated with CVI (continued)
Pt Chromosomal aberration Male/ 
female
Ga
(weeks)
ID MrI brain report epilepsy other 
factor
31 Trisomy 21* M 37 +
32 Trisomy 21* M 28 + -
33 Trisomy 21* M +
34 Trisomy 21* M + -
35 Trisomy 21* M 40 -
36 Trisomy 21* M +
37 Trisomy 21* M 38 + -
38 Trisomy 21* M + -
39 Trisomy 21* M 32 + -
AT=at term, G=hypoglycaemia, GA= gestational age, ID=intellectual disability, P=perinatal problems. *Indi-
cates that CVI has been reported previously in this aberration.
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has been found by Vernier acuity measurements and steady state and sweep visual evoked 
potentials in combination with behavioural testing.130,234
In another two patients (patients 15 and 16) a deletion del(17)(p13.3) was present, causing 
Miller-Dieker syndrome. The main feature of this syndrome is lissencephaly and it is caused 
by the haploinsufficiency of the LIS1-gene.211,235 In a study by Nabi et al. in 20 patients with 
Miller-Dieker syndrome, one patient was diagnosed with CVI,211 making the lissencephaly 
associated with CVI in both patients.
A deletion del(22)(q13.3), identified in two other patients (patients 14 and 40), leads to 
Phelan-McDermid syndrome. This syndrome presents with neonatal hypotonia, intellectual 
disability and dysmorphism.236 CVI has been observed in about 6% of the patients with this 
syndrome, but it is most likely still underdiagnosed.236
The last known syndromal association with CVI was the 1p36.3 deletion syndrome, present 
in patient 1. This clinically recognizable syndrome with intellectual disability and structural 
brain abnormalities is characterized by typical facial features, including straight eyebrows, 
deep set eyes, midface hypoplasia, broad and flat nasal root/bridge, long philtrum, and 
pointed chin.128,129 In literature CVI features like visual inattentiveness, such as absence of 
attentive visual behaviour with fixation and following movements are present in 30%-64% 
of the patients.128,129 However, visual acuity assessment was not mentioned in those reports.
Aberrations newly associated with CVI
There were 15 patients with 20 chromosomal aberrations that have not been associated with 
CVI so far. In seven patients these aberrations caused well-know OMIM (Online Mendelian 
Inheritance in Man) annotated syndromes (http://www.ncbi.nlm.nih.gov/omim) and those 
syndromes will be discussed more extensively.
The first OMIM-annotated syndrome is Wolf-Hirschhorn syndrome (OMIM #194190), caused 
by 4p-deletion. This recognizable syndrome features intellectual disability, microcephaly, a 
Greek warrior helmet appearance of the nose, epilepsy and growth delay.237 In our cohort a 
4p-deletion was identified in patients 3, 44 and 45. For patient 44 and 45 it remained unknown 
whether the chromosomal aberration was related to CVI, because in patient 44 the gestational 
age was unknown and patient 45 had West syndrome. In patient 3, however, there was no other 
possible explanation for CVI. In literature 20 patients with Wolf-Hirschhorn syndrome have been 
reported, who underwent investigation for ocular abnormalities. However, the visual acuity nor 
assessment for cerebral visual impairment were reported.238,239
The 9p-deletion syndrome (OMIM #158170) was identified in four persons. This syndrome is 
characterized by intellectual disability, hypotonia, dysmorphic facial features, such as trigono-
cephaly, midface hypoplasia, and a long philtrum.240,241 For one patient (patient 7) the deletion 
was associated with CVI, whereas for the three others (patients 54, 55 and 65) other possible 
contributive factors might have played a role. There are several reports of patients with a 9p-
deletion, however, ophthalmological examination has not been described.240,241
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A 5p deletion leading to cri du chat syndrome (OMIM #123450) was identified in a single 
patient (patient 5). The key feature of this syndrome is a typical high-pitch cat-like cry, and 
is present when the deletion comprises the cytogenetic band “5p15.3”. Patients with a dele-
tion comprising the cytogenetic band “5p15.2” have distinct facial dysmophisms, strabismus, 
microcephaly, pre- and postnatal growth deficiency, and intellectual disability.242,243 The ocular 
phenotype may consist of divergent strabismus, myopia and cataract.
Another OMIM-annotated syndrome identified in patient 11: a mosaic tetrasomy 12p, 
causing the Pallister-Killian syndrome (OMIM #601803). Patients with this syndrome have intel-
lectual disability, pigmentary skin abnormalities, congenital malformations, and craniofacial 
dysmorphisms, including bitemporal alopecia and hypertelorism.244 In Pallister-Killian syn-
drome several ocular disorders have been described, such as strabismus, nystagmus, cataract 
and optic nerve atrophy but no CVI, so far.245
A deletion on chromosome 5, del(5)(q35), including the NSD1-gene, was identified in patient 
6. Deletion of and mutations in this gene cause Sotos syndrome (OMIM #117550), that is char-
acterized by overgrowth resulting in tall stature and macrocephaly. Furthermore, learning dis-
ability and a characteristic facial appearance consisting of a high broad forehead and a pointed 
chin are present in more than 90% of the affected.246 So far, no large scale ophthalmological 
study in a cohort of Sotos patients has been performed, but astigmatism, myopia, cataract, 
delayed visual maturation, and nystagmus have been described.246
One patient (patient 2) had three aberrations, a deletion on chromosome 2 del(2)(q37.3), 
a duplication on chromosome 2dup(2)(q37.3) and a deletion on chromosome 15 del(15)
(q24.3q26). The latter deletion comprises the cytogenetic bands 15q25.2 and 15q25.3 which 
have been reported to cause a rather variable phenotype (OMIM #614294).247 One reported 
patient inherited the deletion from a normal parent; however, ophthalmological examination 
is not described.
A deletion on the long arm of chromosome 18, overlapping the 18q22.3q23 region, was 
identified in patient 18, which led to the De Grouchy syndrome (OMIM #601808). The features 
of this syndrome are intellectual disability, short stature, delayed myelination, congenital aural 
atresia, foot deformities, and dysmorphism including midface hypoplasia, hypertelorism and 
microcephaly.248 There is only one report of a girl with severe epilepsy, optic atrophy and visual 
loss.249
In summary, in our large cohort of patients with CVI, chromosomal aberrations are associated 
with CVI in 7%. Further, we were able to associate several chromosomal regions with CVI for 
the first time. Our study warrants chromosomal investigations in patients with CVI, because 
identifying the underlying cause is of great value for patients and his/her family and ensures 
the best clinical care for the patient. When more aberrations will be found in CVI this may 
further narrow down the candidate regions identified and may even lead to candidate genes 
which will eventually lead to an increased understanding of the development and function of 
the visual system.
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supplementary Table 2: Phenotype of patients with CVI and a chromosomal aberration
Patient 1 2 3 4 5 6 7 8 9
Male/ Female F M F M M F M M F
Gestational age (weeks) 40 37 40 AT 37 40 41 42 40
Birth weight (gram) 2200 3325 2080 2650 2100 2170 3800 3340 2500
Intellectual disability + + + + + + + + -
Developmental age at 
calender age
9 months at 2+3 years 3+1 years at 5 years IQ 77-89
MRI cerebrum 
abnormalities (based on 
reports)
Minor aspecific 
abnormalities occipital
Small area with 
low signal density 
left temporal in 
optic radiation, 
probably cavernous 
haemangioma.
Normal Small choroid plexus 
cyst
Normal
Epilepsy + - - - + - -
Hearing impairment - - - - - - + -
Other Factor P
Age at investigation 
(years)
4 3+11 16 36 6 4 9 months 10 33
Refraction OD S+3.00=C-1.75x160” S+5.50=C-2.00x180” S+6.25=C-0.50x131” S+1.00 S+8.50 S+2.00=C-5.00x180” S-0.50=C-0.50x180” S-0.50=C-1.25x100”
Refraction OS S+3.00=C-1.75x175” S+5.50=C-2.00x180” S+6.25=C-0.50x131” S-1.00 S+9.00 S+1.00=C-4.00x180” S-0.75 S-1.75=C-1.75x90”
Correction - - - + - + - -
Vision 20/94 (0.2) 2/15 (0.13) 20/190 (0.10) 5/25 (0.2) 20/130 (0.15) 20/130 (0.15) LP 6/24 (0.25) 5/38 (0.13)
Method TAC (55 cm) LH (2 m) TAC (55 cm) Landolt C 5 m TAC (55 cm) TAC (55 cm) Numbers (6 m) Landolt C (5 m)
Visual field defects + - - + - + +
Strabismus + - + + + + + + -
Nystagmus + - - - - + - - -
(Partial) optic disc pallor - - - + - - - - -
Fluctuating visual 
performances
+ + +
G=hypoglycaemia, H=hydrocephalus, LH= Lea Hyvarinen, LP =light perception, M=meningitis/encephalitis,  
P=perinatal problems , S=stroke, TAC= Teller Acuity Cards, W=West syndrome.
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supplementary Table 2: Phenotype of patients with CVI and a chromosomal aberration
Patient 1 2 3 4 5 6 7 8 9
Male/ Female F M F M M F M M F
Gestational age (weeks) 40 37 40 AT 37 40 41 42 40
Birth weight (gram) 2200 3325 2080 2650 2100 2170 3800 3340 2500
Intellectual disability + + + + + + + + -
Developmental age at 
calender age
9 months at 2+3 years 3+1 years at 5 years IQ 77-89
MRI cerebrum 
abnormalities (based on 
reports)
Minor aspecific 
abnormalities occipital
Small area with 
low signal density 
left temporal in 
optic radiation, 
probably cavernous 
haemangioma.
Normal Small choroid plexus 
cyst
Normal
Epilepsy + - - - + - -
Hearing impairment - - - - - - + -
Other Factor P
Age at investigation 
(years)
4 3+11 16 36 6 4 9 months 10 33
Refraction OD S+3.00=C-1.75x160” S+5.50=C-2.00x180” S+6.25=C-0.50x131” S+1.00 S+8.50 S+2.00=C-5.00x180” S-0.50=C-0.50x180” S-0.50=C-1.25x100”
Refraction OS S+3.00=C-1.75x175” S+5.50=C-2.00x180” S+6.25=C-0.50x131” S-1.00 S+9.00 S+1.00=C-4.00x180” S-0.75 S-1.75=C-1.75x90”
Correction - - - + - + - -
Vision 20/94 (0.2) 2/15 (0.13) 20/190 (0.10) 5/25 (0.2) 20/130 (0.15) 20/130 (0.15) LP 6/24 (0.25) 5/38 (0.13)
Method TAC (55 cm) LH (2 m) TAC (55 cm) Landolt C 5 m TAC (55 cm) TAC (55 cm) Numbers (6 m) Landolt C (5 m)
Visual field defects + - - + - + +
Strabismus + - + + + + + + -
Nystagmus + - - - - + - - -
(Partial) optic disc pallor - - - + - - - - -
Fluctuating visual 
performances
+ + +
G=hypoglycaemia, H=hydrocephalus, LH= Lea Hyvarinen, LP =light perception, M=meningitis/encephalitis,  
P=perinatal problems , S=stroke, TAC= Teller Acuity Cards, W=West syndrome.
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supplementary Table 2: Phenotype of patients with CVI and a chromosomal aberration (continued)
Patient 10 11 12 13 14 15 16 17 18
Male/ Female M M F M F F M M M
Gestational age (weeks) 40 37 38 40 43 40 39 38
Birth weight (gram) 3000 3500 3205 2860 3425 2750
Intellectual disability + + + + + + + + +
Developmental age at 
calender age
2 years at 8 years 12-15 months at 17 years 1+2 years at
1+8 years
MRI cerebrum 
abnormalities (based on 
reports)
Normal Lissencephaly Lissencephaly
Epilepsy - + - + - + + -
Hearing impairment - - - - - - +
Other Factor
Age at investigation 
(years)
8 8 16 17 12 5 7 7 8
Refraction OD S+3.50 S+4.50=C-2.50x170” S-6.00 S+2.00=C-0.50x90” S+5.00=C-2.00x180” S+1.00 S+3.00=C-1.00x180” S+1.00=C-1.00x180”
Refraction OS S+2.50 S+3.00=C-1.25x30” S-6.00 S+1.50 S+5.00=C-2.00x180” S+3.00 S+3.5=C-0.50x180” S+1.75=C-0.75x180”
Correction - - - - - - - -
Vision 20/190 (0.10) 20/150 (0.13) 20/63 (0.3) 20/260 (0.08) 20/300 (0.07) 20/150 (0.13) 20/1900 (0.01) 20/190 (0.10) 20/200 (0.10)
Method TAC (55 cm) TAC (38 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (38 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm)
Visual field defects - - + - + - -
Strabismus + + + + + + + + +
Nystagmus + + - - - - - +
(Partial) optic disc pallor - - - + - - - - -
Fluctuating visual 
performances
+ +
G=hypoglycaemia, H=hydrocephalus, LH= Lea Hyvarinen, LP =light perception, M=meningitis/encephalitis,
P=perinatal problems , S=stroke, TAC= Teller Acuity Cards, W=West syndrome.
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supplementary Table 2: Phenotype of patients with CVI and a chromosomal aberration (continued)
Patient 10 11 12 13 14 15 16 17 18
Male/ Female M M F M F F M M M
Gestational age (weeks) 40 37 38 40 43 40 39 38
Birth weight (gram) 3000 3500 3205 2860 3425 2750
Intellectual disability + + + + + + + + +
Developmental age at 
calender age
2 years at 8 years 12-15 months at 17 years 1+2 years at
1+8 years
MRI cerebrum 
abnormalities (based on 
reports)
Normal Lissencephaly Lissencephaly
Epilepsy - + - + - + + -
Hearing impairment - - - - - - +
Other Factor
Age at investigation 
(years)
8 8 16 17 12 5 7 7 8
Refraction OD S+3.50 S+4.50=C-2.50x170” S-6.00 S+2.00=C-0.50x90” S+5.00=C-2.00x180” S+1.00 S+3.00=C-1.00x180” S+1.00=C-1.00x180”
Refraction OS S+2.50 S+3.00=C-1.25x30” S-6.00 S+1.50 S+5.00=C-2.00x180” S+3.00 S+3.5=C-0.50x180” S+1.75=C-0.75x180”
Correction - - - - - - - -
Vision 20/190 (0.10) 20/150 (0.13) 20/63 (0.3) 20/260 (0.08) 20/300 (0.07) 20/150 (0.13) 20/1900 (0.01) 20/190 (0.10) 20/200 (0.10)
Method TAC (55 cm) TAC (38 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (38 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm)
Visual field defects - - + - + - -
Strabismus + + + + + + + + +
Nystagmus + + - - - - - +
(Partial) optic disc pallor - - - + - - - - -
Fluctuating visual 
performances
+ +
G=hypoglycaemia, H=hydrocephalus, LH= Lea Hyvarinen, LP =light perception, M=meningitis/encephalitis,
P=perinatal problems , S=stroke, TAC= Teller Acuity Cards, W=West syndrome.
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supplementary Table 2: Phenotype of patients with CVI and a chromosomal aberration (continued)
Patient 19 20 21 22 23 24 25 26 27
Male/ Female M M M F F M M M M
Gestational age (weeks) 41 39 40 39
Birth weight (gram) 2575 3415 3500 2800
Intellectual disability + + + + + + + + +
Developmental age at 
calender age
7 months at 3+4 years 2 months at 10 months 1+6 years at
3+10 years
MRI cerebrum 
abnormalities (based on 
reports)
Normal
Epilepsy - - - + + - -
Hearing impairment - + + -
Other Factor
Age at investigation 
(years)
4 8 5 18 5 7 months 7 6 7
Refraction OD S+3.00 S+3.50=C-1.50x180” S+0.25=C-2.00x172” S-6.00 S+4.75=C-0.50x180” S+2.50=C-1.50x180” S+6.00=C-1.50x90” S+3.00=C-1.75x40” S+3.75=C-0.25x90”
Refraction OS S+3.00 S+3.00=C-1x180” S-1.50=C-1.75x160” S-5.00 S+5.50=C-0.50x180” S+2.50=C-1.00x180” S+4.50 S+2.25=C-0.75x30” S+3.75
Correction - - - - + - - + -
Vision 20/470 (0.04) 20/130 (0.15) 20/180 (0.11) 20/190 (0.10) 20/130 (0.15) LP 20/63 (0.3) 3/10 (0.3) 20/94 (0.2)
Method TAC (55 cm) TAC (55 cm) TAC (38 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm) Amsterdam pictures (3m) TAC (55 cm)
Visual field defects - - - + - -
Strabismus + - - + - + - - -
Nystagmus + - - + + + - + -
(Partial) optic disc pallor - - - - - - -
Fluctuating visual 
performances
+ +
G=hypoglycaemia, H=hydrocephalus, LH= Lea Hyvarinen, LP =light perception, M=meningitis/encephalitis,
P=perinatal problems , S=stroke, TAC= Teller Acuity Cards, W=West syndrome.
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supplementary Table 2: Phenotype of patients with CVI and a chromosomal aberration (continued)
Patient 19 20 21 22 23 24 25 26 27
Male/ Female M M M F F M M M M
Gestational age (weeks) 41 39 40 39
Birth weight (gram) 2575 3415 3500 2800
Intellectual disability + + + + + + + + +
Developmental age at 
calender age
7 months at 3+4 years 2 months at 10 months 1+6 years at
3+10 years
MRI cerebrum 
abnormalities (based on 
reports)
Normal
Epilepsy - - - + + - -
Hearing impairment - + + -
Other Factor
Age at investigation 
(years)
4 8 5 18 5 7 months 7 6 7
Refraction OD S+3.00 S+3.50=C-1.50x180” S+0.25=C-2.00x172” S-6.00 S+4.75=C-0.50x180” S+2.50=C-1.50x180” S+6.00=C-1.50x90” S+3.00=C-1.75x40” S+3.75=C-0.25x90”
Refraction OS S+3.00 S+3.00=C-1x180” S-1.50=C-1.75x160” S-5.00 S+5.50=C-0.50x180” S+2.50=C-1.00x180” S+4.50 S+2.25=C-0.75x30” S+3.75
Correction - - - - + - - + -
Vision 20/470 (0.04) 20/130 (0.15) 20/180 (0.11) 20/190 (0.10) 20/130 (0.15) LP 20/63 (0.3) 3/10 (0.3) 20/94 (0.2)
Method TAC (55 cm) TAC (55 cm) TAC (38 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm) Amsterdam pictures (3m) TAC (55 cm)
Visual field defects - - - + - -
Strabismus + - - + - + - - -
Nystagmus + - - + + + - + -
(Partial) optic disc pallor - - - - - - -
Fluctuating visual 
performances
+ +
G=hypoglycaemia, H=hydrocephalus, LH= Lea Hyvarinen, LP =light perception, M=meningitis/encephalitis,
P=perinatal problems , S=stroke, TAC= Teller Acuity Cards, W=West syndrome.
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supplementary Table 2: Phenotype of patients with CVI and a chromosomal aberration (continued)
Patient 28 29 30 31 32 33 34 35 36
Male/ Female M F M M M M M M M
Gestational age (weeks) 39 39 39 37 28 40
Birth weight (gram) 2800 4012 2880 3250
Intellectual disability + + + + + + + +
Developmental age at 
calender age
12-15 months at 12 
years
3+6 years at
18 years
MRI cerebrum 
abnormalities (based 
on reports)
Epilepsy - - - - -
Hearing impairment - + - - - -
Other Factor P
Age at investigation 
(years)
7 12 10 27 6 16 10 4 7
Refraction OD S+1.75 S+3.00=C-0.50x180” S-10.00 S+1.50=C-1.25x102” S+3.50=C-2.50x180” S+3.00=C-0.50x90” S+3.00=C-1.00x180” S+2.00
Refraction OS S+1.75 S+3.00 S-5.00 S+2.25=C-1.00x12” S+3.75=C-2.00x180” S+3.50=C-0.50x90” S+3.00=C-1.00x180” S+1.00
Correction - - + - - - + -
Vision 20/63 (0.3) 20/94 (0.2) 20/190 (0.10) 20/130 (0.15) 20/94 (0.2) 6/19 (0.3) 20/94 (0.2) 20/190 (0.10) 3/9.5 (0.3)
Method TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm) Cardiff (1 m) TAC (55 cm) TAC (55 cm) LH (3 m)
Visual field defects - - - + - - - - -
Strabismus - + + + + - + - +
Nystagmus - - - + + + - + -
(Partial) optic disc pallor - + - - - - - + -
Fluctuating visual 
performances
G=hypoglycaemia, H=hydrocephalus, LH= Lea Hyvarinen, LP =light perception,
M=meningitis/encephalitis, P=perinatal problems , S=stroke, TAC= Teller Acuity Cards, W=West syndrome.
117
Chromosomal aberrations in CVI
Ch
ap
te
r 2
.2
supplementary Table 2: Phenotype of patients with CVI and a chromosomal aberration (continued)
Patient 28 29 30 31 32 33 34 35 36
Male/ Female M F M M M M M M M
Gestational age (weeks) 39 39 39 37 28 40
Birth weight (gram) 2800 4012 2880 3250
Intellectual disability + + + + + + + +
Developmental age at 
calender age
12-15 months at 12 
years
3+6 years at
18 years
MRI cerebrum 
abnormalities (based 
on reports)
Epilepsy - - - - -
Hearing impairment - + - - - -
Other Factor P
Age at investigation 
(years)
7 12 10 27 6 16 10 4 7
Refraction OD S+1.75 S+3.00=C-0.50x180” S-10.00 S+1.50=C-1.25x102” S+3.50=C-2.50x180” S+3.00=C-0.50x90” S+3.00=C-1.00x180” S+2.00
Refraction OS S+1.75 S+3.00 S-5.00 S+2.25=C-1.00x12” S+3.75=C-2.00x180” S+3.50=C-0.50x90” S+3.00=C-1.00x180” S+1.00
Correction - - + - - - + -
Vision 20/63 (0.3) 20/94 (0.2) 20/190 (0.10) 20/130 (0.15) 20/94 (0.2) 6/19 (0.3) 20/94 (0.2) 20/190 (0.10) 3/9.5 (0.3)
Method TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm) Cardiff (1 m) TAC (55 cm) TAC (55 cm) LH (3 m)
Visual field defects - - - + - - - - -
Strabismus - + + + + - + - +
Nystagmus - - - + + + - + -
(Partial) optic disc pallor - + - - - - - + -
Fluctuating visual 
performances
G=hypoglycaemia, H=hydrocephalus, LH= Lea Hyvarinen, LP =light perception,
M=meningitis/encephalitis, P=perinatal problems , S=stroke, TAC= Teller Acuity Cards, W=West syndrome.
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supplementary Table 2: Phenotype of patients with CVI and a chromosomal aberration (continued)
Patient 37 38 39 40 41 42 43 44 45
Male/ Female M M M F F F F F M
Gestational age (weeks) 38 32 39 41 34
Birth weight (gram) 2800 1425 3390 2085 1970 2550
Intellectual disability + + + + + + + + +
Developmental age at 
calender age
7 months at
9 years
6 months at
5 years
MRI cerebrum 
abnormalities (based 
on reports)
Slightly enlarged 
ventricles and slightly 
delayed myelination.
Epilepsy - - - - - - + + +
Hearing impairment - - - - + + -
Other Factor G M W
Age at investigation 
(years)
13 17 6 5 11 12 2+11 10 2
Refraction OD S-2.00 S-9.00=C-1.50x62” S-0.50=C-0.25x180” S+3.00 S+2.00=C-3.00x180” S+4.00=C-2.25x20”
Refraction OS S-3.00=C-1.00x180” Splan=C-2.00x180” S-8.00=C-1.00x115” S+0.75=C-1.00x180” S+3.00 S+4.50=C-2.00x180” S+3.00=C-2.50x180”
Correction - - + - - -
Vision 20/150 (0.13) 20/130 (0.15) 3/9.5 (0.3) 20/150 (0.13) 20/130 (0.15) 20/380 (0.05) 20/710 (0.03) 20/710 (0.03) LP
Method TAC (38 cm) TAC (55 cm) LH (3 m) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm)
Visual field defects - - - - - + + -
Strabismus + + - + + - + + -
Nystagmus - - - - - - + - -
(Partial) optic disc pallor - - - - - - - - -
Fluctuating visual 
performances
+ +
G=hypoglycaemia, H=hydrocephalus, LH= Lea Hyvarinen, LP =light perception, M=meningitis/encephalitis,
P=perinatal problems , S=stroke, TAC= Teller Acuity Cards, W=West syndrome.
119
Chromosomal aberrations in CVI
Ch
ap
te
r 2
.2
supplementary Table 2: Phenotype of patients with CVI and a chromosomal aberration (continued)
Patient 37 38 39 40 41 42 43 44 45
Male/ Female M M M F F F F F M
Gestational age (weeks) 38 32 39 41 34
Birth weight (gram) 2800 1425 3390 2085 1970 2550
Intellectual disability + + + + + + + + +
Developmental age at 
calender age
7 months at
9 years
6 months at
5 years
MRI cerebrum 
abnormalities (based 
on reports)
Slightly enlarged 
ventricles and slightly 
delayed myelination.
Epilepsy - - - - - - + + +
Hearing impairment - - - - + + -
Other Factor G M W
Age at investigation 
(years)
13 17 6 5 11 12 2+11 10 2
Refraction OD S-2.00 S-9.00=C-1.50x62” S-0.50=C-0.25x180” S+3.00 S+2.00=C-3.00x180” S+4.00=C-2.25x20”
Refraction OS S-3.00=C-1.00x180” Splan=C-2.00x180” S-8.00=C-1.00x115” S+0.75=C-1.00x180” S+3.00 S+4.50=C-2.00x180” S+3.00=C-2.50x180”
Correction - - + - - -
Vision 20/150 (0.13) 20/130 (0.15) 3/9.5 (0.3) 20/150 (0.13) 20/130 (0.15) 20/380 (0.05) 20/710 (0.03) 20/710 (0.03) LP
Method TAC (38 cm) TAC (55 cm) LH (3 m) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm)
Visual field defects - - - - - + + -
Strabismus + + - + + - + + -
Nystagmus - - - - - - + - -
(Partial) optic disc pallor - - - - - - - - -
Fluctuating visual 
performances
+ +
G=hypoglycaemia, H=hydrocephalus, LH= Lea Hyvarinen, LP =light perception, M=meningitis/encephalitis,
P=perinatal problems , S=stroke, TAC= Teller Acuity Cards, W=West syndrome.
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supplementary Table 2: Phenotype of patients with CVI and a chromosomal aberration (continued)
Patient 46 47 48 49 50 51 52 53 54
Male/ Female M M F F M F F F M
Gestational age (weeks) 27 37 41 42 39 41
Birth weight (gram) 1280 3186 2800 2650 3800 3400
Intellectual disability + + + + + + + +
Developmental age at 
calender age
4 years at 10 years 1+4 years at
3+2 years
1+3 years at
9 years
MRI cerebrum 
abnormalities (based 
on reports)
Hypoplasia of 
corpus callosum and 
colpocephaly
Enlarged ventricles 
and periventricular 
leukomalacia.
Small cerebellum Normal Ventral corpus callosum 
agenesia and enlarged 
ventricles.
Hydrocephalus Hydrocephaly, delayed 
development of 
frontal lobes, delayed 
myelination
Epilepsy - + + - + - - - +
Hearing impairment + - - +
Other Factor P W H H H G
Age at investigation 
(years)
1 1+3 10 4 5 5 9 5 4
Refraction OD S+1.00=C-1.00x90” S+8.00 C-2.00x180” S+2.00=C-0.25x180” S- 15.00= C+8.00x110” S-1.50=C-2.50x15”
Refraction OS S+1.00=C-1.00x90” S+8.00 S-2.50 S+2.50 S-14.00= C+6.50x90” S-2.00=C-2.25x150”
Correction - - - + -
Vision LP LP 20/94 (0.2) 20/130 (0.15) 20/63 (0.3) 20/80 (0.25) 20/80 (0.25) 20/1200 (0.02) LP
Method TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm)
Visual field defects - - + + +
Strabismus + + - + - + + + +
Nystagmus + + - - - - + +
(Partial) optic disc pallor + + - - - + + +
Fluctuating visual 
performances
G=hypoglycaemia, H=hydrocephalus, LH= Lea Hyvarinen, LP =light perception, M=meningitis/encephalitis,
P=perinatal problems , S=stroke, TAC= Teller Acuity Cards, W=West syndrome.
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supplementary Table 2: Phenotype of patients with CVI and a chromosomal aberration (continued)
Patient 46 47 48 49 50 51 52 53 54
Male/ Female M M F F M F F F M
Gestational age (weeks) 27 37 41 42 39 41
Birth weight (gram) 1280 3186 2800 2650 3800 3400
Intellectual disability + + + + + + + +
Developmental age at 
calender age
4 years at 10 years 1+4 years at
3+2 years
1+3 years at
9 years
MRI cerebrum 
abnormalities (based 
on reports)
Hypoplasia of 
corpus callosum and 
colpocephaly
Enlarged ventricles 
and periventricular 
leukomalacia.
Small cerebellum Normal Ventral corpus callosum 
agenesia and enlarged 
ventricles.
Hydrocephalus Hydrocephaly, delayed 
development of 
frontal lobes, delayed 
myelination
Epilepsy - + + - + - - - +
Hearing impairment + - - +
Other Factor P W H H H G
Age at investigation 
(years)
1 1+3 10 4 5 5 9 5 4
Refraction OD S+1.00=C-1.00x90” S+8.00 C-2.00x180” S+2.00=C-0.25x180” S- 15.00= C+8.00x110” S-1.50=C-2.50x15”
Refraction OS S+1.00=C-1.00x90” S+8.00 S-2.50 S+2.50 S-14.00= C+6.50x90” S-2.00=C-2.25x150”
Correction - - - + -
Vision LP LP 20/94 (0.2) 20/130 (0.15) 20/63 (0.3) 20/80 (0.25) 20/80 (0.25) 20/1200 (0.02) LP
Method TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm)
Visual field defects - - + + +
Strabismus + + - + - + + + +
Nystagmus + + - - - - + +
(Partial) optic disc pallor + + - - - + + +
Fluctuating visual 
performances
G=hypoglycaemia, H=hydrocephalus, LH= Lea Hyvarinen, LP =light perception, M=meningitis/encephalitis,
P=perinatal problems , S=stroke, TAC= Teller Acuity Cards, W=West syndrome.
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supplementary Table 2: Phenotype of patients with CVI and a chromosomal aberration (continued)
Patient 55 56 57 58 59 60 61 62 63
Male/ Female F M M F F F M M M
Gestational age (weeks) 40 38 39 40 32 37 38
Birth weight (gram) 2700 3515 1710 3710 2000 2795 4250
Intellectual disability + + + + + + +
Developmental age at 
calender age
6-10 years at
16 years
MRI cerebrum 
abnormalities (based 
on reports)
Hydrocephalus and 
delayed myelination
Ischaemic damage 
thalamus and left 
occipital damage due to 
abcess.
Enlarged ventricles and 
delayed myelination
Normal Delayed myelination, 
enlarged ventricles, 
small cerebellum, mega 
cisterna magna.
Normal
Epilepsy + + - + + - + - +
Hearing impairment + - + + - - - -
Other Factor W H,P M,S W
Age at investigation 
(years)
26 13 35 1+9 1+10 4 14 1+6 26
Refraction OD S-3.25=C-1.25x3” S-5.00 S-10.00 S+1.75 S+2.00=C-1.00x180”
Refraction OS S-1.00 S-3.00=C-1.00x170” S-2.00 S-9.00 S+1.75 S+2.00=C-1.00x180”
Correction - - + + - - + - -
Vision 20/190 (0.10) 20/130 (0.15) 6/18 (0.3) 20/260 (0.08) LP 20/130 (0.15) 20/130 (0.15) 20/130 (0.15) 5/20 (0.25)
Method TAC (55 cm) TAC (55 cm) Numbers (6 m) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm) Landolt C (5 m)
Visual field defects + - + + - +
Strabismus + + + + + + - -
Nystagmus + - - + - - + +
(Partial) optic disc pallor - + + - + - + + +
Fluctuating visual 
performances
+ +
G=hypoglycaemia, H=hydrocephalus, LH= Lea Hyvarinen, LP =light perception, M=meningitis/encephalitis,
P=perinatal problems , S=stroke, TAC= Teller Acuity Cards, W=West syndrome.
supplementary Table 2: Phenotype of patients with CVI and a chromosomal aberration (continued)
Patient 55 56 57 58 59 60 61 62 63
Male/ Female F M M F F F M M M
Gestational age (weeks) 40 38 39 40 32 37 38
Birth weight (gram) 2700 3515 1710 3710 2000 2795 4250
Intellectual disability + + + + + + +
Developmental age at 
calender age
6-10 years at
16 years
MRI cerebrum 
abnormalities (based 
on reports)
Hydrocephalus and 
delayed myelination
Ischaemic damage 
thalamus and left 
occipital damage due to 
abcess.
Enlarged ventricles and 
delayed myelination
Normal Delayed myelination, 
enlarged ventricles, 
small cerebellum, mega 
cisterna magna.
Normal
Epilepsy + + - + + - + - +
Hearing impairment + - + + - - - -
Other Factor W H,P M,S W
Age at investigation 
(years)
26 13 35 1+9 1+10 4 14 1+6 26
Refraction OD S-3.25=C-1.25x3” S-5.00 S-10.00 S+1.75 S+2.00=C-1.00x180”
Refraction OS S-1.00 S-3.00=C-1.00x170” S-2.00 S-9.00 S+1.75 S+2.00=C-1.00x180”
Correction - - + + - - + - -
Vision 20/190 (0.10) 20/130 (0.15) 6/18 (0.3) 20/260 (0.08) LP 20/130 (0.15) 20/130 (0.15) 20/130 (0.15) 5/20 (0.25)
Method TAC (55 cm) TAC (55 cm) Numbers (6 m) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm) Landolt C (5 m)
Visual field defects + - + + - +
Strabismus + + + + + + - -
Nystagmus + - - + - - + +
(Partial) optic disc pallor - + + - + - + + +
Fluctuating visual 
performances
+ +
G=hypoglycaemia, H=hydrocephalus, LH= Lea Hyvarinen, LP =light perception, M=meningitis/encephalitis,
P=perinatal problems , S=stroke, TAC= Teller Acuity Cards, W=West syndrome.
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supplementary Table 2: Phenotype of patients with CVI and a chromosomal aberration (continued)
Patient 65 66 67 68 69 70 71 72 73
Male/ Female F M F F F F F F M
Gestational age (weeks) 40 41 38 42 41 38 36 40
Birth weight (gram) 3150 3200 3115 2900 3310 3100 3685 1810
Intellectual disability + + + + + + + + +
Developmental age at 
calender age
8 months at
1+4 years
2+6 years at
6 years
9 months at
2 years
1+3 years at
11 years
1+3 years at
7 years
12-15 months at 13 
years
6 months at
2+10 years
MRI cerebrum 
abnormalities (based 
on reports)
Hypomyelination periventricular white 
matter abnormalities
Agnesia corpus 
callosum, delayed 
myelination
Pachygyria and white 
matter abnormalities
Vermis atrophy Small brainvolume, 
agenesia corpus 
callosum, abnormal 
position of temporal 
lobes.
Normal Pontocerebellar 
Hypoplasia type 2
Cortical dysplasia, thin 
corpus callosum, delayed 
myelination of right 
hemisphere.
Epilepsy - - - - - - + + +
Hearing impairment - - - - - - -
Other Factor
Age at investigation 
(years)
2+1 7 1 11 7 13 7 2+6 10
Refraction OD S-1.75=C-0.50x26” emmetropia C-4.50x55” S+5.25=C-1.00x10” S+1.25=C-0.25x20” S+1.00 S-1.50=C-1.50x45”
Refraction OS S-1.75=C-0.50x26” S+1.00=C-1.00x90” S-1.50=C-3.00x133” S+5.50=C-1.50x3” S+0.75=C-0.50x45” S+1.00 S-2.25
Correction - + + - - - -
Vision 20/190 (0.10) 3/12 (0.25) LP 20/130 (0.15) 20/260 (0.08) 20/130 (0.15) 20/94 (0.2) 20/260 (0.08) 20/94 (0.2)
Method TAC (55 cm) LH (3 m) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm)
Visual field defects - + + + + - + -
Strabismus - - + - + + + +
Nystagmus + + - - - + + - -
(Partial) optic disc pallor + - + - - - + +
Fluctuating visual 
performances
+ +
G=hypoglycaemia, H=hydrocephalus, LH= Lea Hyvarinen, LP =light perception, M=meningitis/encephalitis,
P=perinatal problems , S=stroke, TAC= Teller Acuity Cards, W=West syndrome.
125
Chromosomal aberrations in CVI
Ch
ap
te
r 2
.2
supplementary Table 2: Phenotype of patients with CVI and a chromosomal aberration (continued)
Patient 65 66 67 68 69 70 71 72 73
Male/ Female F M F F F F F F M
Gestational age (weeks) 40 41 38 42 41 38 36 40
Birth weight (gram) 3150 3200 3115 2900 3310 3100 3685 1810
Intellectual disability + + + + + + + + +
Developmental age at 
calender age
8 months at
1+4 years
2+6 years at
6 years
9 months at
2 years
1+3 years at
11 years
1+3 years at
7 years
12-15 months at 13 
years
6 months at
2+10 years
MRI cerebrum 
abnormalities (based 
on reports)
Hypomyelination periventricular white 
matter abnormalities
Agnesia corpus 
callosum, delayed 
myelination
Pachygyria and white 
matter abnormalities
Vermis atrophy Small brainvolume, 
agenesia corpus 
callosum, abnormal 
position of temporal 
lobes.
Normal Pontocerebellar 
Hypoplasia type 2
Cortical dysplasia, thin 
corpus callosum, delayed 
myelination of right 
hemisphere.
Epilepsy - - - - - - + + +
Hearing impairment - - - - - - -
Other Factor
Age at investigation 
(years)
2+1 7 1 11 7 13 7 2+6 10
Refraction OD S-1.75=C-0.50x26” emmetropia C-4.50x55” S+5.25=C-1.00x10” S+1.25=C-0.25x20” S+1.00 S-1.50=C-1.50x45”
Refraction OS S-1.75=C-0.50x26” S+1.00=C-1.00x90” S-1.50=C-3.00x133” S+5.50=C-1.50x3” S+0.75=C-0.50x45” S+1.00 S-2.25
Correction - + + - - - -
Vision 20/190 (0.10) 3/12 (0.25) LP 20/130 (0.15) 20/260 (0.08) 20/130 (0.15) 20/94 (0.2) 20/260 (0.08) 20/94 (0.2)
Method TAC (55 cm) LH (3 m) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm)
Visual field defects - + + + + - + -
Strabismus - - + - + + + +
Nystagmus + + - - - + + - -
(Partial) optic disc pallor + - + - - - + +
Fluctuating visual 
performances
+ +
G=hypoglycaemia, H=hydrocephalus, LH= Lea Hyvarinen, LP =light perception, M=meningitis/encephalitis,
P=perinatal problems , S=stroke, TAC= Teller Acuity Cards, W=West syndrome.
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supplementary Table 2: Phenotype of patients with CVI and a chromosomal aberration (continued)
Patient 74 75 76 77 78 79
Male/ Female M M M M F F
Gestational age (weeks) 40 39 36 38 41
Birth weight (gram) 2750 2735 2475 2500 3250
Intellectual disability + + + + + +
Developmental age at calender 
age
6 months at 6 years
MRI cerebrum abnormalities 
(based on reports)
Hyperdense abnormalities dorsal 
thalamus
Dysgenesia corpus callosum and 
intraventricular cyst
Inschaemic damage left and right 
parieto-occipital, periventricular 
leukomalacia, diffuse cerebral 
atrophy
Epilepsy + + + +
Hearing impairment + -
Other Factor W H S S
Age at investigation (years) 6 4 9 3 8 months 18
Refraction OD S+2.00 S+2.50=C-1.50x90” S-1.00=C-2.00x180” emmetropia
Refraction OS S+2.00 S+2.50=C-1.50x90” S-1.50=C-2.50x180” emmetropia
Correction + - - - - -
Vision 20/63 (0.3) 20/130 (0.15) 20/260 (0.08) 20/1200 (0.02) 20/710 (0.03) 20/960 (0.02)
Method TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm)
Visual field defects + - - + - -
Strabismus + + - + +
Nystagmus + + - + - +
(Partial) optic disc pallor - - + - -
Fluctuating visual performances +
G=hypoglycaemia, H=hydrocephalus, LH= Lea Hyvarinen, LP =light perception, M=meningitis/encephalitis,
P=perinatal problems , S=stroke, TAC= Teller Acuity Cards, W=West syndrome.
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supplementary Table 2: Phenotype of patients with CVI and a chromosomal aberration (continued)
Patient 74 75 76 77 78 79
Male/ Female M M M M F F
Gestational age (weeks) 40 39 36 38 41
Birth weight (gram) 2750 2735 2475 2500 3250
Intellectual disability + + + + + +
Developmental age at calender 
age
6 months at 6 years
MRI cerebrum abnormalities 
(based on reports)
Hyperdense abnormalities dorsal 
thalamus
Dysgenesia corpus callosum and 
intraventricular cyst
Inschaemic damage left and right 
parieto-occipital, periventricular 
leukomalacia, diffuse cerebral 
atrophy
Epilepsy + + + +
Hearing impairment + -
Other Factor W H S S
Age at investigation (years) 6 4 9 3 8 months 18
Refraction OD S+2.00 S+2.50=C-1.50x90” S-1.00=C-2.00x180” emmetropia
Refraction OS S+2.00 S+2.50=C-1.50x90” S-1.50=C-2.50x180” emmetropia
Correction + - - - - -
Vision 20/63 (0.3) 20/130 (0.15) 20/260 (0.08) 20/1200 (0.02) 20/710 (0.03) 20/960 (0.02)
Method TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC (55 cm)
Visual field defects + - - + - -
Strabismus + + - + +
Nystagmus + + - + - +
(Partial) optic disc pallor - - + - -
Fluctuating visual performances +
G=hypoglycaemia, H=hydrocephalus, LH= Lea Hyvarinen, LP =light perception, M=meningitis/encephalitis,
P=perinatal problems , S=stroke, TAC= Teller Acuity Cards, W=West syndrome.

Chapter 3
Identifying genes for CVI

3.1
Novel genetic causes for cerebral visual 
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aBsTraCT
Cerebral visual impairment (CVI) is a major cause of low vision in children due to impairment 
in projection and/or interpretation of the visual input in the brain. Although acquired causes 
for CVI are well known, genetic causes underlying CVI are largely unidentified. DNAs of 25 pa-
tients with CVI and intellectual disability, but without acquired (e.g perinatal) damage, were 
investigated by whole exome sequencing. The data were analysed for de novo, autosomal re-
cessive and X-linked variants, and subsequently, classified into known, candidate or unlikely 
to be associated with CVI. This classification was based on the Online Mendelian Inheritance 
in Man database, literature reports, variant characteristics and functional relevance of the 
gene. After classification, variants in four genes known to be associated with CVI (AHDC1, 
NGLY1, NR2F1, PGAP1) in five patients (20%) were identified, establishing a conclusive genetic 
diagnosis for CVI. In addition, in 11 patients (44%) with CVI, variants in one or more candi-
date genes were identified (ACP6, AMOT, ARHGEF10L, ATP6V1A, DCAF6, DLG4, GABRB2, GRIN1, 
GRIN2B, KCNQ3, KCTD19, RERE, SLC1A1, SLC25A16, SLC35A2, SOX5, UFSP2, UHMK1, ZFP30). Our 
findings show that diverse genetic causes underlie CVI; some of which will provide insight 
into the biology underlying this disease process.
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InTroDuCTIon
Cerebral visual impairment (CVI) is one of the major causes of visual impairment in West-
ern countries, as it accounts for 27% of low vision in childhood.53 CVI is a collective term 
of visual disorders, resulting from damage or malfunctioning of cerebral parts of the visual 
system, such as the optic tracts, optic radiations and the visual cortex. It is diagnosed when 
no ocular abnormality can explain the impairment in vision, which can consist of a reduced 
visual acuity, and/or visual field defects.47 In addition, abnormal visual behaviour, such as 
staring into light or delayed fixation can be present. Deficits in higher perceptual functions, 
for example difficulties with recognition of objects and faces, or visio-spatial disorders can 
occur, and are sometimes the only features of CVI.46,50,85 CVI can occur in isolation, but more 
often additional features are present, such as intellectual disability (ID), epilepsy and/or 
deafness.51,79,250 An important cause of CVI is acquired damage to the brain, mainly the result 
of perinatal problems (e.g. cerebral haemorrhage or periventricular leukomalacia), but also 
other types of acquired damage, such as congenital infection, hypoglycaemia, meningitis or 
head trauma can be causal.47 Furthermore, West syndrome and hydrocephalus can result in 
CVI.115,116 So far, less attention has been paid to genetic causes of CVI, although associations 
with several neurodegenerative causes and chromosomal aberrations have been described.62 
Recently, we reported in 7% of CVI patients associations with copy number variants, among 
others trisomy 21, 1p36 deletion, and 22q13.3 deletion (Phelan-McDermid syndrome).251 
Moreover, CVI was recently shown to be caused by de novo variants in NR2F1, leading to the 
Bosch-Boonstra-Schaaf optic atrophy syndrome (#615722, http://www.NR2F1gene.com).191 
In other neurological disorders, such as ID, epileptic encephalopathies or autism, a high rate 
of (probably) disease causing de novo variants were identified by whole exome sequencing 
(WES) by using a child-parents trio approach.179,180,182-185,252 In addition, WES has also shown to 
be a powerful tool for identifying autosomal recessive and X-linked variants in persons with 
ID.170,183,184,253-255 Here, we used WES to identify underlying genetic causes for CVI.
suBjeCTs anD MeThoDs
Twenty-five patients with CVI and a visual acuity ≤0.3 were included and WES was performed 
in the patients and their parents (detailed methods are presented in the Supplementary Meth-
ods). After performing quality filtering the common variants (>1%) were excluded, and the data 
were analysed for variants following a de novo, X-linked and autosomal recessive inheritance 
pattern. Truncating variants and variants predicted to affect function were validated by Sanger 
sequencing. The genes in which the variants were identified were further classified partly based 
on the method reported by de Ligt et al. and Gilissen et al. (Figure 1).182,256
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A second, more stringent filtering was used for the de novo and X-linked variants (frequency 
≤0.1% in controls) and truncating variants (frequency of truncating variants in controls across 
the whole gene ≤0.1% or ≤1.0% (autosomal recessive) in controls). This study was approved 
by the Ethics Committee of the Radboud university medical center (Commissie Mensgebon-
den Onderzoek, regio Arnhem-Nijmegen), and written informed consent was obtained for 
all enrolled subjects. Three patients (12, 13, and 23) were part of previous reports.191,257 The 
variants identified have been submitted to the Leiden Open Variation Databases (LOVDs) 
(http://databases.lovd.nl/, patient IDs #00025011 and #00039389 - #000394012).
resulTs
The clinical characteristics of the 25 patients analysed were as described in Table 1 and in 
more detail per patient in Supplementary Table S1. The mean age was 12 years (range 1– 33 
years) and one patient had a visual acuity <0.05, which is defined as blindness by the WHO 
yes (n=16)
yes (n=7)
yes (n=4)
no (n=6)
no (n=20)
yes (n=14)
no (n=3)
no (n=5)
OMIM disease gene?
Identied aberrant genes (n=34)
•  De novo (n=22)
•  Autosomal recessive (n=11)
•  X-linked recessive (n=1)
≥ 2 following items
•  PhyloP >3.5 / truncating†
•  Enriched GO term
•  Enriched MP term
•  Brain expression
Unlikely to be related to CVI (n=11)
•  De novo (n=4)
•  Autosomal recessive (n=6)
•  X-linked recessive (n=1)
Candidate gene for CVI (n=19)
•  De novo (n=16)
•  Autosomal recessive (n=3)
•  X-linked recessive (n=0)
Known CVI-associated gene (n=4)
•  De novo (n=2)
•  Autosomal recessive (n=2)
•  X-linked recessive (n=0)
Corresponding
•  Phenotype
•  Inheritance pattern 
•  Mutation type
Gene previously associated with CVI?
GRIN1*
figure 1: flow chart of gene classification
*Inheritance does not fit with the reported OMIM disease (autosomal recessive instead of the reported de 
novo autosomal dominant). However, this variant is further classified according to de Ligt and Gilissen et al, 
see result section. †Frameshift, nonsense or splice site variant.
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Table 1: Cohort characteristics
Characteristic number of patients
Gender
Male 17
Female 8
Age group
<4 years 4
4-10 years 9
11-20 years 6
>20 years 6
Visual acuity
 ≤0.3 and ≥0.05 24
<0.05 1
Fixation abnormalities
Yes 13
No 12
Visual field defects
Yes 17
No 8
Developmental delay and/or intellectual disability
Yes 25
No 0
Able to walk independently
Yes 15
No 10
Speak words
Yes 12
No 13
Microcephaly (<3th centile)
Yes 4
No 20
Unknown 1
Macrocephaly (>97th centile)
Yes 3
No 21
Unknown 1
Abnormality on brain MRI
Yes 14
No 8
Not assessed 3
Epilepsy
Yes 9
No 16
Hearing loss
Yes 1
No 23
Unknown 1
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(http://apps.who.int/classifications/icd10/browse/2015/en). In addition to CVI, all patients 
had ID, ranging from mild to severe.
In all patients WES was performed by trio approach with an average read depth of 120x 
(Illumina Hiseq 2000, Illumina, San Diego, CA, USA), 115x (Illumina HiSeq, Illumina, San Diego, 
CA, USA) or 72x (Solid 5500XL, Life Technologies, Carlsbad, CA, USA). A de novo ratio could 
not be established, because only protein truncating variants and missense variants predicted 
to affect function were validated. After prioritization and validation of the identified variants 
in a patient and its parents, further segregation analysis for the autosomal recessive and 
X-linked variants was performed in the families for whom this was possible. The variants in 
one autosomal recessive gene, ITPRIPL1, and five variants in X-linked genes, CACNA1F, CNGA2, 
FLNA, PCDH11X, and ZMAT1, could be discarded because of their presence in healthy (male) 
family members (Supplementary Table S2).
All 45 genes were classified, but 11 genes (AKAP9, ALAS2, FAM166B, KAL1, MAP3K15, MUT, 
POF1B, PPFIA4, SLC6A13, SPTBN5, and TRIOBP), which were excluded based on the more strin-
gent criteria (Supplementary Table S4), are not further discussed. Of the remaining 34 genes, 
14 have previously been indicated in OMIM diseases (Figure 1).
For seven genes the phenotype of the patients was in line with the reported phenotype: CVI 
was reported previously in four genes, AHDC1, NGLY1, NR2F1, and PGAP1, whereas the other 
three genes were classified as candidate genes for CVI, GRIN2B, KCNQ3, and SLC35A2.191,258-260
For five genes, HSPG2, PHKB, SRP72, SYNE1 and TENM3, the reported phenotype in litera-
ture was not in line with the phenotype of the patient, and those variants were classified as 
unlikely to be causative for CVI in those patients (#224410, #255800, #261750, #614675, 
#612998, #610743, #615145). In APOPT1 the phenotype was also not in line with the reported 
phenotype (#220110). Moreover, we identified a de novo heterozygous variant in this gene, 
whereas the related OMIM disease has an autosomal recessive inheritance pattern and no 
second variant could be identified in the raw exome data. For another OMIM disease gene, 
GRIN1 (#614254), de novo heterozygous variants in this gene have been reported to cause ID; 
however, we identified a homozygous variant. Therefore, this variant was further classified 
according to the method by de Ligt et al. and Gilissen et al. as a candidate gene for CVI.182,256 
This method was also used for the non-OMIM disease related genes (n=20) and consisted of 
the assessment of the variant characteristics (PhyloP/truncating variant) in combination with 
the functional relevance of the gene (GO-terms, MP-terms and brain expression), leading to 
a classification of 15 candidate genes for CVI and 5 genes as unlikely to be related with CVI 
(Figure 1).
In total, four known CVI-associated genes, 19 candidate CVI genes and 11 genes unlikely 
to be related to CVI were identified (Table 2 and Supplementary Table S3), and in five of the 
25 patients (20%) a genetic diagnosis for the CVI could be established. In another 11 patients 
(44%) one or more candidate genes for CVI could be identified. Photographs of the patients 
in whom variants in known or candidate genes were identified are shown in Figure 2 and 
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Table 2: Identified known and candidate genes for CVI per patient
Patient Dominant de novo autosomal recessive
1 DLG4
2 NGLY1†
3
4
5
6 SLC35A2
7 AHDC1†
8 GABRB2, ARHGEF10L
9 AMOT
10 UHMK1
11 SLC25A16 GRIN1, DCAF6
12 PGAP1†
13 NR2F1†
14
15
16
17 SOX5, KCTD19
18
19 GRIN2B, ZFP30
20 ATP6V1A, UFSP2
21
22 RERE, SLC1A1*
23 NR2F1† ACP6
24 KCNQ3
25
*Probably mosaic mutation. †Identified known CVI-associated gene.
Patient 22 Patient 24Patient 20Patient 19
Patient 17
Patient 1
Patient 10Patient 8
Patient 7Patient 2 Patient 6
Patient 9
figure 2: Photographs of the patients in whom known or candidate genes for CVI were identified
Consent to publish photographs was not obtained for patient 11.
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their clinical features are summarized in Table 1 and Supplementary Table S1. Pictures of 
patients 12, 13, and 23 have previously been published.191,257
DIsCussIon
WES was performed in 25 patients with CVI and a visual acuity of ≤0.3, without acquired risk 
factors for CVI nor pathogenic copy number variants. We identified variants in four known 
CVI-associated genes, namely AHDC1, NGLY1, NR2F1 and PGAP1, and 19 candidate genes 
for CVI. In some patients multiple variants in more than one gene were found. In addition, 
de novo variants in NR2F1 were identified in two patients (13 and 23). The identification of 
variants in known CVI-associated genes strengthened our hypothesis that WES is the right 
approach to identify the underlying genetic causes in patients with CVI. Moreover, several 
identified candidate genes have a functional link with genes known to be associated with 
CVI.
Three genes, in which variants were identified, have been implicated in glycosylation: 
NGLY1, SLC35A2, and PGAP1. Previously, CVI has been reported as part of congenital disorders 
of glycosylation (CDG) type 1a (PMM2), type 1q (SRD5A3) and type 1v (NGLY1).126,127,250,259 The 
phenotype of patient 2 with NGLY1 variants is similar to the previously reported patients, 
including the microcephaly, hypotonia, movement disorder and alacrima.259,261,262 Variants in 
SLC35A2 lead to CDG type 2m, featured by ID, epilepsy, facial dysmorphisms and transient 
abnormalities in transferin testing.263-265 In the seven reported patients with CDG type 2m, 
CVI has not been mentioned, but other features, including the facial dysmorphism, epilepsy 
and severe ID were present in patient 6. The third glycosylation gene in which a variant was 
identified, PGAP1 (patient 12, reported elsewhere), is important in the GPI-anchor synthesis 
pathway.257 Several other genes, PIGA, PIGN and PIGT, implicated in this pathway are known 
to be implicated in CVI and ID as well,260,266-269 and, recently, also PGAP1 variants were found 
to be associated with CVI and ID.260,270
RERE is another gene with a functional link with a gene known to be aberrant in CVI. A de 
novo variant in this arginine-glutamic acid repeats-encoding gene was identified in patient 
22. RERE binds directly to NR2F1, which has recently been identified to be aberrant in Bosch-
Boonstra-Schaaf optic atrophy syndrome, of which one of the features is CVI.191,271 In addition, 
RERE null mice show severe central nervous system abnormalities and defects of the optic 
vesicles.272 Furthermore, RERE forms a complex with NR2F2 and EP300 and positively regu-
lates retinoic acid signalling in mice.273 Retinoic acid signaling induces optic vesicle and brain 
development and Nr2f1 and Nr2f2 transcription in mice stem cells.274 These findings indicate 
that RERE is a likely candidate gene for CVI (http://www.REREgene.com).
Several other candidate genes, GRIN2B, GRIN1, KCNQ3, GABRB2 and SOX5, have been im-
plicated in neurological diseases other than CVI. In GRIN2B a de novo missense variant was 
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identified in patient 19. Variants in GRIN2B have previously been found in individuals with 
ID.275 GRIN2B encodes the subunit NR2B of the NMDA receptor, which is present during de-
velopment. In the first decade, during the critical period of developing cerebral visual cortex, 
NR2B is replaced by NR2A, encoded by GRIN2A.276 For GRIN2A one 4-year-old girl has been 
reported with low vision.277 So it might be expected that variants in GRIN2B can lead to a 
disturbed development and subsequently CVI. So far, 18 patients with GRIN2B variants have 
been reported.180,181,252,275,278-280 In two patients with West syndrome poor eye contact was re-
ported,279 whereas in the other patients no assessment for CVI or visual acuity measurement 
was mentioned.
In patient 11 a homozygous missense variant in GRIN1 was identified. GRIN1 encodes for 
NR1, which, together with NR2B or NR2A, forms the NMDA-receptor. NR1 is an essential 
subunit for the NMDA-receptor, and full Nr1 knockout mice are not viable.281 So far, only four 
patients with de novo heterozygous variants in GRIN1 have been reported with ID with or 
without epilepsy.180,282,283 Those variants are located in or nearby the transmembrane do-
mains,282 in contrast to the homozygous variant identified in patient 11, which is situated in 
the extracellular ligand-binding domain of GRIN1 (http://www.ebi.ac.uk/interpro).284 Whether 
the here identified variant might be considered as a hypomorphic variant, giving rise to an 
autosomal recessive disorder, awaits functional proof.
In patient 24, with ID and absence seizures, a de novo missense variant in KNCQ3 was identi-
fied. The same variant was previously reported in a patient with severe ID and multifocal ab-
normalities on EEG.185 KNCQ3 encodes a potassium channel subunit, and has been implicated 
in benign epileptic seizures. Several families have been reported with seizures that resolve 
before the age of 6 years without CVI or ID.285-293 However, recently, two additional families 
with seizures and variants in KCNQ3 have been reported in which family members had vari-
ous IQ levels from severe ID to normal.294,295 Therefore, the phenotypic spectrum of KCNQ3 
variants appeared to be broader than benign epilepsy only and might well include CVI.
A de novo GABRB2 variant in the transmembrane domain was identified in patient 8. In 
addition to CVI and ID, by EEG he had continuous spike and wave during slow wave sleep 
(CSWS) epilepsy, a severe epileptic encephalopathy, from the age of 6 years. One de novo 
GABRB2 variant, in the N-terminal extracellular domain implicated in GABA-binding, has 
been reported in a patient with ID and febrile seizures, tonic clonic convulsions and partial 
seizures.296 Variants in other genes encoding GABA type A-receptor subunits have been iden-
tified in different epilepsy syndromes, making GABRB2 a likely explanation for the phenotype 
in our patient.
Finally, in patient 17 a de novo missense variant in SOX5 was identified, located in the HMG-
domain, which is important for DNA- and protein binding. Intragenic deletions in SOX5 have 
been reported as a cause for ID.297-299 In one patient optic nerve hypoplasia was reported, 
which is in agreement with the slightly pale optic discs in our patient. However, several 
intragenic deletions are reported in healthy individuals in the Database of Genomic Variants 
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(http://dgv.tcag.ca/dgv/app/home).147 Without functional assays it is difficult to ascertain 
whether the here identified missense variant leads to loss or gain of function.
In literature several genes, for example PAX6 and SOX2, are reported to influence the 
structural development of eye and brain.300 These genes may affect other parts of the visual 
system as well. However, whether aberrant genes lead to a vision disorder exclusively owing 
to structural eye defects, or whether an additional cerebral component is present, is difficult 
to distinguish. In the here presented patients without structural eye abnormalities no rare 
variants have been identified in these genes.
In total, in 5 out of the 25 patients (20%) a genetic diagnosis for the CVI could be established. 
The proportion of genetically solved cases is lower than previously reported for ID, but this is 
probably due to the fact that only a few CVI genes are yet known.182-185 In another 11 patients 
(44%) variants in one or more candidate genes for CVI could be identified with several showing 
a functional link with known genes for CVI. In addition, several candidate genes have been 
implicated in a neurological disorder, such as ID and epilepsy. In those reported patients oph-
thalmological investigation has not always been performed or mentioned, and especially in 
patients with ID CVI can easily remain unnoticed.225 In addition, for some disorders only few 
patients have been reported, and the full clinical spectrum and its variability is probably not 
yet clear. Nevertheless, for the identified candidate genes reported here it is of importance to 
find more patients with CVI and a variant in the same gene to establish a causal relationship. In 
combination with additional functional studies this will increase our insight into the develop-
ment of the visual system. So far, CVI has been mainly investigated in the light of acquired brain 
damage. Previously, we associated several chromosomal aberrations and NR2F1 with CVI.191,251 
Here, we show the importance of monogenetic disorders in the pathogenesis of CVI and the 
necessity to test for genetic defects using genome-wide diagnostic tools.
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suPPleMenTary MeThoDs
Subjects
Twenty-five patients with CVI and a visual acuity ≤0.3 were included. The history was taken, and no 
potential risk factors for CVI, such as preterm birth, perinatal problems or hydrocephalus, were present. 
CVI was diagnosed when no other ocular diagnosis could explain the visual impairment. The diagnosis 
was made by a paediatric ophthalmologist after ophthalmological examination. This examination 
included visual acuity testing, crowding measurements, the examination of eye movements, fixation 
and oculomotor abnormalities, visual field measurements, slit lamp examination, and funduscopy. In 
patient with a lower cognitive level visual acuity was measured with forced preferential looking by 
using Teller acuity cards (TAC).64 In patients with higher developmental level tests based on object 
recognition, such as the LH test or Landolt C test were used.66 Visual fields were measured by using a 
confrontational method with white Stycar balls on a stick.75
 In addition, the patients were clinically examined by a clinical geneticist and pathogenic chromo-
somal aberrations were excluded by array CGH. WES was performed in the patients and their parents, 
and except for patient 11, the parents were unrelated.
Whole exome sequencing
 In all 25 patients WES was performed using the trio approach (patient-parents).179 In 11 trios (patients 
1-11) WES was performed on an Illumina HiSeq platform with the Agilent SureSelect All Exon V4 re-
agent for target enrichment (Agilent Technologies, Inc., Santa Clara, CA, USA). Alignment and variants 
and indels were called with Burrows-Wheeler Aligner, BWA, and Genome Analysis Toolkit, GATK.301,302 
WES was executed in 10 trios (patients 12-21) at the Baylor-Hopkins Center for Mendelian Genomics 
on a Illumina Hiseq 2000 platform (Illumina, San Diego, CA, USA) and in three trios (patients 22, 23 
and 24) on a Solid 5500 XL platform (Life Technologies, Carlsbad, CA, USA) of which the methods have 
been reported previously.191,303 In one trio (patient 25) the WES was also performed on a Solid 5500 XL 
platform, but the Agilent XL SureSelect All Exon 50Mb reagent was used for target enrichment (Agilent 
Technologies, Inc., Santa Clara, CA, USA) and the variants and indels were called with Lifescope v2.1 (Life 
Technologies, Carlsbad, CA, USA). In all 25 patients and their parents the sequence reads were mapped 
and aligned to the USCS genome Browser GRCh37/hg19 Human Genome Reference Assembly.
Variant prioritization and validation
After quality filtering (variant reads >15%) local and global variants (≥1% allele occurrence 
in intramural database, dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) or Exome Variant Server, 
NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (http://evs.gs.washington.edu/EVS/) 
were excluded (Supplementary Figure S1). For the 10 patients for which WES was performed at 
the Baylor-Hopkins Center for Mendelian Genomics, the data were also filtered for cohort allele 
frequency ≤2% (cohort consisted of patients with various disorders and their healthy parents, 
n=200) and an additional quality score was used (PHRED ≥80 or passed). The exonic nonsyn-
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onymous and canonical splice site variants were selected for further analysis. A de novo analysis was 
performed for all trios. Furthermore, the results were analysed for homozygous variants (>80% variant 
reads), compound heterozygous (two or more variants present in one gene) and hemizygous variants 
in males (X-chromosome, >80% variant reads). When the autosomal recessive variants were present on 
one allele, the variants were excluded (based on the raw data (BAM-file) of a patient and its parents). 
Truncating variants, consisting of frameshift, nonsense or splice site variants (assessed using Interac-
tive Biosoftware Alamut version 2.3 rev2), and missense variants predicted to affect function (majority 
vote of Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/), MutPred (http://mutpred.mutdb.org/) 
and SNPs&GO (http://snps.path.uab.edu/snps-and-go/pages/method.html)) were validated by Sanger 
sequencing in patient and parents.304-306 For compound heterozygous variants at least one of the vari-
ants should be predicted to be protein truncating, or, when concerning missense variants, both variants 
should be predicted to affect function. For the maternally inherited variants on the X-chromosome in 
males and the autosomal recessive variants further segregation analysis in the family was undertaken, 
whenever possible.
Gene classification
For the validated variants in genes that were previously indicated in the Online Mendelian Inheri-
tance in Man (OMIM) database (www.omim.org) the inheritance pattern and the variant type were 
compared. Furthermore, a phenotypic comparison of the patient and the reported individuals in 
literature was performed by a clinical geneticist and assessment was made whether the pheno-
type showed similarities. If the phenotype was distinct the gene was classified as unlikely to be 
causative. When the phenotype showed similarities and the patients reported did not have CVI, 
the gene was classified as a candidate gene for CVI. Genes that were previously reported to be 
involved in the pathogenesis of CVI were classified as “known CVI-associated gene”. The remaining 
(non-OMIM disease related) validated variants were classified based on the previously reported 
method by De Ligt et al. and Gilissen et al.182,256 In brief, the variants were scored for their functional 
relevance on four items. First, it was assessed whether the variant was disruptive or whether the 
missense variants involved a conserved nucleotide (phyloP >3.5). Subsequently, the list of 525 
genes known to be associated with ID from Gilissen et al. was loaded into ToppGene to select 
Gene Ontology (GO) and Mouse Phenotype (MP) terms with a significant enrichment (FDR<0.05 
by Benjamini Hochberg method) (https://toppgene.cchmc.org/, January 2015).256,307 When there 
was overlap between the enriched terms and the GO- or MP-terms for the genes identified in the 
present study the variant scored positive. Finally, it was assessed whether the gene was expressed 
during brain development in the Human Brain Transcriptome (http://hbatlas.org/).308 A gene was 
considered to be expressed when the Log2 intensity was ≥6 for at least three periods of the devel-
oping brain (<20 years of age). When the detected variant and/or the gene scored positive for at 
least two items (conservation/disruptive, brain expression, GO- and/or MP term) the aberrant gene 
was classified as a possible candidate gene for CVI. Otherwise the aberrant gene was classified as 
unlikely to be causative for CVI.
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Stringent criteria
For the de novo and X-linked missense variants, the variants with an allele frequency ≥0.1% 
in intramural database, dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) or Exome Variant Server, 
NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (http://evs.gs.washington.edu/
EVS/) were excluded. This frequency of 0.1% is, with a wide margin, based on the estimated 
incidence of 0.0225% of CVI in children in the Netherlands.53 In addition, for loss of function 
variants, the ExAC browser (Exome Aggregation Consortium (ExAC), Cambridge, MA (http://
exac.broadinstitute.org) [(June, 2015 accessed]) was used to obtain all the loss of function 
variants in the identified gene. Genes with a truncating allele frequency ≥0.1% (de novo or 
X-linked variants) or ≥1.0% (autosomal recessive variants) were excluded.
suPPleMenTary fIGures anD TaBles
Autosomal recessive
• Homozygous (>80% variant  reads)
• Compound heterozygous 
  (bi-allelic mutations)
Quality ltering
• Variant reads >15%
• PHRED1 or 2 qualityscore* ≥80 or PASS
Excluded common variants
• dbSNP allele frequency <1%
• Intramural allele frequency <1%
• Cohort allele frequency* ≤2%
Gene component
• Exonic nonsynonymous
• Canonical splice acceptor and donor site
Truncating variant†
Missense variant: 
majority vote: aect function
(Mutpred, SNPs&Go, PolyPhen-2)
X-linked recessive in males 
(>80% variant reads)Dominant (De novo)
Validation & segregation analysis
supplementary figure s1: flow chart of variant prioritization
*Only used for the 10 patients in whom WES was performed at the Baylor-Hopkins Center for Mendelian 
Genomics. †Frameshift, nonsense or splice site variant.
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supplementary Table s1: additional clinical characteristics of the patients
in which whole exome sequencing was performed.
Patient 1 2 3 4
Gender M M M M
Birth weight (grams) 3640 (75th centile) 2415 (15th centile) Normal 3750
Gestational age (weeks) 39 37 41 At term
Age at investigations (years) 5 3+7 33 30
Height (cm) 118 cm (50th centile) 97 (15th centile)
OFC (cm) 51.5 cm (40th centile) 47.0 (1st centile) 55.5 (10th centile) 56.0 (15th centile)
Development 2-3 years at 6 years 11 months at 1+9 months Delayed Delayed
First words 9 months - - -
Walk independently 1+10 years - 10 years -
Dysmorphisms Long eyelashes, full nasal tip, long columella, thin 
upper lip, large ears, fragmented palmar creases, 
short distal finger phalanges, longitudinally grooved 
fingernails, fetal finger pads, short distal toe 
phalanges, syndactyly II-III toes, clinodactyly IV-V toes
Metopic ridge, medial flaring of 
eyebrows, long upward slanted 
palpebral fissures, small mouth, 
small ears, tapering fingers, 
bilateral clinodactyly IV and V toes, 
hypoplastic toenails, extension 
restriction of knee, small penis
Coarse facial features, prominente ridge above the eyes, upward 
slanted palpebral fissures, broad nasal ridge, protruding ears, 
extension restriction of knees and fingers, hypoplastic toenails
Deepset eyes, prominent nose, small nostrils, full alae nasi, 
broad chin, single tranverse palmar crease right, tapering 
fingers, broad proximal interphalangeal joints, long toes and 
overriding II toes
Hearing Normal Normal Normal Normal
Other abnormalities Autism, hypermobility Alacrima, cryptorchidism, feeding 
problems, hypotonia, involuntary 
movements, axonal polyneuropathy
- Automutilation, recurrent otitis
Epilepsy - - + +
Report MRI brain Normal Delayed myelination NP NP
Refraction error, right eye S+0.25 S+1.00 S+1.00=C-1.00x90” S-3.00=C-1.00x45”
Refraction error, left eye S+0.50 Emmetropic S+1.00=C-1.00x90” S-3.00=C-1.00x135”
Correction of refraction - - - -
Visual acuity, both eyes 20/63 (0.3) 20/190 (0.1) 20/260 (0.08) 0.1
Method (distance) TAC (55 cm) TAC (55 cm) TAC (55 cm) Cardiff (1 m)
Strabismus - + + +
Motility disorder of the eyes not 
leading to strabismus
- + + +
Nystagmus Manifest - - -
Visual field defects - + - +
Slit lamp examination Iris transillumination Cornea scar Normal Normal
Optic disc Partial pale Partial pale Normal Pale
Macula Normal NP Normal Normal
VEP (age) NP NP Flash: prolonged latency time. Pattern: normal (10 years) NP
ERG (age) NP NP NP
Visual behaviour, fixation and visual 
attention
Fluctuating visual attention, looking away from the target, short 
fixation, auditive stimuli dominates
Short fixation
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supplementary Table s1: additional clinical characteristics of the patients
in which whole exome sequencing was performed.
Patient 1 2 3 4
Gender M M M M
Birth weight (grams) 3640 (75th centile) 2415 (15th centile) Normal 3750
Gestational age (weeks) 39 37 41 At term
Age at investigations (years) 5 3+7 33 30
Height (cm) 118 cm (50th centile) 97 (15th centile)
OFC (cm) 51.5 cm (40th centile) 47.0 (1st centile) 55.5 (10th centile) 56.0 (15th centile)
Development 2-3 years at 6 years 11 months at 1+9 months Delayed Delayed
First words 9 months - - -
Walk independently 1+10 years - 10 years -
Dysmorphisms Long eyelashes, full nasal tip, long columella, thin 
upper lip, large ears, fragmented palmar creases, 
short distal finger phalanges, longitudinally grooved 
fingernails, fetal finger pads, short distal toe 
phalanges, syndactyly II-III toes, clinodactyly IV-V toes
Metopic ridge, medial flaring of 
eyebrows, long upward slanted 
palpebral fissures, small mouth, 
small ears, tapering fingers, 
bilateral clinodactyly IV and V toes, 
hypoplastic toenails, extension 
restriction of knee, small penis
Coarse facial features, prominente ridge above the eyes, upward 
slanted palpebral fissures, broad nasal ridge, protruding ears, 
extension restriction of knees and fingers, hypoplastic toenails
Deepset eyes, prominent nose, small nostrils, full alae nasi, 
broad chin, single tranverse palmar crease right, tapering 
fingers, broad proximal interphalangeal joints, long toes and 
overriding II toes
Hearing Normal Normal Normal Normal
Other abnormalities Autism, hypermobility Alacrima, cryptorchidism, feeding 
problems, hypotonia, involuntary 
movements, axonal polyneuropathy
- Automutilation, recurrent otitis
Epilepsy - - + +
Report MRI brain Normal Delayed myelination NP NP
Refraction error, right eye S+0.25 S+1.00 S+1.00=C-1.00x90” S-3.00=C-1.00x45”
Refraction error, left eye S+0.50 Emmetropic S+1.00=C-1.00x90” S-3.00=C-1.00x135”
Correction of refraction - - - -
Visual acuity, both eyes 20/63 (0.3) 20/190 (0.1) 20/260 (0.08) 0.1
Method (distance) TAC (55 cm) TAC (55 cm) TAC (55 cm) Cardiff (1 m)
Strabismus - + + +
Motility disorder of the eyes not 
leading to strabismus
- + + +
Nystagmus Manifest - - -
Visual field defects - + - +
Slit lamp examination Iris transillumination Cornea scar Normal Normal
Optic disc Partial pale Partial pale Normal Pale
Macula Normal NP Normal Normal
VEP (age) NP NP Flash: prolonged latency time. Pattern: normal (10 years) NP
ERG (age) NP NP NP
Visual behaviour, fixation and visual 
attention
Fluctuating visual attention, looking away from the target, short 
fixation, auditive stimuli dominates
Short fixation
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supplementary Table s1: additional clinical characteristics of the patients
in which whole exome sequencing was performed (continued)
Patient 5 6 7 8
Gender M F F M
Birth weight (grams) 4250 (95th centile) 3560 (70th centile)
Gestational age (weeks) 39 39 43 40
Age at investigations (years) 27 23 22 17
Height (cm) 190 (84th centile) 167 (30th centile)
OFC (cm) 59.0 (70th centile) 50.5 (<1st centile) 59.0 (99th centile)
Development PIQ = 55-69 and VIQ = 35-40 Delayed Delayed Delayed
First words 2-2+6 years - 4 years -
Walk independently 2-2+6 years - + 7 years
Dysmorphisms Synophrys, full eyebrows, high palate, retrognathia, 
prominent ear lobes, broad distal phalanges, broad 
hallux
Full eyebrows, stiff hair, mid facial 
hypoplasia, full lips, soft skin of the 
hands, hyperlaxity of the fingers
Long asymmetric face, proptosis, broad nose, full lips, broad 
mouth, wide space teeth, small high palate, simple left ear, 
overfolding of the right superior helices, hyperlordosis, soft 
skin, IV finger clinodactyly, fetal finger pads, pes equines, many 
moles
Broad nose, full lips, large hands, broad fingers
Hearing Normal Normal Normal Normal
Other abnormalities Recurrent otitis, PDD-NOS, ADHD, hypotonia Unilateral congenital talipes 
equinovarus, hypotonia, scoliosis, 
swallowing problems resulting into 
PEG tube for fluid
Hypotonia, adenotonsillectomy Gastroesophageal reflux, autism
Epilepsy + + + +
Report MRI brain Normal Enlarged peripheral liquor system, 
delayed myelination
Asymmetric wide ventricles, thin corpus callosum NP
Refraction error, right eye S+2.00=C-1.00x180” S+1.00=C-2.50x153” S+0.50=C-1.00x66” S-6.00
Refraction error, left eye S+1.75=C-1.25x180” S-1.00=C-3.50x12” S+1.00=C-1.75x91” S-6.00
Correction of refraction - - - -
Visual acuity, both eyes 3/10 (0.3) 20/190 (0.1) 3/12 (0.25) 20/260 (0.06)
Method (distance) Landolt C (5 m) TAC (55 cm) LH (3 m) TAC (55 cm)
Strabismus - - + +
Motility disorder of the eyes not 
leading to strabismus
+ + + -
Nystagmus Manifest and latent - Manifest and latent -
Visual field defects + + - +
Slit lamp examination Normal Normal Normal Normal
Optic disc Partial pale Partial pale Normal Pale, enlarged excavations
Macula Not recognizable Normal Normal Normal
VEP (age) Flash: normal. Pattern: normal (11 years) Pattern: normal. Flash: variable 
response with normal latency time 
(1+8 years)
NP NP
ERG (age) Normal (13 years) NP Normal (2 months) NP
Visual behaviour, fixation and visual 
attention
Fixation problems, looking away from the target, 
periods of diminished visual attention
Fixation abnormalities Does not use his vision
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in which whole exome sequencing was performed (continued)
Patient 5 6 7 8
Gender M F F M
Birth weight (grams) 4250 (95th centile) 3560 (70th centile)
Gestational age (weeks) 39 39 43 40
Age at investigations (years) 27 23 22 17
Height (cm) 190 (84th centile) 167 (30th centile)
OFC (cm) 59.0 (70th centile) 50.5 (<1st centile) 59.0 (99th centile)
Development PIQ = 55-69 and VIQ = 35-40 Delayed Delayed Delayed
First words 2-2+6 years - 4 years -
Walk independently 2-2+6 years - + 7 years
Dysmorphisms Synophrys, full eyebrows, high palate, retrognathia, 
prominent ear lobes, broad distal phalanges, broad 
hallux
Full eyebrows, stiff hair, mid facial 
hypoplasia, full lips, soft skin of the 
hands, hyperlaxity of the fingers
Long asymmetric face, proptosis, broad nose, full lips, broad 
mouth, wide space teeth, small high palate, simple left ear, 
overfolding of the right superior helices, hyperlordosis, soft 
skin, IV finger clinodactyly, fetal finger pads, pes equines, many 
moles
Broad nose, full lips, large hands, broad fingers
Hearing Normal Normal Normal Normal
Other abnormalities Recurrent otitis, PDD-NOS, ADHD, hypotonia Unilateral congenital talipes 
equinovarus, hypotonia, scoliosis, 
swallowing problems resulting into 
PEG tube for fluid
Hypotonia, adenotonsillectomy Gastroesophageal reflux, autism
Epilepsy + + + +
Report MRI brain Normal Enlarged peripheral liquor system, 
delayed myelination
Asymmetric wide ventricles, thin corpus callosum NP
Refraction error, right eye S+2.00=C-1.00x180” S+1.00=C-2.50x153” S+0.50=C-1.00x66” S-6.00
Refraction error, left eye S+1.75=C-1.25x180” S-1.00=C-3.50x12” S+1.00=C-1.75x91” S-6.00
Correction of refraction - - - -
Visual acuity, both eyes 3/10 (0.3) 20/190 (0.1) 3/12 (0.25) 20/260 (0.06)
Method (distance) Landolt C (5 m) TAC (55 cm) LH (3 m) TAC (55 cm)
Strabismus - - + +
Motility disorder of the eyes not 
leading to strabismus
+ + + -
Nystagmus Manifest and latent - Manifest and latent -
Visual field defects + + - +
Slit lamp examination Normal Normal Normal Normal
Optic disc Partial pale Partial pale Normal Pale, enlarged excavations
Macula Not recognizable Normal Normal Normal
VEP (age) Flash: normal. Pattern: normal (11 years) Pattern: normal. Flash: variable 
response with normal latency time 
(1+8 years)
NP NP
ERG (age) Normal (13 years) NP Normal (2 months) NP
Visual behaviour, fixation and visual 
attention
Fixation problems, looking away from the target, 
periods of diminished visual attention
Fixation abnormalities Does not use his vision
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supplementary Table s1: additional clinical characteristics of the patients
in which whole exome sequencing was performed (continued)
Patient 9 10 11 12
Gender F M F M
Birth weight (grams) 3300 (40th centile) 4250 (85th centile) 2900 3550 gram (70th centile)
Gestational age (weeks) 40 42 At term 38
Age at investigations (years) 13 12 6 7
Height (cm) 161 (50th centile) 131 (50th centile)
OFC (cm) 54.0 (50th centile) 55.0 (85th centile) 50.5 (35th centile) 52.5 (50th centile)
Development 1+6-2+6 years at 5+7 years < 24 months Delayed IQ 49
First words 2 years - - 2-2+6 years
Walk independently 2+6 years - - 2-2+6 years
Dysmorphisms Large, slightly protruding ears, broad nasal tip with 
vertical dimple in nasal ridge, high palate, full lips, 
long fingers, additional flexion creases of III fingers, 
fragmented palmar creases, long hallux, long small 
feet, dry skin, longtitudinal creases in fingernails
Upward slanted palpebral fissures, 
deep-set eyes, broad nose, large 
left ear, prominent crux superior, 
fetal finger pads, pes equines, hallux 
valgus, syndactyly II-III toe
Upward slanted palpebral fissures, full nasal tip and alae nasi, 
large tongue, broad alveolar ridges
Upward slanted palpebral fissures, deep set eyes, large ear lobes, 
prominent helices and antihelices, tooth had extra mammelons, 
diminished enamel
Hearing Normal Mild increased hearing treshold Normal Normal
Other abnormalities Autism Bilateral cheilognathopalatoschisis, 
gastroesophageal reflux, periods of 
restlessness and sleeping problems
Central hypotonia, recurrent upper airway infections, feeding 
problems
Hypotonia, factor XII deficiency
Epilepsy - - - -
Report MRI brain Cerebellar atrophy and to a less extent of cerebrum Cavum septum pellucidum, thin 
corpus callosum
Probably white matter abnormalities (poor quality scan due 
to movement)
Normal
Refraction error, right eye S+5.25=C-1.00x95” S+2.00=C-0.75x8” S+3.25=C-3.75x20” Emmetropic
Refraction error, left eye S+3.00=C-0.25x90” S+1.50=C-1.00x3” S+4.25=C-4.25x166” Emmetropic
Correction of refraction + - - -
Visual acuity, both eyes 10/32 (0.3) 20/130 (0.15) 20/190 (0.1) 3/10 (0.3)
Method (distance) LH (3 m) TAC (55 cm) TAC (55 cm) Landolt C (5 m)
Strabismus + + + +
Motility disorder of the eyes not 
leading to strabismus
+ - +
Nystagmus - - - Latent, and minimal manifest
Visual field defects - + + -
Slit lamp examination Normal Normal Megalocornea Normal
Optic disc Normal Normal Normal Normal
Macula Normal Normal Normal Normal
VEP (age) NP NP Flash: normal. Pattern reversal: normal (10 months) NP
ERG (age) NP NP Normal (9 months) NP
Visual behaviour, fixation and visual 
attention
Fixation abnormalities Fluctuating visual attention, slow 
visual reaction
Staring at lights Crowding, short fixation
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in which whole exome sequencing was performed (continued)
Patient 9 10 11 12
Gender F M F M
Birth weight (grams) 3300 (40th centile) 4250 (85th centile) 2900 3550 gram (70th centile)
Gestational age (weeks) 40 42 At term 38
Age at investigations (years) 13 12 6 7
Height (cm) 161 (50th centile) 131 (50th centile)
OFC (cm) 54.0 (50th centile) 55.0 (85th centile) 50.5 (35th centile) 52.5 (50th centile)
Development 1+6-2+6 years at 5+7 years < 24 months Delayed IQ 49
First words 2 years - - 2-2+6 years
Walk independently 2+6 years - - 2-2+6 years
Dysmorphisms Large, slightly protruding ears, broad nasal tip with 
vertical dimple in nasal ridge, high palate, full lips, 
long fingers, additional flexion creases of III fingers, 
fragmented palmar creases, long hallux, long small 
feet, dry skin, longtitudinal creases in fingernails
Upward slanted palpebral fissures, 
deep-set eyes, broad nose, large 
left ear, prominent crux superior, 
fetal finger pads, pes equines, hallux 
valgus, syndactyly II-III toe
Upward slanted palpebral fissures, full nasal tip and alae nasi, 
large tongue, broad alveolar ridges
Upward slanted palpebral fissures, deep set eyes, large ear lobes, 
prominent helices and antihelices, tooth had extra mammelons, 
diminished enamel
Hearing Normal Mild increased hearing treshold Normal Normal
Other abnormalities Autism Bilateral cheilognathopalatoschisis, 
gastroesophageal reflux, periods of 
restlessness and sleeping problems
Central hypotonia, recurrent upper airway infections, feeding 
problems
Hypotonia, factor XII deficiency
Epilepsy - - - -
Report MRI brain Cerebellar atrophy and to a less extent of cerebrum Cavum septum pellucidum, thin 
corpus callosum
Probably white matter abnormalities (poor quality scan due 
to movement)
Normal
Refraction error, right eye S+5.25=C-1.00x95” S+2.00=C-0.75x8” S+3.25=C-3.75x20” Emmetropic
Refraction error, left eye S+3.00=C-0.25x90” S+1.50=C-1.00x3” S+4.25=C-4.25x166” Emmetropic
Correction of refraction + - - -
Visual acuity, both eyes 10/32 (0.3) 20/130 (0.15) 20/190 (0.1) 3/10 (0.3)
Method (distance) LH (3 m) TAC (55 cm) TAC (55 cm) Landolt C (5 m)
Strabismus + + + +
Motility disorder of the eyes not 
leading to strabismus
+ - +
Nystagmus - - - Latent, and minimal manifest
Visual field defects - + + -
Slit lamp examination Normal Normal Megalocornea Normal
Optic disc Normal Normal Normal Normal
Macula Normal Normal Normal Normal
VEP (age) NP NP Flash: normal. Pattern reversal: normal (10 months) NP
ERG (age) NP NP Normal (9 months) NP
Visual behaviour, fixation and visual 
attention
Fixation abnormalities Fluctuating visual attention, slow 
visual reaction
Staring at lights Crowding, short fixation
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supplementary Table s1: additional clinical characteristics of the patients
in which whole exome sequencing was performed (continued)
Patient 13 14 15 16
Gender M M M M
Birth weight (grams) 3510 (7th centile) 3980 (70th centile) 3520 2900 (<2th centile)
Gestational age (weeks) 42 42 At term 42
Age at investigations (years) 12 3+8 1+7 21
Height (cm) 159 (p84) 162 (<1st centile)
OFC (cm) 57.0 (98th centile) 53.3 (87th centile) 45.2 (1st centile) 54.5 (2nd centile)
Development IQ 48 7 months at 2+7 years 5-7 months at 2+8 years Delayed
First words 1 year - - -
Walk independently 2 years - - 7 years
Dysmorphisms Protruding ears, long nostrils, prominent alae nasi, 
flattened thorax, long fingers and toes.
Epicanthal folds, blepharophimosis, 
upward slanted palpebral fissures, 
flattened nasal tip, long philtrum, 
small teeth, retrognathia, deep 
palmar creases, long tapering 
fingers, longtitudinal creases in 
fingernails, long hallux
Broad forehead, hypertelorism, broad mouth with thin upper 
lip, pointed helices, prominent crus of the ear, flattened upper 
helices, short broad hands, tapering fingers, fragmented 
palmar creases
Upward slanting palpebral fissures, hypertelorism, prominent 
nose, broad mouth with full lips, small ears, protruding ear lobes, 
flattened folded helices, prominent antihelices, soft skin of the 
hands and feet, fetal finger pads, unilateral tranverse palmar 
crease, pes equinis, deep set toenails
Hearing Normal Normal Normal Normal
Other abnormalities - Hypotonia, feeding problems, 
hyperlaxity of joints
Feeding problems Hypotonia, restless, temper tantrums
Epilepsy - - - -
Report MRI brain Normal Cerebellar dysplasia and white 
matter abnormalities
Normal Normal
Refraction error, right eye S+7.25=C-2.25x164” S+0.50 S+1.50=C-1.00x180” S+1.00
Refraction error, left eye S+6.75=C-1.75x30” S+1.25=C-0.50x180” S+2.00=C-1.25x180” S-0.50
Correction of refraction + - - -
Visual acuity, both eyes 10/80 (0.125) 20/260 (0.08) 20/170 (0.12) 20/1600 (0.01)
Method (distance) LH (3 m) TAC (55 cm) TAC (55 cm) TAC 55 cm
Strabismus + + - +
Motility disorder of the eyes not 
leading to strabismus
- - - +
Nystagmus Latent Latent Manifest -
Visual field defects + - + +
Slit lamp examination Iris transillumination Cloudy lens Normal Normal
Optic disc Small, enlarged excavation Normal Slightly small Temporal pale, enlarged excavation
Macula Not recognizable Normal Normal Normal
VEP (age) Flash: late response Pattern onset: late response. 
Pattern reversal: normal respons (8 years)
NP Pattern reversal: no reproducible responses NP
ERG (age) Normal (8 years) NP NP NP
Visual behaviour, fixation and visual 
attention
Crowding, fluctuating visual performance, excentric 
fixation
Staring into light
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supplementary Table s1: additional clinical characteristics of the patients
in which whole exome sequencing was performed (continued)
Patient 13 14 15 16
Gender M M M M
Birth weight (grams) 3510 (7th centile) 3980 (70th centile) 3520 2900 (<2th centile)
Gestational age (weeks) 42 42 At term 42
Age at investigations (years) 12 3+8 1+7 21
Height (cm) 159 (p84) 162 (<1st centile)
OFC (cm) 57.0 (98th centile) 53.3 (87th centile) 45.2 (1st centile) 54.5 (2nd centile)
Development IQ 48 7 months at 2+7 years 5-7 months at 2+8 years Delayed
First words 1 year - - -
Walk independently 2 years - - 7 years
Dysmorphisms Protruding ears, long nostrils, prominent alae nasi, 
flattened thorax, long fingers and toes.
Epicanthal folds, blepharophimosis, 
upward slanted palpebral fissures, 
flattened nasal tip, long philtrum, 
small teeth, retrognathia, deep 
palmar creases, long tapering 
fingers, longtitudinal creases in 
fingernails, long hallux
Broad forehead, hypertelorism, broad mouth with thin upper 
lip, pointed helices, prominent crus of the ear, flattened upper 
helices, short broad hands, tapering fingers, fragmented 
palmar creases
Upward slanting palpebral fissures, hypertelorism, prominent 
nose, broad mouth with full lips, small ears, protruding ear lobes, 
flattened folded helices, prominent antihelices, soft skin of the 
hands and feet, fetal finger pads, unilateral tranverse palmar 
crease, pes equinis, deep set toenails
Hearing Normal Normal Normal Normal
Other abnormalities - Hypotonia, feeding problems, 
hyperlaxity of joints
Feeding problems Hypotonia, restless, temper tantrums
Epilepsy - - - -
Report MRI brain Normal Cerebellar dysplasia and white 
matter abnormalities
Normal Normal
Refraction error, right eye S+7.25=C-2.25x164” S+0.50 S+1.50=C-1.00x180” S+1.00
Refraction error, left eye S+6.75=C-1.75x30” S+1.25=C-0.50x180” S+2.00=C-1.25x180” S-0.50
Correction of refraction + - - -
Visual acuity, both eyes 10/80 (0.125) 20/260 (0.08) 20/170 (0.12) 20/1600 (0.01)
Method (distance) LH (3 m) TAC (55 cm) TAC (55 cm) TAC 55 cm
Strabismus + + - +
Motility disorder of the eyes not 
leading to strabismus
- - - +
Nystagmus Latent Latent Manifest -
Visual field defects + - + +
Slit lamp examination Iris transillumination Cloudy lens Normal Normal
Optic disc Small, enlarged excavation Normal Slightly small Temporal pale, enlarged excavation
Macula Not recognizable Normal Normal Normal
VEP (age) Flash: late response Pattern onset: late response. 
Pattern reversal: normal respons (8 years)
NP Pattern reversal: no reproducible responses NP
ERG (age) Normal (8 years) NP NP NP
Visual behaviour, fixation and visual 
attention
Crowding, fluctuating visual performance, excentric 
fixation
Staring into light
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supplementary Table s1: additional clinical characteristics of the patients
in which whole exome sequencing was performed (continued)
Patient 17 18 19 20
Gender M F M M
Birth weight (grams) 2545 (20th centile) 2910 (4th centile) 3870 (75th centile) 2820 (15th centile)
Gestational age (weeks) 37 42 40 38
Age at investigations (years) 12 11 8 8
Height (cm) 162 (84th centile) 124 (10th centile)
OFC (cm) 53.5 (35th centile) 57.5 (>99th centile) 51.5 (30th centile) 49.5 (5th centile)
Development 5 years at 11 years Delayed Delayed 9-11 months at 2+11 years
First words 3 years - - +
Walk independently 2+9 5+6 - 6 years
Dysmorphisms Marfanoid habitus, straight nose, full lips, 
fragmentated palmar creases, long fingers, fetal 
V-shaped pads
Full hair, prominent forehead, 
low-set eyebrows, epicanthal folds, 
broad nasal root, short philtrum, 
full lips, small ears, prominent 
antihelices, flattened helices, 
supernumerary nipples, fragmented 
palmar creases, broad proximal 
interphalangeal joints, long hands
Straight low set eyebrows, long eye lashes, down slanted 
palpebral fissures, large ears, cupid bow upper lip, thin upper 
lip, telangiectasias on back
Fetal finger pads, flat nails.
Hearing Normal Normal Normal NA
Other abnormalities Small mandible Palatoschisis, clenched hands, 
hypotonia, sleeping problems, 
recurrent otitis, stereotypic 
movements
Adenotonsillectomy, recurrent otitis, bilateral cryptorchidism, 
hypotonia, constipation, hand biting, eye poking
Amelogenesis imperfecta, otitis
Epilepsy - - - +
Report MRI brain Normal Bifrontal pachygyria, wide virchow 
robin spaces, dysplastic cerebellum
Normal Small areas of gliosis occipital
Refraction error, right eye S+1.50=C-0.50x146” Splan=C-6.00x55” S+6.00=C-5.00x12” S+1.00
Refraction error, left eye S+1.00=C-0.25x116” S-2.50=C-2.50x135” S+4.00=C-4.00x167” S+1.25
Correction of refraction - + + -
Visual acuity, both eyes 10/32 (0.3) 20/130 (0.15) 20/130 (0.15) 20/130 (0.15)
Method (distance) LH (3 m) TAC (84 cm) TAC (55 cm) TAC (55cm)
Strabismus + + + -
Motility disorder of the eyes not 
leading to strabismus
+ - + +
Nystagmus - - Manifest -
Visual field defects + + + +
Slit lamp examination Normal Normal Normal Normal
Optic disc Slightly pale Normal Enlarged excavations Pale
Macula Hypoplastic Normal Normal No clear macula reflex
VEP (age) NP NP NP NP
ERG (age) Normal (8 years) NP NP NP
Visual behaviour, fixation and visual 
attention
Crowding Fixation abnormalities Looking away from the target, fixation abnormalities
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supplementary Table s1: additional clinical characteristics of the patients
in which whole exome sequencing was performed (continued)
Patient 17 18 19 20
Gender M F M M
Birth weight (grams) 2545 (20th centile) 2910 (4th centile) 3870 (75th centile) 2820 (15th centile)
Gestational age (weeks) 37 42 40 38
Age at investigations (years) 12 11 8 8
Height (cm) 162 (84th centile) 124 (10th centile)
OFC (cm) 53.5 (35th centile) 57.5 (>99th centile) 51.5 (30th centile) 49.5 (5th centile)
Development 5 years at 11 years Delayed Delayed 9-11 months at 2+11 years
First words 3 years - - +
Walk independently 2+9 5+6 - 6 years
Dysmorphisms Marfanoid habitus, straight nose, full lips, 
fragmentated palmar creases, long fingers, fetal 
V-shaped pads
Full hair, prominent forehead, 
low-set eyebrows, epicanthal folds, 
broad nasal root, short philtrum, 
full lips, small ears, prominent 
antihelices, flattened helices, 
supernumerary nipples, fragmented 
palmar creases, broad proximal 
interphalangeal joints, long hands
Straight low set eyebrows, long eye lashes, down slanted 
palpebral fissures, large ears, cupid bow upper lip, thin upper 
lip, telangiectasias on back
Fetal finger pads, flat nails.
Hearing Normal Normal Normal NA
Other abnormalities Small mandible Palatoschisis, clenched hands, 
hypotonia, sleeping problems, 
recurrent otitis, stereotypic 
movements
Adenotonsillectomy, recurrent otitis, bilateral cryptorchidism, 
hypotonia, constipation, hand biting, eye poking
Amelogenesis imperfecta, otitis
Epilepsy - - - +
Report MRI brain Normal Bifrontal pachygyria, wide virchow 
robin spaces, dysplastic cerebellum
Normal Small areas of gliosis occipital
Refraction error, right eye S+1.50=C-0.50x146” Splan=C-6.00x55” S+6.00=C-5.00x12” S+1.00
Refraction error, left eye S+1.00=C-0.25x116” S-2.50=C-2.50x135” S+4.00=C-4.00x167” S+1.25
Correction of refraction - + + -
Visual acuity, both eyes 10/32 (0.3) 20/130 (0.15) 20/130 (0.15) 20/130 (0.15)
Method (distance) LH (3 m) TAC (84 cm) TAC (55 cm) TAC (55cm)
Strabismus + + + -
Motility disorder of the eyes not 
leading to strabismus
+ - + +
Nystagmus - - Manifest -
Visual field defects + + + +
Slit lamp examination Normal Normal Normal Normal
Optic disc Slightly pale Normal Enlarged excavations Pale
Macula Hypoplastic Normal Normal No clear macula reflex
VEP (age) NP NP NP NP
ERG (age) Normal (8 years) NP NP NP
Visual behaviour, fixation and visual 
attention
Crowding Fixation abnormalities Looking away from the target, fixation abnormalities
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in which whole exome sequencing was performed (continued)
Patient 21 22 23 24
Gender F M F F
Birth weight (grams) 3310 (20th centile) 4190 (87th centile) 3855 (70th centile) 2840 (8th centile)
Gestational age (weeks) 41 40 41 40
Age at investigations (years) 7 10 2+4 4
Height (cm) 157 (98th centile) 87 (16th centile) 112 (86th centile)
OFC (cm) 50.5 (16th centile) 55.5 (86th centile) 49.0 (55th centile) 49.5 (40th centile)
Development Delayed 6-24 months at 9 years Delayed 11-15 months at 3+6 years
First words 2+2 years - 1+6 years 3+6 years
Walk independently - + - 1+9 years
Dysmorphisms Ptosis, broad mouth, full lips, low hairline, small V 
fingers
Prominent forehead, deep-set eyes, 
bilateral blepharophimosis, full 
nose, full lips, broad large incisors, 
broad alveolar ridges, small high 
palate, thick helices and flattened 
upper helices
Epicanthal folds, upturned nasal tip, broad mouth, full lips, 
simple protruding ears with upturned ear lobes, tapering 
fingers and fetal fingers pads, curly slow growing hair
Upward slanted palpebral fissures, blepharophimosis, pear 
shaped nose, full nasal tip, full everted lower lip, small teeth, long 
tapering fingers, fetal finger pads. Straight blond hair with an 
occipital hair spot with dark curly hair
Hearing Normal Normal Normal Normal
Other abnormalities Hypotonia, feeding problems, gastroesophageal 
reflux, cerebellar ataxia
Hypotonia, feeding problems, 
pyloric hypertrophy, 
gastroesophageal reflux, 
vesicourethral reflux, recurrent 
airway infections
Hypotonia Recurrent upper airway infections
Epilepsy - + - +
Report MRI brain Periventricular white matter abnormalities, vermis 
atrophy
Wide ventricles, small archnoid cyst, 
possible frontal falx agenesis
Small optic chiasm and optic nerve, white matter abnormalities 
periventricular parieto-occipitaal
Bilateral subcortical periventricular white matter abnormalities
Refraction error, right eye S+5.25=x-1.00x10” Emmetropic S+3.00 S+1.00
Refraction error, left eye S+5.50=C-1.50x3” Emmetropic S+3.00 S+1.00
Correction of refraction + - - -
Visual acuity, both eyes 20/260 (0.08) 20/380 (0.05) 20/260 (0.08) 20/260 (0.08)
Method (distance) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC 955cm)
Strabismus - + + +
Motility disorder of the eyes not 
leading to strabismus
+ - - +
Nystagmus - - - -
Visual field defects + - + +
Slit lamp examination No pupilreflex, mild lens clouding Normal Normal Normal
Optic disc Normal Pale Pale Partial pale
Macula Normal Immature reflex Normal Normal
VEP (age) NP NP Flash: long latency times (10 months) NP
ERG (age) NP NP NP NP
Visual behaviour, fixation and visual 
attention
Fixation abnormalities Reaching at target without looking Short fixation, fluctuating visual attention
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in which whole exome sequencing was performed (continued)
Patient 21 22 23 24
Gender F M F F
Birth weight (grams) 3310 (20th centile) 4190 (87th centile) 3855 (70th centile) 2840 (8th centile)
Gestational age (weeks) 41 40 41 40
Age at investigations (years) 7 10 2+4 4
Height (cm) 157 (98th centile) 87 (16th centile) 112 (86th centile)
OFC (cm) 50.5 (16th centile) 55.5 (86th centile) 49.0 (55th centile) 49.5 (40th centile)
Development Delayed 6-24 months at 9 years Delayed 11-15 months at 3+6 years
First words 2+2 years - 1+6 years 3+6 years
Walk independently - + - 1+9 years
Dysmorphisms Ptosis, broad mouth, full lips, low hairline, small V 
fingers
Prominent forehead, deep-set eyes, 
bilateral blepharophimosis, full 
nose, full lips, broad large incisors, 
broad alveolar ridges, small high 
palate, thick helices and flattened 
upper helices
Epicanthal folds, upturned nasal tip, broad mouth, full lips, 
simple protruding ears with upturned ear lobes, tapering 
fingers and fetal fingers pads, curly slow growing hair
Upward slanted palpebral fissures, blepharophimosis, pear 
shaped nose, full nasal tip, full everted lower lip, small teeth, long 
tapering fingers, fetal finger pads. Straight blond hair with an 
occipital hair spot with dark curly hair
Hearing Normal Normal Normal Normal
Other abnormalities Hypotonia, feeding problems, gastroesophageal 
reflux, cerebellar ataxia
Hypotonia, feeding problems, 
pyloric hypertrophy, 
gastroesophageal reflux, 
vesicourethral reflux, recurrent 
airway infections
Hypotonia Recurrent upper airway infections
Epilepsy - + - +
Report MRI brain Periventricular white matter abnormalities, vermis 
atrophy
Wide ventricles, small archnoid cyst, 
possible frontal falx agenesis
Small optic chiasm and optic nerve, white matter abnormalities 
periventricular parieto-occipitaal
Bilateral subcortical periventricular white matter abnormalities
Refraction error, right eye S+5.25=x-1.00x10” Emmetropic S+3.00 S+1.00
Refraction error, left eye S+5.50=C-1.50x3” Emmetropic S+3.00 S+1.00
Correction of refraction + - - -
Visual acuity, both eyes 20/260 (0.08) 20/380 (0.05) 20/260 (0.08) 20/260 (0.08)
Method (distance) TAC (55 cm) TAC (55 cm) TAC (55 cm) TAC 955cm)
Strabismus - + + +
Motility disorder of the eyes not 
leading to strabismus
+ - - +
Nystagmus - - - -
Visual field defects + - + +
Slit lamp examination No pupilreflex, mild lens clouding Normal Normal Normal
Optic disc Normal Pale Pale Partial pale
Macula Normal Immature reflex Normal Normal
VEP (age) NP NP Flash: long latency times (10 months) NP
ERG (age) NP NP NP NP
Visual behaviour, fixation and visual 
attention
Fixation abnormalities Reaching at target without looking Short fixation, fluctuating visual attention
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sequencing was performed (continued)
Patient 25
Gender M
Birth weight (grams) 3180 (15th centile)
Gestational age (weeks) 41
Age at investigations (years) 7
Height (cm)
OFC (cm) 50.0 (15th centile)
Development 2+6 years at 6+9 years
First words +
Walk independently 1+9 years
Dysmorphisms Ptosis, upward slanted palpebral fissures, broad nasal rige, bifid nasal tip, 
full lips, prominent incisors with extra mammelons, prominent uvula, simple 
ears with squared helices, prominent antihelices, hypermobility of fingers 
and elbows, long fongers with distal brachydactyly, fragmented palmar 
creases, clinodactyly IV-V toes, shawl scrotum
Hearing Normal
Other abnormalities Polyhydramnion, hypotonia, drooling, feeding problems, bilateral hernia 
inguinalis, bilateral cryptorchidism, hyperactive behavior
Epilepsy -
Report MRI brain Periventricular white matter abnormalities
Refraction error, right eye Emmetropic
Refraction error, left eye S+1.00=C-1.00x90”
Correction of refraction -
Visual acuity, both eyes 3/12 (0.25)
Method (distance) LH (3 m)
Strabismus -
Motility disorder of the eyes not leading to 
strabismus
+
Nystagmus -
Visual field defects -
Slit lamp examination Normal
Optic disc Pale
Macula Not seen
VEP (age) Pattern: normal (6 months)
ERG (age) Normal (6 months)
Visual behaviour, fixation and visual attention Fixation abnormalities
ADHD: attention deficit hyperactivity disorder. ERG: Electroretinography. LH: Lea Hyvärinen test eye charts. 
NA: Not available. NP: Not performed. OFC: Occipital frontal head circumference. PDD-NOS: Pervasive de-
velopmental disorder-not otherwise specified. PEG: Percutaneous endoscopic gastrostomy. PIQ: Perfor-
mance IQ. TAC: Teller acuity cards. VEP: Visual evoked potential. VIQ: Verbal IQ.
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Patient Gene Inheritance segregation in 
anamnestically 
healthy family 
members
refseq accession 
number
oMIM database 
reference numbers
Chromosomal position 
(hg 19)
Dna change Protein change dbsnP allele 
frequency (%)
eVs allele 
frequency (%)
Intramural allele 
frequency (%)
2 FLNA X, maternal
Present in maternal 
grandfather
NM_001456.3
*300017
chrX:153577258 c.7879G>A p.(Glu2627Lys) 0 0.0098 0
14 ZMAT1 X, maternal
Present in maternal 
grandfather
NM_001011657.3 chrX:101141628 c.581T>A p.(Met194Lys) 0 0 0
14 CNGA2 X, maternal
Present in maternal 
grandfather
NM_005140.1
*300338
chrX:150911796 c.821G>A p.(Arg274His) 0.1757 0.1327 0.15
15 CACNA1F X, maternal
Present in maternal 
grandfather*
NM_005183.3
*300110
chrX:49083534 c.1174C>T p.(Arg392Trp) 0.0239 0.0095 0
20 PCDH11X X, maternal
Present in two 
brothers
NM_032968.4
*300246
chrX:91090781 c.278G>A p.(Arg93His) 0.0439 0.0095 0
21 ITPRIPL1 Paternal Present in sister NM_178495.5 chr2:96992802 c.457G>C p.(Glu153Gln) 0 0 0
21 ITPRIPL1 Maternal Present in sister NM_178495.5 chr2:96993332 c.987del p.(Trp329Cysfs*5) 0 0.0080 0
*An electroretinography excluded subclinical congenital stationary night blindness
type II in the grandfather.
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Patient Gene Inheritance segregation in 
anamnestically 
healthy family 
members
refseq accession 
number
oMIM database 
reference numbers
Chromosomal position 
(hg 19)
Dna change Protein change dbsnP allele 
frequency (%)
eVs allele 
frequency (%)
Intramural allele 
frequency (%)
2 FLNA X, maternal
Present in maternal 
grandfather
NM_001456.3
*300017
chrX:153577258 c.7879G>A p.(Glu2627Lys) 0 0.0098 0
14 ZMAT1 X, maternal
Present in maternal 
grandfather
NM_001011657.3 chrX:101141628 c.581T>A p.(Met194Lys) 0 0 0
14 CNGA2 X, maternal
Present in maternal 
grandfather
NM_005140.1
*300338
chrX:150911796 c.821G>A p.(Arg274His) 0.1757 0.1327 0.15
15 CACNA1F X, maternal
Present in maternal 
grandfather*
NM_005183.3
*300110
chrX:49083534 c.1174C>T p.(Arg392Trp) 0.0239 0.0095 0
20 PCDH11X X, maternal
Present in two 
brothers
NM_032968.4
*300246
chrX:91090781 c.278G>A p.(Arg93His) 0.0439 0.0095 0
21 ITPRIPL1 Paternal Present in sister NM_178495.5 chr2:96992802 c.457G>C p.(Glu153Gln) 0 0 0
21 ITPRIPL1 Maternal Present in sister NM_178495.5 chr2:96993332 c.987del p.(Trp329Cysfs*5) 0 0.0080 0
*An electroretinography excluded subclinical congenital stationary night blindness
type II in the grandfather.
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1 1 DLG4 De novo NP NM_001365.3 *602887 chr17:7107520 c.277dup p.(Tyr93Leufs*2) 0 0 0
2 2 NGLY1 Paternal & maternal NP NM_018297.3 *610661 chr3:25775422 c.1201A>T p.(Arg401*) 0 0.0231 0.08
3 3 HSPG2 Paternal Present in affected sister NM_001291860.1 *142461 chr1:22211048 c.1630C>T p.Arg544Cys 0 0 0.02
4 3 HSPG2 Maternal Present in affected sister NM_001291860.1 *142461 chr1:22206977 c.2077G>A p.Val693Met 0.1829 0.2466 0.6
5 3 TENM3 Paternal & maternal Homozygous present in 
affected sister
NM_001080477.1 *610083 chr4:183601761 c.1705G>A p.Gly569Ser 0.87 0.0493 0.06
6 6 SLC35A2 De novo NP NM_005660.1 *314375 chrX:48762386 c.800A>G p.(Tyr267Cys) 0 0 0
7 6 SRP72 De novo NP NM_006947.3 *602122 chr4:57356532 c.1354G>C p.Glu452Gln 0 0 0
8 7 AHDC1 De novo NP NM_001029882.2 *615790 chr1:27877225 c.1402dup p.(Cys468Leufs*49) 0 0 0
9 8 ARHGEF10L De novo NP NM_018125.3 *612494 chr1:18023681 c.3646G>A p.(Asp1216Asn) 0 0 0
10 8 GABRB2 De novo NP NM_021911.2 *600232 chr5:160761837 c.754C>G p.(Pro252Ala) 0 0 0
11 9 AMOT De novo NP NM_001113490.1 *300410 chrX:112035060 c.1926G>C p.Gln642His 0 0 0
12 10 OR52M1 De novo NP NM_001004137.1 - chr11:4566479 c.59C>T p.(Pro20Leu) 0 0 0
13 10 UHMK1 De novo NP NM_175866.4 *608849 chr1:162492294 c.1214C>T p.(Pro405Leu) 0 0 0
14 11 SLC25A16 De novo NP NM_152707.3 *139080 chr10:70246950 c.793C>T p.(Arg265Cys) 0 0 0
15 11 DCAF6 Paternal & maternal NP NM_001198956.1 *610494 chr1:168014447 c.2240G>A p.(Arg747Gln) 0.0471 0.0308 0.15
16 11 PHKB Paternal & maternal NP NM_000293.2 *172490 chr16:47536996 c.400G>A p.(Asp134Asn) 0.1115 0.1463 0.61
17 11 GRIN1 Paternal & maternal NP NM_007327.3 *138249 chr9:140051128 c.679G>C p.(Asp248His) 0 0 0
18 12 PGAP1 Maternal Not present in sister NM_024989.3 *611655 chr2:197761857 c.921_925del p.(Lys308Asnfs*25) 0 0 0
19 12 PGAP1 Paternal Heterozygous in sister NM_024989.3 *611655 chr2:197784746 c.274_276del p.(Pro92del) 0 0 0
20 13 NR2F1 De novo NP NM_005654.4 *132890 chr5:92921073 c.344G>C p.(Arg115Pro) 0 0 0
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1 1 DLG4 De novo NP NM_001365.3 *602887 chr17:7107520 c.277dup p.(Tyr93Leufs*2) 0 0 0
2 2 NGLY1 Paternal & maternal NP NM_018297.3 *610661 chr3:25775422 c.1201A>T p.(Arg401*) 0 0.0231 0.08
3 3 HSPG2 Paternal Present in affected sister NM_001291860.1 *142461 chr1:22211048 c.1630C>T p.Arg544Cys 0 0 0.02
4 3 HSPG2 Maternal Present in affected sister NM_001291860.1 *142461 chr1:22206977 c.2077G>A p.Val693Met 0.1829 0.2466 0.6
5 3 TENM3 Paternal & maternal Homozygous present in 
affected sister
NM_001080477.1 *610083 chr4:183601761 c.1705G>A p.Gly569Ser 0.87 0.0493 0.06
6 6 SLC35A2 De novo NP NM_005660.1 *314375 chrX:48762386 c.800A>G p.(Tyr267Cys) 0 0 0
7 6 SRP72 De novo NP NM_006947.3 *602122 chr4:57356532 c.1354G>C p.Glu452Gln 0 0 0
8 7 AHDC1 De novo NP NM_001029882.2 *615790 chr1:27877225 c.1402dup p.(Cys468Leufs*49) 0 0 0
9 8 ARHGEF10L De novo NP NM_018125.3 *612494 chr1:18023681 c.3646G>A p.(Asp1216Asn) 0 0 0
10 8 GABRB2 De novo NP NM_021911.2 *600232 chr5:160761837 c.754C>G p.(Pro252Ala) 0 0 0
11 9 AMOT De novo NP NM_001113490.1 *300410 chrX:112035060 c.1926G>C p.Gln642His 0 0 0
12 10 OR52M1 De novo NP NM_001004137.1 - chr11:4566479 c.59C>T p.(Pro20Leu) 0 0 0
13 10 UHMK1 De novo NP NM_175866.4 *608849 chr1:162492294 c.1214C>T p.(Pro405Leu) 0 0 0
14 11 SLC25A16 De novo NP NM_152707.3 *139080 chr10:70246950 c.793C>T p.(Arg265Cys) 0 0 0
15 11 DCAF6 Paternal & maternal NP NM_001198956.1 *610494 chr1:168014447 c.2240G>A p.(Arg747Gln) 0.0471 0.0308 0.15
16 11 PHKB Paternal & maternal NP NM_000293.2 *172490 chr16:47536996 c.400G>A p.(Asp134Asn) 0.1115 0.1463 0.61
17 11 GRIN1 Paternal & maternal NP NM_007327.3 *138249 chr9:140051128 c.679G>C p.(Asp248His) 0 0 0
18 12 PGAP1 Maternal Not present in sister NM_024989.3 *611655 chr2:197761857 c.921_925del p.(Lys308Asnfs*25) 0 0 0
19 12 PGAP1 Paternal Heterozygous in sister NM_024989.3 *611655 chr2:197784746 c.274_276del p.(Pro92del) 0 0 0
20 13 NR2F1 De novo NP NM_005654.4 *132890 chr5:92921073 c.344G>C p.(Arg115Pro) 0 0 0
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1 0.01 - - D C B G M Candidate 0.01 -
2 0.05 #615273 + K D NA NA NA NA Known 0.05 #615273
3 NA #224410, #255800 - - P - NA NA NA Unlikely NA #224410, #255800
4 NA #224410, #255800 - - P - NA NA NA Unlikely NA #224410, #255800
5 NA #615145 - - P C NA NA NA Unlikely NA #615145
6 NA #300896 + - P C NA NA NA Candidate NA #300896
7 NA #614675 - - P C NA NA NA Unlikely NA #614675
8 0 #615829 + K D NA NA NA NA Known 0 #615829
9 NA - - P C B - - Candidate NA -
10 NA - - P C B G M Candidate NA -
11 NA - - D (splice effect) NA B G M Candidate NA -
12 NA - - P - - - - Unlikely NA -
13 NA - - P C B G - Candidate NA -
14 NA - - P C - G - Candidate NA -
15 NA - - P - B G - Candidate NA -
16 NA #261750 - - P C NA NA NA Unlikely NA #261750
17 NA #614254 -§ - P C B - - Candidate NA #614254
18 0.02 #615802 + K D NA NA NA NA Known 0.02 #615802
19 0.02 #615802 + K - NA NA NA NA Known 0.02 #615802
20 NA #615722 + K P C NA NA NA Known NA #615722
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1 0.01 - - D C B G M Candidate 0.01 -
2 0.05 #615273 + K D NA NA NA NA Known 0.05 #615273
3 NA #224410, #255800 - - P - NA NA NA Unlikely NA #224410, #255800
4 NA #224410, #255800 - - P - NA NA NA Unlikely NA #224410, #255800
5 NA #615145 - - P C NA NA NA Unlikely NA #615145
6 NA #300896 + - P C NA NA NA Candidate NA #300896
7 NA #614675 - - P C NA NA NA Unlikely NA #614675
8 0 #615829 + K D NA NA NA NA Known 0 #615829
9 NA - - P C B - - Candidate NA -
10 NA - - P C B G M Candidate NA -
11 NA - - D (splice effect) NA B G M Candidate NA -
12 NA - - P - - - - Unlikely NA -
13 NA - - P C B G - Candidate NA -
14 NA - - P C - G - Candidate NA -
15 NA - - P - B G - Candidate NA -
16 NA #261750 - - P C NA NA NA Unlikely NA #261750
17 NA #614254 -§ - P C B - - Candidate NA #614254
18 0.02 #615802 + K D NA NA NA NA Known 0.02 #615802
19 0.02 #615802 + K - NA NA NA NA Known 0.02 #615802
20 NA #615722 + K P C NA NA NA Known NA #615722
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21 13 NHLRC2 Maternal NP NM_198514.3 - chr10:115639414 c.869T>C p.(Ile290Thr) 0 0.0077 0
22 13 NHLRC2 Paternal NP NM_198514.3 - chr10:115663307 c.1516del p.(Thr506Glnfs*7) 0 0 0
23 13 OOSP2 Maternal NP NM_173801.3 - chr11:59812142 c.244-2A>G p.? 0 0 0
24 13 OOSP2 Paternal NP NM_173801.3 - chr11:59814500 c.431C>T p.(Thr144Ile) 0 0 0
25 15 RAB11FIP1 De novo NP NM_001002814.2 *608737 chr8:37729253 c.3067del p.(Leu1023Trpfs*17) 0 0 0
26 15 XKRX X, maternal Present in maternal 
grandmother
NM_212559.2 *300684 chrX:100183023 c.271G>A p.(Asp91Asn) 0 0 0
27 17 KCTD19 De novo NP NM_001100915.1 - chr16:67354577 c.215C>A p.(Thr72Asn) 0 0 0
28 17 SOX5 De novo NP NM_006940.4 *604975 chr12:23689544 c.1831C>G p.(Arg611Gly) 0 0 0
29 19 GRIN2B De novo NP NM_000834.3 *138252 chr12:13724844 c.2065G>A p.(Gly689Ser) 0 0 0
30 19 ZFP30 De novo NP NM_014898.2 - chr19:38126712 c.730T>C p.(Cys244Arg) 0 0 0
31 20 ATP6V1A De novo NP NM_001690.3 *607027 chr3:113508639 c.940A>G p.(Asn314Asp) 0 0 0
32 20 UFSP2 De novo NP NM_018359.3 *611482 chr4:186321583 c.1373A>G p.(Tyr458Cys) 0 0 0
33 22 RERE De novo NP NM_012102.3 *605226 chr1:8418302 c.4293C>A p.(His1431Gln) 0 0 0
34 22 SLC1A1† De novo NP NM_004170.5 *133550 chr9:4583108 c.1264G>A p.(Val422Met) 0 0 0
35 22 SYNE1 Maternal NP NM_182961.3 *608441 chr6:152476161 c.23995C>T p.(Arg7999*) 0 0 0
36 22 SYNE1 Paternal NP NM_182961.3 *608441 chr6:152614761 c.17974C>G p.(Pro5992Ala) 0.09 0 0.08
37 23 NR2F1 De novo NP NM_005654.4 *132890 chr5:92921068 c.339C>A p.(Ser113Arg) 0 0 0
38 23 ACP6 Paternal & 
maternal
NP NM_016361.3 *611471 chr1:147131611 c.379G>A p.(Val127Met) 0.1033 0.0846 0.23
39 24 KCNQ3 De novo NP NM_004519.3 *602232 chr8:133192493 c.688C>T p.(Arg230Cys) 0 0 0
40 25 APOPT1 De novo NP NM_032374.3 - chr14:104040507 c.424G>A p.(Gly142Ser) 0 0 0
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21 13 NHLRC2 Maternal NP NM_198514.3 - chr10:115639414 c.869T>C p.(Ile290Thr) 0 0.0077 0
22 13 NHLRC2 Paternal NP NM_198514.3 - chr10:115663307 c.1516del p.(Thr506Glnfs*7) 0 0 0
23 13 OOSP2 Maternal NP NM_173801.3 - chr11:59812142 c.244-2A>G p.? 0 0 0
24 13 OOSP2 Paternal NP NM_173801.3 - chr11:59814500 c.431C>T p.(Thr144Ile) 0 0 0
25 15 RAB11FIP1 De novo NP NM_001002814.2 *608737 chr8:37729253 c.3067del p.(Leu1023Trpfs*17) 0 0 0
26 15 XKRX X, maternal Present in maternal 
grandmother
NM_212559.2 *300684 chrX:100183023 c.271G>A p.(Asp91Asn) 0 0 0
27 17 KCTD19 De novo NP NM_001100915.1 - chr16:67354577 c.215C>A p.(Thr72Asn) 0 0 0
28 17 SOX5 De novo NP NM_006940.4 *604975 chr12:23689544 c.1831C>G p.(Arg611Gly) 0 0 0
29 19 GRIN2B De novo NP NM_000834.3 *138252 chr12:13724844 c.2065G>A p.(Gly689Ser) 0 0 0
30 19 ZFP30 De novo NP NM_014898.2 - chr19:38126712 c.730T>C p.(Cys244Arg) 0 0 0
31 20 ATP6V1A De novo NP NM_001690.3 *607027 chr3:113508639 c.940A>G p.(Asn314Asp) 0 0 0
32 20 UFSP2 De novo NP NM_018359.3 *611482 chr4:186321583 c.1373A>G p.(Tyr458Cys) 0 0 0
33 22 RERE De novo NP NM_012102.3 *605226 chr1:8418302 c.4293C>A p.(His1431Gln) 0 0 0
34 22 SLC1A1† De novo NP NM_004170.5 *133550 chr9:4583108 c.1264G>A p.(Val422Met) 0 0 0
35 22 SYNE1 Maternal NP NM_182961.3 *608441 chr6:152476161 c.23995C>T p.(Arg7999*) 0 0 0
36 22 SYNE1 Paternal NP NM_182961.3 *608441 chr6:152614761 c.17974C>G p.(Pro5992Ala) 0.09 0 0.08
37 23 NR2F1 De novo NP NM_005654.4 *132890 chr5:92921068 c.339C>A p.(Ser113Arg) 0 0 0
38 23 ACP6 Paternal & 
maternal
NP NM_016361.3 *611471 chr1:147131611 c.379G>A p.(Val127Met) 0.1033 0.0846 0.23
39 24 KCNQ3 De novo NP NM_004519.3 *602232 chr8:133192493 c.688C>T p.(Arg230Cys) 0 0 0
40 25 APOPT1 De novo NP NM_032374.3 - chr14:104040507 c.424G>A p.(Gly142Ser) 0 0 0
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21 NA - - - - B - - Unlikely NA -
22 0.02 - - D NA B - - Unlikely# 0.02 -
23 0.02 - - D NA - - - Unlikely 0.02 -
24 NA - - - - - - - Unlikely NA -
25 0.06 - - D - - - - Unlikely 0.06 -
26 NA - - P C - - - Unlikely NA -
27 NA - - P C u G - Candidate NA -
28 NA - - P C B G M Candidate NA -
29 NA #613970 + - P C NA NA NA Candidate NA #613970
30 NA - - P C B - - Candidate NA -
31 NA - - P C B G - Candidate NA -
32 NA - - P C B - - Candidate NA -
33 NA - - P - B G M Candidate NA -
34 NA - - P C B G M Candidate NA -
35 0.35 #612998, #610743 - - D NA NA NA NA Unlikely 0.35 #612998, #610743
36 NA #612998, #610743 - - - - NA NA NA Unlikely NA #612998, #610743
37 NA #615722 + K P - NA NA NA Known NA #615722
38 NA - - P - B G - Candidate NA -
39 NA #121201 + - P - NA NA NA Candidate NA #121201
40 NA #220110 -‡ - P C NA NA NA Unlikely NA #220110
supplementary Table s3: Classification of validated and segregating variants included based on the 
stringent (legend)
B: Brain expressed. C: Evolutionary conserved genomic base (PhyloP>3.5). D: Disruptive mutation. G: GO-
term enrichment. K: Known CVI-associated gene. M: Mouse phenotypic overlap. NA: Not assessed (irrel-
evant due to mutation type/known ID gene). NP= Not performed. P: Predicted pathogenic (≥2 software 
programs). u: Unknown. -: Not. *See method section for classification process. †Mosaic mutation. ‡Phe-
notype did not match and no second mutation was present (autosomal recessive disorder). §Inheritance 
does not fit with the reported OMIM disease (de novo autosomal dominant), this variant is further classified 
according to de Ligt and Gilissen et al, see result section. #Second mutation did not fulfilled the criteria.
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on the stringent filtering, part 2 (continued)
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21 NA - - - - B - - Unlikely NA -
22 0.02 - - D NA B - - Unlikely# 0.02 -
23 0.02 - - D NA - - - Unlikely 0.02 -
24 NA - - - - - - - Unlikely NA -
25 0.06 - - D - - - - Unlikely 0.06 -
26 NA - - P C - - - Unlikely NA -
27 NA - - P C u G - Candidate NA -
28 NA - - P C B G M Candidate NA -
29 NA #613970 + - P C NA NA NA Candidate NA #613970
30 NA - - P C B - - Candidate NA -
31 NA - - P C B G - Candidate NA -
32 NA - - P C B - - Candidate NA -
33 NA - - P - B G M Candidate NA -
34 NA - - P C B G M Candidate NA -
35 0.35 #612998, #610743 - - D NA NA NA NA Unlikely 0.35 #612998, #610743
36 NA #612998, #610743 - - - - NA NA NA Unlikely NA #612998, #610743
37 NA #615722 + K P - NA NA NA Known NA #615722
38 NA - - P - B G - Candidate NA -
39 NA #121201 + - P - NA NA NA Candidate NA #121201
40 NA #220110 -‡ - P C NA NA NA Unlikely NA #220110
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1 2 AKAP9 De novo NP NM_005751.4 *604001 chr7:91694570 c.6005_6008del p.(Met2002Argfs*4) 0 0
2 2 KAL1 X, maternal NP NM_000216.2 *300836 chrX:8503715 c.1759G>T p.(Val587Leu) 0.2417 0.2659
3 10 PPFIA4† De novo NP NM_015053.1 *603145 chr1:203025958 c.769C>T p.(Gln257*) 0 0
4 10 MAP3K15 X, maternal NP NM_001001671.3 *300820 chrX:19398315 c.2512G>A p.(Gly838Ser) 0.2585 0.2562
5 11 SPTBN5 Paternal & maternal NP NM_016642.3 *605916 chr15:42147078 c.9520dup p.(Arg3174Profs*18) 0 0
6 11 FAM166B Paternal NP NM_001164310.1 - chr9:35562084 c.745_748dup p.(Phe250*) 0 0.0528
7 11 FAM166B Maternal NP NM_001164310.1 - chr9:35563190 c.259A>G p.(Ser87Gly) 0 0.0871
8 13 POF1B X, maternal NP NM_024921.3 *300603 chrX:84569452 c.943C>T p.(Arg315Cys) 0.0883 0.0663
9 17 TRIOBP De novo NP NM_001039141.2 *609761 chr22:38121122 c.2559del p.(Thr854Hisfs*25) 0 0
10 18 MUT De novo NP NM_000255.3 *609058 chr6:49419396 c.1115T>C p.(Ile372Thr) 0.1102 0.0462
11 25 SLC6A13 De novo NP NM_016615.4 *615097 chr12:369056 c.163G>A p.(Val55Ile) 0.022 0.0154
12 25 ALAS2 X, maternal Not present in maternal 
uncle or grandfather
NM_001037968.3 *301300 chrX:55054238 c.3G>A p.(Met1?) 0 0.3549
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1 2 AKAP9 De novo NP NM_005751.4 *604001 chr7:91694570 c.6005_6008del p.(Met2002Argfs*4) 0 0
2 2 KAL1 X, maternal NP NM_000216.2 *300836 chrX:8503715 c.1759G>T p.(Val587Leu) 0.2417 0.2659
3 10 PPFIA4† De novo NP NM_015053.1 *603145 chr1:203025958 c.769C>T p.(Gln257*) 0 0
4 10 MAP3K15 X, maternal NP NM_001001671.3 *300820 chrX:19398315 c.2512G>A p.(Gly838Ser) 0.2585 0.2562
5 11 SPTBN5 Paternal & maternal NP NM_016642.3 *605916 chr15:42147078 c.9520dup p.(Arg3174Profs*18) 0 0
6 11 FAM166B Paternal NP NM_001164310.1 - chr9:35562084 c.745_748dup p.(Phe250*) 0 0.0528
7 11 FAM166B Maternal NP NM_001164310.1 - chr9:35563190 c.259A>G p.(Ser87Gly) 0 0.0871
8 13 POF1B X, maternal NP NM_024921.3 *300603 chrX:84569452 c.943C>T p.(Arg315Cys) 0.0883 0.0663
9 17 TRIOBP De novo NP NM_001039141.2 *609761 chr22:38121122 c.2559del p.(Thr854Hisfs*25) 0 0
10 18 MUT De novo NP NM_000255.3 *609058 chr6:49419396 c.1115T>C p.(Ile372Thr) 0.1102 0.0462
11 25 SLC6A13 De novo NP NM_016615.4 *615097 chr12:369056 c.163G>A p.(Val55Ile) 0.022 0.0154
12 25 ALAS2 X, maternal Not present in maternal 
uncle or grandfather
NM_001037968.3 *301300 chrX:55054238 c.3G>A p.(Met1?) 0 0.3549
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1 0 0.23 #611820 - - D NA NA NA NA Unlikely
2 0.04 NA #308700 -ǁ - P C NA NA NA Unlikelyǁ
3 0 26.65 - - D NA u G - Candidate
4 0.84 NA - - P C - G - Candidate
5 0.77 4.72 - - D NA - G - Candidate
6 0.08 15.48 - - D NA u - - Unlikely
7 0.08 NA - - - - u - - Unlikely
8 0 NA #300604 - - P C NA NA NA Unlikely
9 0 2.13 #609823 -‡ - D NA NA NA NA Unlikely
10 0.08 NA #251000 -‡ - P C NA NA NA Unlikely
11 0.23 NA - - P - - G - Unlikely
12 0.38 0 #300751, #300752 - - D NA NA NA NA Unlikely
supplementary Table s4: Classification of validated and segregating variants excluded based on the 
stringent filtering (legend)
B: Brain expressed. C: Evolutionary conserved genomic base (PhyloP>3.5). D: Disruptive mutation. G: GO-
term enrichment. K: Known CVI-associated gene. M: Mouse phenotypic overlap. NA: Not assessed (irrel-
evant due to mutation type/known ID gene). NP= Not performed. P: Predicted pathogenic (≥2 software 
programs). u: Unknown. -: Not.*See method section for classification process. †Mosaic mutation. ‡Pheno-
type did not match and no second mutation was present (autosomal recessive disorder). ǁThe phenotypic 
spectrum of KAL1 is well known, and no CVI is reported, therefore we classified this variant as unlikely to be 
associated with CVI, although some of the other features of the patient might be ascribed to this variant.
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supplementary Table s4: Classification of validated and segregating variants excluded based on the 
stringent filtering (continued)
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1 0 0.23 #611820 - - D NA NA NA NA Unlikely
2 0.04 NA #308700 -ǁ - P C NA NA NA Unlikelyǁ
3 0 26.65 - - D NA u G - Candidate
4 0.84 NA - - P C - G - Candidate
5 0.77 4.72 - - D NA - G - Candidate
6 0.08 15.48 - - D NA u - - Unlikely
7 0.08 NA - - - - u - - Unlikely
8 0 NA #300604 - - P C NA NA NA Unlikely
9 0 2.13 #609823 -‡ - D NA NA NA NA Unlikely
10 0.08 NA #251000 -‡ - P C NA NA NA Unlikely
11 0.23 NA - - P - - G - Unlikely
12 0.38 0 #300751, #300752 - - D NA NA NA NA Unlikely

3.2
Cerebral visual impairment and intellectual 
disability caused by PGAP1 variants
Daniëlle G.M. Bosch, F. Nienke Boonstra, Taroh Kinoshita, Shalini Jhangiani, 
Joep de Ligt, Frans P.M. Cremers, James R. Lupski, Yoshiko Murakami, 
Bert B. A. de Vries
Eur J Hum Genet 2015; 23: 1689-1693.
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Homozygous variants in PGAP1 (post-GPI attachment to proteins 1) have recently been 
identified in two families with developmental delay, seizures and/or spasticity. PGAP1 is a 
member of the glycosylphosphatidylinositol -anchor biosynthesis and remodelling pathway 
and defects in this pathway are a subclass of congenital disorders of glycosylation.
Here we performed whole exome sequencing in an individual with cerebral visual impair-
ment (CVI), intellectual disability (ID), and factor XII deficiency and revealed compound hetero-
zygous variants in PGAP1, c.274_276del (p.(Pro92del)) and c.921_925del (p.(Lys308Asnfs*25)). 
Subsequently, PGAP1-deficient Chinese hamster ovary (CHO)-cell lines were transfected with 
either mutant or wild-type constructs and their sensitivity to phosphatidylinositol-specific 
phospholipase C (PI-PLC) treatment was measured. The mutant constructs could not rescue 
the PGAP1-deficient CHO cell lines resistance to PI-PLC treatment. In addition, lymphoblastoid 
cell lines (LCLs) of the affected individual showed no sensitivity to PI-PLC treatment, whereas 
the LCLs of the heterozygous carrier parents were partially resistant.
In conclusion, we report novel PGAP1 variants in a boy with CVI and ID and a proven func-
tional loss of PGAP1 and show, to our knowledge, for the first time this genetic association 
with CVI.
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CVI and ID caused by PGAP1 variants
InTroDuCTIon
Cerebral visual impairment (CVI) accounts for 27% of the visual impairment in children, and 
is due to a disorder in projection and/or interpretation of the visual input in the brain.47,53,55 
Acquired damages, for example due to preterm birth, are well known causes of CVI, whereas 
genetic factors are largely unidentified.250 Several chromosomal aberrations have been 
associated with CVI, such as Phelan-McDermid syndrome (22q13.3 deletion) and 1p36 
microdeletion syndrome.251 Moreover, single gene disorders can be implicated in CVI, and, 
recently, we identified de novo variants in NR2F1 as a cause of CVI.191 In addition, in several 
congenital disorders of glycosylation (CDG type 1a, type 1q, and type 1v) CVI has been re-
ported.126,127,250,259 Glycosylation disorders are caused by a defect in the glycosylation of glyco-
proteins and glycolipids, and one subclass is the defect in glycosylphosphatidylinositol-(GPI-) 
anchor glycosylation.309
GPI anchor many cell-surface proteins with various functions, so called GPI-anchored 
proteins (GPI-APs), to the membrane of eukaryotic cells.310-312 GPI is synthesized in the endo-
plasmic reticulum, transferred to the proteins, and remodelled. During the biosynthesis of 
GPI anchors an acyl chain is linked to the inositol. This acyl-chain is a transient structure and 
is necessary for efficient completion of later steps in GPI biosynthesis. After the attachment of 
GPI to the protein, this acyl-chain is removed by PGAP1 (post-GPI attachment to proteins 1), 
the first step of the remodelling phase.313 Subsequently, the GPI-anchor is transported from 
the endoplasmic reticulum to the plasma membrane through the Golgi apparatus and further 
remodelled. When the inositol-linked acyl-chain is not removed this transport is delayed,313 
but the presence of this acyl-chain does not affect the cell surface expression of GPI-APs.270
Several genes known to be involved in the GPI-anchor biosynthesis (PIGA, PIGL, PIGN, PIGT, 
PIGV, PIGO, PIGW and PIGQ) and modelling (PGAP2 and PGAP3) are implicated in X-linked 
and autosomal recessive intellectual disability disorders.169,267,268,314-321 Additional features 
such as seizures, congenital abnormalities and facial dysmorphisms are commonly present. 
Moreover, CVI has been reported in individuals with PIGA, PIGN and PIGT variants, suggesting 
that the GPI-anchor biosynthesis is important in the development of the visual areas of the 
brain.266-269 Recently, two families with developmental delay, seizures and/or spasticity were 
reported with homozygous variants in PGAP1.270,322 However, PGAP1 variants have not to date 
been associated with CVI.
Here, we report an individual with CVI and intellectual disability (ID) and variants in PGAP1, 
thereby showing the association between PGAP1 and CVI.
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Case report
The boy was the second child of healthy unrelated parents. He was born after a normal preg-
nancy by a planned caesarean section, because of a difficult delivery of the previous child. His 
birth weight was 3550 gram (70th centile) at a gestational age of 38 weeks and Apgar scores 
were 9 and 10, after 1 and 5 min, respectively. During the neonatal period he was hypotonic 
and there were feeding difficulties. His development was delayed as he started walking and 
speaking around the age of 2-2½ years. At the age of 8 years 3 months, his total IQ was 49 
(Wechsler Intelligence Scale for Children-III). He was very social in his behaviour. There were 
no signs of epilepsy and an MRI of the brain was normal at age 5 years. Hearing was normal, 
but ophthalmological examination at 7 years revealed CVI with a visual acuity of 0.3 (Landolt 
C). He had strabismus divergence and nystagmus. Slit lamp examination and funduscopy 
were normal. He looked only shortly at a target and he had more difficulties with recognition 
of objects in clutter (crowding) than was expected for his age.
He had mild asthma and his APTT was prolonged due to a factor XII deficiency (factor XII 
activity <1%). His mother and sister also had decreased factor XII activity (40% and 22%, 
respectively), with a normal APTT. There were no signs of immunodeficiency.
Physical examination at 7 years 10 months showed a height of 131 cm (50th centile) and 
head circumference of 52.5 cm (50th centile). Facial dysmorphisms consisted of upward slant-
ing palpebral fissures, deep-set eyes, large ear lobes and prominent helices and antihelices 
(Figure 1). His teeth showed extra mamelons and diminished enamel was noted. Previous 
genetic studies, consisting of FMR1 gene, AIP gene, array CGH and metabolic studies (includ-
ing transferrin glycosylation assay) showed normal results. This study was approved by the 
Ethics Committee of the Radboud university medical center (Commissie Mensgebonden 
Onderzoek, regio Arnhem-Nijmegen), and written informed consent was obtained.
Whole-exome sequencing
WES in this individual (CVI10) was performed as part of a larger study to identify the genetic 
causes of CVI.191 WES was performed by the Baylor-Hopkins Center for Mendelian Genomics, 
using methods reported previously (Supplementary Material and Methods, Whole-exome 
sequencing).191,303 The results were analysed for de novo variants, homozygous variants, 
compound heterozygous variants and hemizygous variants as described in de Ligt et al.182 
Truncating variants, splice site variants and missense variants predicted to be pathogenic 
were validated by Sanger sequencing in the affected subject and his parents. The variants 
identified have been submitted to the Leiden Open Variation Database LOVD database 
(http://databases.lovd.nl/, individual #00025011).
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A
B
C
p.(Pro92del)
p.(Leu197del)
p.(Ala305Val)†† p.(Lys308Asnfs*25)
N C
0 922
c.1952+1G>T†
This study:
Previously
reported:
c.274_276del
(p.(Pro92del))
c.914C>T 
(p.(Ala305Val))
c.921_925del 
(p.(Lys308Asnfs))
Wild-type
uPAR
DAF
CD59
Isotype control
PI-PLC -
PI-PLC +
figure 1: Phenotype of the affected individual and the functional analysis of the variants
A) Photographs of the affected individual, note the upward slanting palpebral fissures, deep set eyes, large 
ear lobes and prominent helices and antihelices. B) Schematic representation of PGAP1, containing trans-
membrane domains (in green). The positions of the variants identified in this study and in the previously 
reports are indicated. †For this variant the effect on amino acid sequence was not studied. ††Considered as 
a variant without functional impact. C) CHO cells deficient for PGAP1 were used to investigate the expected 
structural abnormalities of the GPI-anchors by testing the sensitivity of GPI-APs to PI-PLC. Wild-type PGAP1 
and the construct containing the variant c.914C>T (p.(Ala305Val)) rescued the sensitivity for PI-PLC strongly 
suggesting that this variant is benign. The PGAP1 constructs containing the c.274_276del (p.(Pro92del)) 
and c.921_925del (p.(Lys308Asnfs*25)) variants did not increase the sensitivity for PI-PLC, suggesting that 
both are causal.
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Functional analysis using CHO cells
PGAP1 deficient CHO cells (C10)313 were transiently transfected with wild type or mutant 
pMEFLAG-hPGAP1 by electroporation as reported previously (Supplementary Material and 
Methods, Functional analysis using CHO cells)270 Four days after transfection, cells were 
treated with or without phosphatidylinositol-specific phospholipase C (PI-PLC). Surface 
expression of GPI-APs was determined by staining cells with mouse anti-human CD59 (5H8), 
-human DAF (IA10), -hamster uPAR (5D6) antibodies and analysed by flow cytometry using 
Flowjo software (Tommy Digital Inc., Tokyo, Japan).
PI-PLC treatment and FACS analysis
Heparin blood samples were collected from the affected individual and his unaffected parents 
and lymphoblastoid cell lines (LCLs) were generated (Supplementary Material and Methods, 
PI-PLC treatment and FACS analysis). Four days after transfection, cells were treated with or 
without PI-PLC as reported previously.270 Surface expression of GPI-APs was determined by 
staining cells with mouse anti-human CD59 (5H8), -human DAF (IA10), -human CD48 (BJ40) 
antibodies and analysed by flow cytometry using Flowjo software.
resulTs
WES
WES in the affected individual and the parents was performed with an average coverage of 
126x. After applying the above mentioned prioritizations step only two variants in PGAP1 
remained, a paternal inherited chr2.hg19:g.197784746_197784748del; c.274_276del; 
p.(Pro92del) and a maternal inherited chr2.hg19:g.197761857_197761861del; c.921_925del; 
p.(Lys308Asnfs*25) (MIM 611655, RefSeq accession number NM_024989.3) (Supplementary 
Material, Supplementary Table S1). The variants were validated by Sanger sequencing, and an 
additional maternal inherited variant was identified, chr2.hg19:g.197761868C>T; c.914C>T; 
p.(Ala305Val), which was previously filtered out due to quality settings (Supplementary Mate-
rial, Supplementary Figure S1). In addition, the exome results were screened for rare variants 
(<1% occurrence) in the coding regions of F12 (MIM 610619, RefSeq accession number 
NM_000505.3). A paternal inherited heterozygous variant was identified and validated with 
Sanger sequencing chr5.hg19:g.176831388G>A; c.827G>A; p.(Trp276*).
Functional analysis using CHO cells
Under the presence of PI-PLC structurally normal GPI-APs, without inositol-linked acyl-chain, 
are cleaved from the cell membrane.323 CHO cells deficient for PGAP1 were used to investigate 
the expected structural abnormalities of the GPI-anchors by testing the sensitivity of GPI-APs 
to PI-PLC. Wild-type PGAP1 and the p.(Ala305Val) rescued the sensitivity for PI-PLC (Figure 1 
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and Supplementary Material, Supplementary S2). However, transfection with empty vector, 
the p.(Pro92del) mutant or p.(Lys308Asnfs*25) mutant did not increase the sensitivity for PI-
PLC (Supplementary Material, Supplementary Figure S3).
PI-PLC treatment and FACS analysis
In addition, the LCLs of the affected individual and parents were analysed for PI-PLC resistance. 
The LCLs of the affected individual were completely resistant to PI-PLC treatment, whereas 
the LCLs of the parents were partially resistant (Supplementary Material, Supplementary 
Figure S4).
DIsCussIon
Here we present an individual with CVI, ID, minor facial dysmorphisms and factor XII deficien-
cy. WES revealed compound heterozygous variants in PGAP1, c.274_276del (p.(Pro92del)), 
c.914C>T (p.(Ala305Val)) and c.921_925del (p.(Lys308Asnfs*25)). To investigate the functional 
impact of the variants, PI-PLC sensitivity assay was performed in PGAP1 deficient CHO cells. 
The c.914C>T (p.(Ala305Val)) mutant rescued the PI-PLC-sensitivity in PGAP1 deficient CHO 
cells, similar to wild-type PGAP1. Therefore, this variant was considered to have no functional 
impact. The c.274_276del (p.(Pro92del)) and c.921_925del (p.(Lys308Asnfs*25)) mutant con-
structs, however, were not able to rescue the sensitivity, indicating a functional loss of the 
cDNA constructs. In addition, the PI-PLC sensitivity was investigated in LCLs derived from 
the affected individual and parents. The LCLs of the affected individual were resistant to PI-
PLC, indicating that the GPI-APs are structurally abnormal, whereas the parents showed a 
partial resistance. These results are in line with the reported family with PGAP1 variants by 
Murakami et al. The other family reported by Novarino et al. was not tested.270,322 Besides a 
developmental delay, the phenotype is variable. The reported siblings by Murakami et al. had 
severe developmental delay with seizures, stereotypic movements and brain atrophy (Table 
1). The siblings reported by Novarino et al. had spasticity and structural brain abnormalities. 
In the individual described in this study, no seizures or brain abnormalities were present, but 
he had impaired vision and CVI. No ophthalmological examination was performed in the 
Murakami siblings. In the Novarino siblings no ‘ophthalmological signs’ were present, but 
whether complete ophthalmological examination had been performed remained unclear.
Depending on the genetic background of the mouse strain used, PGAP1 deficiency in mice 
could lead to various phenotypes, ranging from a normal structural brain to forebrain ab-
normalities, including holoprosencephaly.324-327 In the mutant phenotypically abnormal mice 
Wnt signalling and Nodal signaling were reported to be affected.325,327 However, the precise 
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Table 1: phenotype of individuals with PGAP1 variants
This study Murakami
III-2
Murakami
III-3
novarino 1241-
IV-3
novarino
1241-IV-4
Variant identified
(Hg 19)
c.274_276del 
(p.(Pro92del)) 
and c.921_925del 
(p.(Lys308Asnfs*25))
c.589_591del 
(p.(Leu197del)) 
and c.589_591del 
(p.(Leu197del))
c.589_591del 
(p.(Leu197del)) 
and c.589_591del 
(p.(Leu197del))
c.1952+1G>T and 
c.1952+1G>T
c.1952+1G>T and 
c.1952+1G>T
Gender M F M M M
Birth weight 3550 g
(70th centile)
Normal Normal NA NA
Gestational age 
(weeks)
38 Normal Normal NA NA
Age at 
investigations 
(years+months)
7+10 4+5 2+9 6+6 0+9
Height 131 cm
(50th centile)
96 cm
(25th centile)
Normal NA NA
OFC 52.5 cm
(50th centile)
46 cm
(<5th centile)
47 cm
(<5th centile)
NA NA
Delayed 
development
+ + + + +
Walking 
independently 
(years+months)
2+6 4+5 - - -
First words 
(years+months)
2+6 - - NA NA
Hypotonia + + + NA NA
Brain imaging 
(MRI/CT)
Normal (MRI) Pronounced brain 
atrophy (CT)
NP Prominent cortical 
sulci & widened 
sylvian fissures 
(MRI)
Corpus callosum 
agnesis, vermis 
hypoplasia, 
defective 
myelination (MRI)
Hearing 
investigation
Normal NP NP NA NA
Ophthalmo-
logical 
examination
CVI, strabismus, 
nystagmus
NP NP - -
Other 
abnormalities
Factor XII deficiency Stereotypic 
movements, 
seizures
Stereotypic 
movements
Spasticity Spasticity, 
distented 
abdomen
Dysmorphism Upward slanting 
palpebral fissures, deep 
set eyes, large ear lobes, 
prominent helices and 
antihelices, teeth showed 
extra mamelons with 
diminished enamel
Large ears, 
flattenend nasal 
bridge
Large ears, 
flattenend nasal 
bridge
NA NA
NP, not performed; NA, not available.
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role of PGAP1 in the function and development of the brain and more specific of the visual 
system remains to be elucidated.
One marker of CDG-syndromes can be the abnormal glycosylation of transferrin.328 How-
ever, in the subclass of GPI-anchor glycosylation defects no abnormal transferrin is detect-
able, making this marker unreliable in diagnosing GPI-anchor glycosylation defects, such as 
those caused by variants in PGAP1.
One other feature of CDG syndromes is the deficiency of coagulation factors.328 However, 
factor XII deficiency has not been reported so far, neither has a direct functional link between 
factor XII and GPI-APs been made. Factor XII deficiency can be caused by variants in F12; 
a heterozygous variant can lead to an intermediated level of factor XII activity, whereas 
homozygous or compound heterozygous variants lead to almost no activity (<1%).329,330 The 
current individual had a factor XII activity <1%, and a paternal inherited loss of function vari-
ant in F12, c.827G>A (p.(Trp276*)), but his father had a normal factor XII activity. The mother 
had an intermediate factor XII activity, but no variant could be identified in her exome results. 
Whether the variants in PGAP1 are related to the factor XII deficiency is yet unclear.
Two other GPI anchor-modelling proteins, PGAP2 and PGAP3, are implicated in hyper-
phosphatasia with mental retardation syndrome, also named Mabry syndrome.317-319 These 
individuals showed, in addition to ID, seizures, typical facial dysmorphisms and an increased 
alkaline phosphatase (ALP). This increase is due to diminished GPI-APs on the cell surface, 
resulting in less binding of ALP to the cell membrane and more ALP in the plasma.317-319,331,332 
ALP was not measured in the PGAP1-affected individuals, but in PGAP1-deficient cells no 
diminished cell surface expression of GPI-APs was measured, making elevated ALP levels 
less likely.270 In addition, the typical facial dysmorphisms of Mabry syndrome, consisting of 
apparent hypertelorism, long palpebral fissures, short nose with broad nasal bridge and tip 
and tented upper lip vermillion, were not present in the here presented individual.
In conclusion, we identified novel PGAP1 variants in an intellectual disabled boy with a 
proven functional loss of PGAP1, and showed for the first time the genetic association with 
cerebral visual impairment. Additional affected individuals will be required to gain better 
insights into pathophysiology and acquire knowledge of the clinical spectrum of this novel 
disorder.
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Whole-exome sequencing (WES)
WES was performed by the Baylor-Hopkins Center for Mendelian Genomics, using methods 
reported previously.191,303 In short, sequencing was performed on the Illumina HiSeq 2000 
platform (Illumina, San Diego, CA, USA) and the sequence reads were mapped and aligned to 
the Human Genome Reference Assembly GRCh37/hg19 with the BCM-HGSC Mercury pipe-
line.333 Variant calling was performed with the Atlas2334 and SAMtools335 algorithms; variant 
annotation was performed with an intramurally developed annotation pipelin336 based on 
ANNOVAR337 and custom scripts to incorporate multiple databases to inform on identified 
variants.
After quality filtering (variant reads >15%) local and global variants were excluded (>1% 
occurrence in intramural database, dbSNP (http://www.ncbi.nlm.nih.gov/SNP/), Exome Vari-
ant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (http://evs.gs.washington.
edu/EVS/) or cohort frequency ≤2% (cohort of patients with various disorders and their 
healthy parents, N=200).
The exonic nonsynonymous and canonical splice site variants were selected for further 
analysis. A de novo analysis was performed. Furthermore, the results were analysed for homo-
zygous variants (>80% variant reads), compound heterozygous variants (two or more variants 
present in one gene) and hemizygous variants in males (X-chromosome, >80% variant reads). 
When the autosomal recessive variants were present at one allele the variants were excluded 
(based on the raw data, BAM-file, of the affected individual and his parents). Disrupting 
variants, consisting of frameshift, nonsense or splice site variants (assessed using Interac-
tive Biosoftware Alamut version 2.3 rev2), and missense variants predicted to be pathogenic 
(majority vote of Polyphen-2, MutPred and SNP&GO were validated by Sanger sequencing 
in the affected subject and his parents (http://genetics.bwh.harvard.edu/pph2/, http://
mutpred.mutdb.org/, http://snps.path.uab.edu/snps-and-go/pages/method.html).304-306 For 
compound heterozygous variants at least one of the variants should be disrupting, or, when 
concerning missense variants, both variants should be predicted to be pathogenic.
Functional analysis using CHO cells
pMEFLAG-hPGAP1 mutant bearing the variants of the affected individual were generated 
by site directed mutagenesis. PGAP1 deficient CHO cell (C10)313 were transiently transfected 
with wild type or mutant pMEFLAG-hPGAP1 by electroporation. Cells (107) were suspended 
in 0.4 ml of Opti-MEM and electroporated with 20 µg each of the plasmids at 260 V and 960 
mF using a Gene Pulser. Four days after transfection, cells were treated with or without 10 
unit/ml of phosphatidylinositol-specific phospholipase C (PI-PLC, Molecular probes, Eugene, 
OR)) for 1.5 h at 37oC. Surface expression of GPI-APs was determined by staining cells with 
mouse anti-human CD59 (5H8), -human DAF (IA10), -hamster uPAR (5D6) antibodies and 
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each isotype IgG, followed by a PE-conjugated anti-mouse IgG antibody and analysed by 
flow cytometry using Flowjo software (Tommy Digital Inc., Tokyo, Japan).
PI-PLC treatment and FACS analysis
Heparin blood samples were collected from the affected individual and his unaffected parents. 
Lymphoblastoid cell lines (LCLs) were generated and cultured in RPMI 164-R2405 (Sigma-
Aldrich, St. Louis, United States of America) that was supplemented with 15% FCS-F7524, 
Pen/Strep-P4333 and HEPES-H0887 (Sigma-Aldrich, St. Louis, United States of America).
The LCLs were transfected with empty pMEoriP vector or pMEoriPFLAG-humanPGAP1. 
Cells (56106) were suspended in 0.8 ml of Opti-MEM and electroporated with 20 µg each of 
the plasmids at 260 V and 960 mF using a Gene Pulser (Bio Rad, Hercules, CA). Four days after 
transfection, cells were treated with or without 10 unit/ml of PI-PLC for 1.5 h at 37oC. Surface 
expression of GPI-APs was determined by staining cells with mouse anti-human CD59 (5H8), 
-human DAF (IA10), -human CD48 (BJ40) antibodies and each isotype IgG followed by a PE-
conjugated anti-mouse IgG antibody (BJ40, mouse IgG1 and IgG2a, and secondary antibody 
were purchased from BDBiosciences, Franklin Lakes, NJ) and analysed by flow cytometry 
(Cant II; BD Biosciences) using Flowjo software (Tommy Digital Inc., Tokyo, Japan).
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Table s1: Characteristics of the identified variants
Gene PGAP1 PGAP1 PGAP1 F12
RefSeq accession number NM_024989.3 NM_024989.3 NM_024989.3 NM_000505.3
Inheritance Paternal Maternal Maternal Paternal
Coding DNA change (Hg 
19)
c.274_276del c.921_925del c.914C>T c. 827G>A
Protein change p.(Pro92del) p.(Lys308Asnfs*25) p.(Ala305Val) p.(Trp276*)
dbSNP frequency 0 0 0 0
EVS 0 0 0 0
PhyloP NA NA 1.82 NA
Pholyphen2 (score) NA NA Benign NA
SNPs&Go (score) NA NA Neutral NA
MutPred NA NA 0.351 NA
NA, not available.
Father
Mother
Patient
PGAP1 c.274_276del  PGAP1 c.914C>T      PGAP1 c.921_925del
C T T  C C T  G G T  A A T
G G T   A A T  G C T 
Lys        Pro        Gly        Ala
G A T  G C T  G A T
T
Asp       Ala        Asp Thr        Lys      Gln        Val
A C T  A A A  C A A  G T A 
A  A G T   A T G  T A T
p.(Pro92del) p.(Ala305Val)      p.(Lys308Asnfs*25)
C C G T G G T G C
Pro       Trp       Cys
A
F12 c.827G>A
p.(Trp276*)
figure s1: sanger sequences results of identified variants
Paternal inherited variants in PGAP1 (NM_024989.3 , c.274_276del; p.(Pro92del)) and F12 (NM_000505.3, 
c.827G>A; p.(Trp276*)), and two maternal inherited variants in PGAP1 (c.914C>T; p.(Ala305Val) and 
c.921_925del; p.(Lys308Asnfs*25)) were validated by using Sanger sequencing.
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Isotype control
PI-PLC -
PI-PLC +
PGAP1Empty vector
Father
Mother
Aected
CD59CD59 CD48 CD48DAFDAF
figure s4: PI-PlC sensitivity in lCls the individual and his parents
The LCLs of the aff ected individual were completely resistant to PI-PLC treatment, whereas the LCLs of the 
parents were partially resistant (Empty vector in left panels). After transfection of wild-type PGAP1 cDNA, 
sensitivity to PI-PLC was restored to the LCLs of the aff ected individual and the parents (PGAP1 in right 
panels), confi rming that the complete and partial resistance was due to defective PGAP1.
DAF
CD59
c.274_276del
(p.(Pro92del))
c.914C>T 
(p.(Ala305Val))
c.921_925del 
(p.(Lys308Asnfs))Wild-type
Isotype control
PI-PLC -
PI-PLC +
uPAR
c.914C>T 
(p.(Ala305Val))/
c.921_925del 
(p.(Lys308Asnfs)) Empty vector
figure s3: functional analysis of the identifi ed variants using Cho cells
CHO cells defi cient for PGAP1 were used to investigate the expected structural abnormalities of the GPI 
anchors by testing the sensitivity of GPI-APs to PI-PLC. Wild-type PGAP1 and the c.914C>T (p.(Ala305Val)) 
rescued the sensitivity for PI-PLC. However, transfection with empty vector, the c.274_276del (p.(Pro92del)) 
mutant or c.921_925del (p.(Lys308Asnfs*25)) mutant did not increase the sensitivity for PI-PLC.
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NR2F1 mutations cause optic atrophy with 
intellectual disability
Daniëlle G.M. Bosch,* F. Nienke Boonstra,*Claudia Gonzaga-Jauregui,* Mafei Xu, 
Joep de Ligt, Shalini Jhangiani, Wojciech Wiszniewski, Donna M. Muzny, 
Helger G. Yntema, Rolph Pfundt, Lisenka E.L.M. Vissers, Liesbeth Spruijt, 
Ellen A.W. Blokland, Chun-An Chen, Baylor-Hopkins Center for Mendelian Genomics, 
Richard A. Lewis, Sophia Y. Tsai, Richard A. Gibbs, Ming-Jer Tsai, James R. Lupski, 
Huda Y. Zoghbi, Frans P.M. Cremers,† Bert B. A. de Vries,† Christian P. Schaaf†
Am J Hum Genet 2014; 94: 303-309.
*These authors contributed equally to this work. 
†These authors contributed equally to this work and are co-senior authors.
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Optic nerve atrophy and hypoplasia can be primary disorders or can result from trans-synaptic 
degeneration arising from cerebral visual impairment (CVI). Here we report six individuals 
with CVI and/or optic nerve abnormalities, born after an uneventful pregnancy and delivery, 
who have either de novo heterozygous missense mutations in NR2F1, also known as COUP-
TFI, or deletions encompassing NR2F1. All affected individuals show mild to moderate intel-
lectual impairment. NR2F1 encodes a nuclear receptor protein that regulates transcription. A 
reporter assay showed that missense mutations in the zinc-finger DNA-binding domain and 
the putative ligand-binding domain decrease NR2F1 transcriptional activity. These findings 
indicate that NR2F1 plays an important role in the neurodevelopment of the visual system 
and that its disruption can lead to optic atrophy with intellectual disability.
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rePorT
Optic nerve abnormalities are increasingly recognized as a cause of poor vision. The most fre-
quently identified abnormalities consist of optic nerve atrophy or hypoplasia, due to either 
genetic or acquired causes.55 Optic nerve hypoplasia is often reported as part of a syndrome, 
for example, in conjunction with structural malformations of the brain or hypopituitarism, as 
observed in SOX2-related disorders [MIM 184429],338 or combined with anterior segmental 
defects of the eye, such as iris coloboma in PAX6-related diseases [MIM 307108].339 Optic 
nerve atrophy, however, can be part of a progressive syndromic or nonsyndromic disorder. 
The genetic defects underlying many syndromic forms of optic atrophy are known, but the 
molecular bases of nonsyndromic forms have been elucidated in only a few instances: muta-
tions in OPA1 [MIM 605290] and OPA3 [MIM 606580] (autosomal dominant inheritance),340,341 
in TMEM126A [MIM 612988] (autosomal recessive inheritance),342 and in mitochondrial DNA 
as part of the Leber Hereditary Optic Neuropathy (LHON) [MIM 535000].343 Both optic atrophy 
and hypoplasia can be caused by trans-synaptic degeneration as a part of cerebral visual 
impairment (CVI), a class of disorders of the projection and/or interpretation of visual input 
in the brain.47,105,112 Up to two-thirds of the cases of CVI are thought to be caused by perinatal 
damage, often the result of preterm birth, but genetic defects might play a significant role 
in the aetiology of the remaining cases.51,79,119 The majority of persons with CVI exhibit ad-
ditional clinical features, including intellectual disability (ID).51,53,79,119
We collected 56 individuals with CVI, all born after an uneventful pregnancy and birth, 
without any identifiable causes, and performed clinical, ophthalmological, and copy number 
variant investigations (Table S1). This study was approved by the Ethics Committee of the 
Radboud university medical center (Commissie Mensgebonden Onderzoek, regio Arnhem-
Nijmegen), and written informed consent was obtained for all enrolled subjects. For 12 in-
dividuals and their parents we performed exome sequencing, by using a trio approach.179,182 
Exome sequencing was done in ten of these trios through the Baylor-Hopkins Center for 
Mendelian Genomics: methods have been reported previously.303 In brief, 1 μg of genomic 
DNA from each individual was fragmented in a Covaris sonication system. Whole-exome tar-
geted capture was performed in solution with the BCM-HGSC Core design. Sequencing was 
performed on the Illumina HiSeq 2000 platform (Illumina, San Diego, CA, USA), producing an 
average of 9-10 Gb of raw data per sample. The sequence reads were mapped and aligned 
to the Human Genome Reference Assembly GRCh37/hg19 with the BCM-HGSC Mercury 
pipeline333 at an average depth of coverage of 114x. Variant calling was performed with the 
Atlas2334 and SAMtools335 algorithms; variant annotation was performed with an intramurally 
developed annotation pipeline336 based on ANNOVAR337 and custom scripts to incorporate 
multiple databases to inform on identified variants. In the other two trios we performed 
exome sequencing on a SOLiD 5500XL platform (Life Technologies, Carlsbad, CA, USA) with 
the Agilent SureSelect All Exon V4 reagent for target enrichment (Agilent Technologies, Inc., 
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Santa Clara, CA, USA). The 50 bp paired-end reads were mapped to USCS Genome Browser 
GRCh37/hg19 Human Genome Reference Assembly, and variants and indels were called with 
Lifescope v2.1 (Life Technologies, Carlsbad, CA, USA). There was an average coverage of 76x. 
After quality filtering (variant reads >15%) and exclusion of local and global variants (<1% oc-
currence) a de novo analysis was performed for all trios. Synonymous variants with no effect 
on splicing were excluded.
In two persons (individuals 1 and 2) de novo missense mutations predicted to be patho-
genic were identified in nuclear receptor subfamily 2, group F, member 1 gene, NR2F1 (chr5: 
92,921,073 G>C; c.344G>C; p.Arg115Pro and chr5: 92,921,068 C>A; c.339C>A; p.Ser113Arg, 
respectively; Figure 1, Table S2) [MIM 132890, RefSeq accession number NM_005654.4]. Both 
were situated in the DNA-binding domain. In addition to CVI, individual 1 had small optic 
discs with large excavations and ID; individual 2 manifested pale optic discs, small optic 
nerves on MRI, and developmental delay (Table 1 and Table S3). We screened the remaining 
44 CVI persons for mutations in NR2F1 by Sanger sequencing, and identified a third case 
(individual 3) with a de novo missense mutation, predicted to be pathogenic, in the ligand-
binding domain, chr5: 92,923,914 T>C; c.755T>C; p.Leu252Pro. She had excavated, pale optic 
discs and ID.
The Poisson probability of identifying three de novo mutations by sequencing a cohort 
of 56 persons was calculated for NR2F1. Based on a de novo mutation rate of 1.18x10−8 per 
position,344 and accounting for GC-content and gene size345-347 the Poisson probability is 
p=1.40x10-10, indicating that this is highly unlikely to have occurred by chance. This is further 
strengthened by the consistent clinical phenotype observed in the affected individuals.
Point mutations in NR2F1 have not yet been reported, but large deletions spanning NR2F1 
and other genes have been associated recently with optic atrophy, visual motor integration 
deficit, visual perceptual disorder and ID.348 Therefore, we searched for deletions of NR2F1 in 
both the CVI cohort and the intramural database of the Radboud university medical center, 
Nijmegen, Netherlands, that includes more than 10,000 array analyses from persons with in-
tellectual disability and/or multiple congenital abnormalities. We identified a 5q15 deletion, 
arr 5q15(92,845,157-93,679,748)x1 (Human Genome Reference Assembly GRCh37/hg19) 
comprising NR2F1 with the CytoScan HD array (Affymetrix, Santa Clara, CA, USA) in individual 
4, part of the CVI cohort, who had pale optic discs and mild ID (Figure 1). The inheritance of 
the deletion is unknown, because the deletion was on the paternal allele, but the reportedly 
phenotypically normal father was not available for testing. We also identified a de novo dele-
tion on chr5:91,064,110-93,896,378 (Human Genome Reference Assembly GRCh37/hg19), arr 
SNP 5q14.3q15(SNP_A-1810903->SNP_A-1788922)x1 in the intramural cohort (individual 5) 
with the 250k SNP array (Affymetrix, Santa Clara, CA, USA). Individual 5 had developmental 
delay and ophthalmological examination showed poor visual acuity, CVI, in the right eye a 
small pale optic disc, and in the left eye a pale optic disc with a large excavation.
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figure 1: Phenotype and genotype of the individuals with optic atrophy
(A) Confi rmation by Sanger sequencing of the de novo mutations in NR2F1 [NM_005654.4] found by exome 
sequencing (individuals 1, 2 and 6), the de novo mutation in NR2F1 found by cohort screening (individual 
3), and segregation analyses. The pictures of the individuals show nonspecifi c facial dysmorphisms. (B) 
Schematic representation of NR2F1, containing a DNA-binding domain (DBD) and a ligand-binding do-
main (LBD). The positions of the mutations identifi ed in the aff ected individuals are indicated. (C) Overview 
of the 5q14-q15 region encompassing the two overlapping microdeletions of individual 4 (lower red bar) 
and 5 (upper red bar) comprising NR2F1. The inheritance of the deletion in individual 4 was unknown, 
because the father was not available for testing and the deletion was on the paternal allele. The deletion 
of individual 5 was de novo. The pictures of the aff ected individuals show nonspecifi c facial dysmorphisms.
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In parallel, a single additional individual with congenital optic atrophy and ID was enrolled 
through the Baylor-Hopkins Center for Mendelian Genomics study (individual 6, BAB3468, 
Figure 1 and Table 1). This 35-year-old female also had autism spectrum disorder with marked 
obsessive-compulsive behaviours. The pregnancy and delivery had been uneventful (Table 
S1). Family history was negative for optic nerve atrophy, ID, developmental delay, and autism. 
The family was consented through a research protocol approved by the Institutional Review 
Board (IRB) of Baylor College of Medicine. DNA samples from the proband and her unaffected 
parents were submitted for exome sequencing by using a trio approach as described above 
at an average depth of coverage of 107x and with >91% of the target bases covered at a 
minimum of 20x. Inheritance of the identified variants was examined with the DeNovoCheck 
algorithm.182 Analysis of the variants identified in the proband under a sporadic de novo model 
of inheritance revealed a missense mutation (chr5: 92,921,064 G>A; c.335G>A; p.Arg112Lys) 
in NR2F1. This variant was situated in the DNA-binding domain and was predicted to be 
pathogenic.
 As individual 6 manifested optic nerve atrophy without CVI a cohort of mainly nonsyndromic 
persons (n=37) with optic nerve abnormalities was screened for NR2F1 variants by Sanger 
sequencing (Table S4). In a 68-year-old male with optic atrophy a missense mutation was 
identified, chr5:92,924,068 G>C; c.909G>C; p.Gln303His. However, this variant was also present 
in his unaffected sister and son and was interpreted as a nonpathogenic variant.
NR2F1 encodes a conserved orphan nuclear receptor protein (nuclear receptor subfamily 2, 
group F, member 1), that, activated by a yet unknown ligand, regulates transcription.349 It be-
longs to the nuclear receptor superfamily, of which several members already have been impli-
Table 1: Genotype and phenotype of the affected individuals
Individual 1 Individual 2 Individual 3 Individual 4 Individual 5 Individual 6
Defect in NR2F1 c.344G>C 
p.Arg115Pro
c.339C>A 
p.Ser113Arg
c.755T>C 
p.Leu252Pro
Deletion
(0.83 Mb)
Deletion
(2.85 Mb)
c.335G>A
p.Arg112Lys
Gender Male Female Female Female Female Female
Age 12y 2+4y 18y 24y 4y 35 y
Development IQ 48 DD IQ 55-65 IQ 61-74 DD IQ 52
Behavioural 
abnormalities
- - - - - OCD, autism
OFC (centile) 98th 55th 55th 99th 50th 13th
CVI + + + + + -
Optic disc 
abnormalities
Small and large 
excavation
Pale Pale and large 
excavation
Partial pale Small, pale and 
large excavation
Pale
MRI brain Normal Small optic 
nerve and 
chiasm
ND ND Normal Normal
DD = developmental delay, ND = not done, OCD = obsessive-compulsive disorder, OFC=occipital frontal 
head circumference.
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cated in human disease: NR2E3 [MIM 604485] in retinitis pigmentosa,350 ESRRB [MIM 602167] in 
deafness,351 NR0B1 [MIM 300473] in congenital adrenal hypoplasia,352 and NR2F2 [MIM 107773] 
in congenital diaphragmatic hernia.353 NR2F1 has a classic nuclear receptor structure with two 
main domains, a functional DNA-binding domain (DBD) formed by two zinc-finger structural 
domains and a ligand-binding domain (LBD) with two highly conserved sequence regions.354 
Interestingly, three of the four point mutations that we identified localize to the DBD of NR2F1, 
probably affecting the binding of NR2F1 to its transcriptional targets.
To investigate the functional effects of our identified point mutations in NR2F1, we estab-
lished a reporter assay. In this assay luciferase is under control of an NR2F1 activated promoter 
and cells are cotransfected with this plasmid and either wild-type (WT) or mutant Nr2f1 con-
structs. The luciferase activity reflects the transcriptional activity of the constructs. The expres-
sion plasmids of the mouse Nr2f1 - COUP-TFI, and the NGFI-A (−168/+33) promoter luciferase 
reporter in pXP2 were previously described.355,356 All point mutations were generated with 
the QuickChange site-directed mutagenesis kit (Agilent). For luciferase assays, HEK293T cells 
were plated in 24-well plates (1x105 cells per well) 24 hr prior to transfection. Cells were trans-
fected with 5 ng of reporter per well with Lipofectamine 2000 following the manufacturer’s 
instructions. Forty-eight hr after transfection, cells were harvested and luciferase activity was 
measured by the luciferase assay system (Promega). As indicated in Figure 2, all DNA-binding 
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figure 2: In vitro luciferase reporter assay for nr2f1 point mutations
Effects of the Nr2f1 (COUP-TFI) mutations on activation of an NGFI-A promoter-driven reporter. Top shows 
that pXP2-NGFI-A was cotransfected with 5 ng FLAG-tagged Nr2f1 (COUP-TFI) WT, FLAG-tagged Nr2f1 
(COUP-TFI) mutations or empty vector into HEK293T cells as indicated. The cell sample transfected with 
pXP2-NGFI-A and vector served as the control, and its value (relative luciferase activity) was set as 1. The 
relative luciferase activities of the other samples are normalized to this control. Data are means ± SD (n = 3). 
Bottom shows immunoblot analysis of Nr2f1 (COUP-TFI) expression in transfection. Results indicate similar 
expression of WT and mutant Nr2f1 (COUP-TFI) constructs.
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domain mutants (p.Arg112Lys, p.Ser113Arg, and p.Arg115Pro) and the ligand-binding domain 
mutant (p.Leu252Pro) lost their ability to fully activate NR2F1 - COUP-TFI reporter. This result 
supports our contention that persons who have these mutations do not have fully functional 
NR2F1 - COUP-TFI product.
Additionally, the function of NR2F1 has been investigated in mice. The mouse ortholog, 
Nr2f1, is expressed in various tissues throughout development, with important functions in 
cell fate determination, differentiation, migration, and survival, and an apparently important 
role in organogenesis354. In the developing nervous system, it is mainly expressed at high lev-
els in the optic nerve, thalamus, and pallium (future cortex).357-359 Studies of Nr2f1 knockout 
mice indicate that the protein is important for neurodevelopment, including oligodendrocyte 
differentiation (partly in vitro experiment),357 cortical patterning,360-362 and guidance of thala-
mocortical axons,363 as well as eye and optic nerve development.356,364 Furthermore, overex-
pression of Nr2f1 in mouse neuronal differentiating teratocarcinoma PCC7 cells antagonized 
neuronal differentiation induced by retinoic acid signalling.365 Given our results from the in 
vitro reporter assays and because deletions of NR2F1 give rise to a similar phenotype, we 
hypothesize that the heterozygous mutations identified in our affected individuals cause loss 
of function and that the observed phenotypes are due to haploinsufficiency. Interestingly, it 
appears that the latter are restricted to brain and optic nerves, because no other major organ 
abnormalities are observed in our cohort of patients with either NR2F1 point mutations or 
deletions. This might be due directly to levels of NR2F1 reduced below a threshold necessary 
during brain development or indirectly via the target genes it regulates for specific expres-
sion in brain development. Brown et al. proposed haploinsufficiency of NR2F1 as the cause 
of deafness and multiple congenital anomalies in an individual with NR2F1 deletion and 
paracentric inversion inv(5)(q15q33.2).366 The absence of deafness and multiple congenital 
anomalies in the affected individuals 4 and 5 suggests that these might be caused by the 
more complex chromosomal rearrangement identified in the reported person, although 
phenotypic variability cannot be ruled out at this time.
In addition to the optic nerve abnormalities, five out of six individuals were diagnosed with 
CVI. This potentially could reflect thalamocortical axon projection disorders, as reported in 
Nr2f1 knockout mice.363 Until now, optic atrophy in combination with optic disc excavation 
was thought to be the result of perinatal damage.80,81,102 We showed, however, that optic disc 
excavations can also be present in individuals with a genetic cause of CVI (individuals 1, 3 and 
5). NR2F1 investigation should, therefore, also be considered in preterm children with CVI.
In conclusion, four individuals with optic atrophy and CVI of unknown cause had hetero-
zygous de novo point mutations in NR2F1, and two persons with a similar phenotype had 
deletions comprising NR2F1. Our findings indicate that NR2F1 has an important role in the 
development of the visual system and that haploinsuffiency can lead to optic atrophy with 
intellectual impairment.
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suPPleMenTal TaBles
Table s1: Description of CVI cohort
Person In 
manuscript
age at 
examination in 
years (+ months 
when under 4 
years)
Gender Gestational 
age (weeks)
Intellectual 
disability/ 
developmental 
delay
nGs (platform)
CVI1 Individual 1 12 M 42 + + (Illumina Hiseq 2000)
CVI2 3+8 M 42 + + (Illumina Hiseq 2000)
CVI3 1+7 M At term + + (Illumina Hiseq 2000)
CVI4 21 M 40 + + (Illumina Hiseq 2000)
CVI5 12 M 37 + + (Illumina Hiseq 2000)
CVI6 11 F 42 + + (Illumina Hiseq 2000)
CVI7 8 M 40 + + (Illumina Hiseq 2000)
CVI8 7 M 38 + + (Illumina Hiseq 2000)
CVI9 7 F 41 + + (Illumina Hiseq 2000)
CVI10 7 M 38 + + (Illumina Hiseq 2000)
CVI11 Individual 2 4 F 41 + + (SOLiD 5500XL)
CVI12 4 F 40 + + (SOLiD 5500XL)
CVI13 9 M 40 +
CVI14 Individual 3 18 F At term +
CVI15 Individual 4 24 F 36 +
CVI16 3+7 M 37 +
CVI17 3+4 M 35 +
CVI18 2+10 M 41 +
CVI19 2+1 F 40 +
CVI20 1+6 M 37 +
CVI21 38 F At term +
CVI22 36 M 42 +
CVI23 33 F At term -
CVI24 33 M 41 +
CVI25 30 F 40 +
CVI26 29 M At term +
CVI27 28 M At term +
CVI28 28 F At term +
CVI29 26 F At term +
CVI30 26 M 39 +
CVI31 23 F 39 +
CVI32 22 F 42 +
CVI33 20 F 40 +
CVI34 18 M At term +
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Table s1: Description of CVI cohort (continued)
Person In 
manuscript
age at 
examination in 
years (+ months 
when under 4 
years)
Gender Gestational 
age (weeks)
Intellectual 
disability/ 
developmental 
delay
nGs (platform)
CVI35 17 M 40 +
CVI36 17 M At term -
CVI37 15 F 40 +
CVI38 15 M 42 +
CVI39 2 F 38 +
CVI40 14 M 32 -
CVI41 13 M 40 -
CVI42 13 F At term +
CVI43 13 F 40 +
CVI44 12 M 42 +
CVI45 10 M 39 +
CVI46 9 M 40 +
CVI47 7 M 41 +
CVI48 7 F 40 +
CVI49 7 M 38 +
CVI50 6 M 41 +
CVI51 6 M 37 +
CVI52 6 M 37 +
CVI53 6 F At term +
CVI54 5 M At term +
CVI55 5 M 39 +
Table s2: Pathogenicity prediction of the identified mutations in NR2F1
Individual 1 Individual 2 Individual 3 Individual 6
Coding DNA change c.344G>C c.339C>A c.755T>C c.335G>A
Protein change p.Arg115Pro p.Ser113Arg p.Leu252Pro p.Arg112Lys
PhyloP 5.05 1.90 4.56 5.05
Conservation down to C. elegans C. elegans C. elegans C. elegans
Pholyphen2 (score) Probably damaging 
(1.00)
Probably damaging 
(1.00)
Probably damaging 
(0.99)
Probably damaging 
(0.995)
Sift (score) Deleterious (0.00) Deleterious (0.00) Deleterious (0.00) Deleterious (0.00)
Mutation Taster (Score) Disease causing (0.99) Disease causing (0.99) Disease causing (0.99) Disease causing (0.99)
MutPred 0.888 0.848 0.939 0.947
EVS frequency 0 0 0 0
dbSNP frequency 0 0 0 0
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Table s3: additional phenotype of the individuals in which a NR2F1 defect was identified
Individual 1 Individual 2 Individual 3 Individual 4 Individual 5 Individual 6
Gender M F F F F F
Birth weight (grams) 3510 (p7) 3855 (p70) 3780 (p70) 2500 (p50) 4150 (p86) 2800 (p12)
GA (weeks) 42 41 AT 36 41 40
Age at investigations (years) 12 2+4 18 24 4 35
Height (cm) 159 (p84) 87 (p16) 185 (p99) 170 (p50) 107 (p55) 158 (p21)
Dysmorphisms Protruding ears, long nostrils, 
prominent alea nasi, flattened 
thorax, long fingers and toes.
Epicanthal folds, upturned nose 
point, broad mouth, full lips, 
simple protruding ears with 
upturned ear lobes, tapering 
fingers and fetal fingers pads, 
curly slow growing hair.
Upslanting palpebral 
fissures, small nasal ridge, 
retrognathia, high palate, 
long fingers and toes.
Tapering fingers, extra flexion crease dig 
IV right, II-III syndactyly toes.
Broad high nasal bridge, prominent 
antihelix of the ear, clinodactyly dig V.
Right helix incompletely folded. Prominent 
Darwin’s tubercle on right ear. Pointed chin. 
Synophrys (familial).
Hearing - - - - - -
Other abnormalities Hypotonia. Hypotonia. Neonatal feeding problems. Neonatal feeding problems. Mild slowing in rapid alternating 
movements. Mild spasticity.
Refraction error OD S+7.25=C-2.25x164” OD S+3 OD S+0.25=C-0.50x4” OD S 0=C-1.00x111” OD S+1.75 OD S-2.00=C+4.00x180”
OS S+6.75=C-1.75x30” OS S+3 OS S-0.25=C-0.75x11” OS S-0.71=C-0.25x50” OS S+1.75 OS S-2.00=C+4.00x180”
Correction of refraction + - - + - -
Visual acuity OD 0.06 ND 0.08 0.08 ND 0.1
Visual acuity OS 0.03 ND 0.1 0.2 ND 0.1
Visual acuity ODS 0.125 20/260 (0.08) 0.16 0.25 0,2 0.1
Method (distance) LH (3 m) TAC (55 cm) Landolt C 2.6’ (5 m) Landolt C 2.6’ (5 m) TAC (55 cm) Snellen
Strabismus + + + + + +
Oculomotor disturbance - - + - + -
Nystagmus Latent. - Latent. Latent. Latent. -
Visual field defects + + + - + ND
Slit lamp examination Iris transillumination. - - Deep anterior chamber, mild lens 
opacity.
Slight iris transillumination Bilateral keratoconus.
Optic disc Small and large excavation. Pale. Pale and large 
excavation.
Partial pale. OD small and pale.
OS pale and large excavation.
Pale.
Macula Not recognizable. Normal. Normal. Normal. Normal. Inner retinal atrophy with muted umbo and 
foveal light reflexes.
VEP (age) Flash: late response; pattern onset: 
late response; pattern reversal: 
normal respons (8 years).
Flash: long latency times (10 
months).
Flash:normal; pattern 
reversal: long latency (8 
years).
ND ND ND
ERG (age) Normal (8 years). ND Normal ( 8 years). Normal (11 years). ND ND
Other ocular features Crowding, fluctuating visual 
performance, excentric fixation.
Crowding. Keratitis sicca managed with punctal plugs 
OU.
GA = gestational age, ND = not done.
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Table s3: additional phenotype of the individuals in which a NR2F1 defect was identified
Individual 1 Individual 2 Individual 3 Individual 4 Individual 5 Individual 6
Gender M F F F F F
Birth weight (grams) 3510 (p7) 3855 (p70) 3780 (p70) 2500 (p50) 4150 (p86) 2800 (p12)
GA (weeks) 42 41 AT 36 41 40
Age at investigations (years) 12 2+4 18 24 4 35
Height (cm) 159 (p84) 87 (p16) 185 (p99) 170 (p50) 107 (p55) 158 (p21)
Dysmorphisms Protruding ears, long nostrils, 
prominent alea nasi, flattened 
thorax, long fingers and toes.
Epicanthal folds, upturned nose 
point, broad mouth, full lips, 
simple protruding ears with 
upturned ear lobes, tapering 
fingers and fetal fingers pads, 
curly slow growing hair.
Upslanting palpebral 
fissures, small nasal ridge, 
retrognathia, high palate, 
long fingers and toes.
Tapering fingers, extra flexion crease dig 
IV right, II-III syndactyly toes.
Broad high nasal bridge, prominent 
antihelix of the ear, clinodactyly dig V.
Right helix incompletely folded. Prominent 
Darwin’s tubercle on right ear. Pointed chin. 
Synophrys (familial).
Hearing - - - - - -
Other abnormalities Hypotonia. Hypotonia. Neonatal feeding problems. Neonatal feeding problems. Mild slowing in rapid alternating 
movements. Mild spasticity.
Refraction error OD S+7.25=C-2.25x164” OD S+3 OD S+0.25=C-0.50x4” OD S 0=C-1.00x111” OD S+1.75 OD S-2.00=C+4.00x180”
OS S+6.75=C-1.75x30” OS S+3 OS S-0.25=C-0.75x11” OS S-0.71=C-0.25x50” OS S+1.75 OS S-2.00=C+4.00x180”
Correction of refraction + - - + - -
Visual acuity OD 0.06 ND 0.08 0.08 ND 0.1
Visual acuity OS 0.03 ND 0.1 0.2 ND 0.1
Visual acuity ODS 0.125 20/260 (0.08) 0.16 0.25 0,2 0.1
Method (distance) LH (3 m) TAC (55 cm) Landolt C 2.6’ (5 m) Landolt C 2.6’ (5 m) TAC (55 cm) Snellen
Strabismus + + + + + +
Oculomotor disturbance - - + - + -
Nystagmus Latent. - Latent. Latent. Latent. -
Visual field defects + + + - + ND
Slit lamp examination Iris transillumination. - - Deep anterior chamber, mild lens 
opacity.
Slight iris transillumination Bilateral keratoconus.
Optic disc Small and large excavation. Pale. Pale and large 
excavation.
Partial pale. OD small and pale.
OS pale and large excavation.
Pale.
Macula Not recognizable. Normal. Normal. Normal. Normal. Inner retinal atrophy with muted umbo and 
foveal light reflexes.
VEP (age) Flash: late response; pattern onset: 
late response; pattern reversal: 
normal respons (8 years).
Flash: long latency times (10 
months).
Flash:normal; pattern 
reversal: long latency (8 
years).
ND ND ND
ERG (age) Normal (8 years). ND Normal ( 8 years). Normal (11 years). ND ND
Other ocular features Crowding, fluctuating visual 
performance, excentric fixation.
Crowding. Keratitis sicca managed with punctal plugs 
OU.
GA = gestational age, ND = not done.
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Table s4: optic nerve abnormality cohort
Person Variant identified Gender age (years) Disease
ONA1 c.909G>C; p.Gln303His M 68 OPA
ONA2 V 68 OPA
ONA3 M 60 OPA
ONA4 V 39 OPA
ONA5 M 48 OPA
ONA6 M 46 OPA
ONA7 M 41 OPA
ONA7 M 74 LHON
ONA8 M 69 LHON
ONA9 M 64 LHON
ONA10 V 63 LHON
ONA11 M 63 LHON
ONA12 M 58 LHON
ONA13 M 57 LHON
ONA14 V 56 LHON
ONA15 V 56 LHON
ONA16 M 53 LHON
ONA17 M 52 LHON
ONA18 M 52 LHON
ONA19 V 51 LHON
ONA20 M 51 LHON
ONA21 V 47 LHON
ONA22 M 45 LHON
ONA23 M 44 LHON
ONA24 V 38 LHON
ONA25 M 34 LHON
ONA26 M 33 LHON
ONA27 V 25 LHON
ONA28 M 25 LHON
ONA29 V 21 LHON
ONA30 M 13 LHON
ONA31 M 13 LHON
ONA32 V 9 LHON
ONA33 M 50 LHON
ONA34 M 3 Opticopathy and developmental delay
ONA35 V 33 Optic nerve abnormaliy
ONA36 V 30 OPA and deafness
OPA = optic atrophy, LHON = Leber hereditary optic neuropathy.
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4.1 CharaCTerIsTICs anD resulTs of The CohorT
To investigate the genetics of cerebral visual impairment (CVI) a cohort of 828 patients with 
low vision and no major ocular disorders was obtained. After applying stringent criteria, de-
scribed in chapter 1.5, 56 patients were included for further dysmorphological and ophthal-
mological investigations (Figure 1). A thorough clinical examination was performed, and the 
clinical characteristics are presented in Table 1. Subsequently DNA investigations, including 
targeted gene analysis, microarray and whole exome sequencing (WES) were performed. The 
identified aberrations were classified into known CVI-associated aberrations (CVI had been 
previously reported for this specific region or gene), candidate aberrations for CVI (CVI had 
not been previously reported for this specific region or gene), and unlikely to be related to 
CVI (based on variant and gene characteristics). In 26 patients a microarray had not been 
performed previously, thus a genome wide CytoScan HD array (Affymetrix Inc., Santa Clara, 
California, USA) was done. This led to the identification of five deletions, classified into known 
CVI-associated deletions (n=2) and candidate deletions for CVI (n=3) (Table 2). In 32 patients 
whole exome sequencing (WES) was accomplished, and a known CVI-associated aberrant 
gene was identified in 9 individuals, and a candidate aberrant gene for CVI was found in 16 
individuals.
- Risk factor and/or known    
genetic disorder (n=631)
- Deceased (n=58)
Initial cohort 
(n=828)
Eligible
(n=139)
Included for study described 
in chapter 3 and 4
(n=56)
- Declined (n=53)
- Unreachable (n=30)
figure 1: flow diagram of the patient inclusion for the study described in chapter 3
Chapter 4
208
Table 1: Cohort characteristics (n=56)
Characteristic number of patients
Gender
Male 35
Female 21
age group
<4 years 8
4-10 years 19
11-20 years 13
>20 years 16
Visual acuity
≥0.05 54
<0.05 2
fixation abnormalities
Yes 17
No 39
Visual field defects
Yes 27
No 26
Unknown 3
Developmental delay and/or intellectual disability
Yes 52
No 4
head circumference
Microcephaly (<3th centile) 12
Normocephaly (3th-97th centile) 38
Macrocephaly (>97th centile) 5
Unknown 1
abnormality on brain MrI
Yes 28
No 15
Not assessed 13
epilepsy
Yes 15
No 41
Major congenital abnormality (not the brain)
Yes 10
No 46
facial dysmorphisms >2
Yes 49
No 7
hearing loss
Yes 3
No 52
Unknown 1
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Table 2: Identified aberrant regions or genes (possibly) associated with CVI
Patient ID Wes Known CVI-associated aberration Candidate aberration for CVI reference
1 + NR2F1 191
2 + ARGHEF10L, GABRB2 367
3 +
4 + UHMK1 367
5 + AHDC1 367
6 + NR2F1 368
7 +
8 +
9
10 + AMOT 367
11 + DLG4 367
12 + KCNQ3 367
13 + NR2F1 ACP6 191
14 + KAT6B
15 + ATP6V1A, UFSP2 367
16 +
17 +
18 + DCAF6, GRIN1, SLC25A16 367
19 +
20 + PGAP1 257
21 + GRIN2B, ZFP30 367
22 + KCTD19, SOX5 367
23 +
24 +
25 + SHOC2
26 + RERE, SLC1A1 367
27 + SLC35A2 367
28 + NGLY1 367
29
30
31
32
33
34 +* RARS 369
35 +* RARS 369
36 del 10p12 370
37 del 4q28.3q31.1 251
38
39
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Table 2: Identified aberrant regions or genes (possibly) associated with CVI (continued)
Patient ID Wes Known CVI-associated aberration Candidate aberration for CVI reference
40 del 5q15 191
41
42
43
44 del 1p36.33p36.23
45
46 +* MEF2C
47 +* MAGEL2
48 +* PLP1 371
49 del Xp22.11
50
51 NR2F1 191
52
53
54
55
56
number of genetic 
diagnosis
11 (20%) 19† (34%)
*WES was initiated by others and led to a diagnosis.
†In patient 13 also a variant in a known CVI-associated gene was identified. Therefore the candidate gene is 
not counted in the total number of diagnosis.
Patients 8 and 9, and patients 34 and 35 were sibs.
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4.2 ConClusIons anD IMPlICaTIons
In this thesis we studied files followed by a study to identify the molecular diagnosis underly-
ing low vision CVI.
Of the initial cohort of 828 individuals 58 patients (6.8%) were deceased. This is a high rate 
compared to the overall mortality rate in the Netherlands, i.e. 0.8% in 2013 (all ages) (http://
statline.cbs.nl/, accessed on June 2015). Taken into account that the patients with CVI were 
mainly children, this indicates that CVI can be present in seriously ill and vulnerable patients.
From the 828 patients, 56 were included for the study in chapter 3 and 4. This 56 individu-
als were selected in order to exclude other potential (genetic) causes. We identified 11 known 
CVI-associated aberrations, establishing a diagnosis in 20% of the individuals. Five of them 
(9%) had an aberration in NR2F1 leading to Bosch-Boonstra-Schaaf optic atrophy syndrome. 
Although it is a small and selected cohort, NR2F1 aberrations are very likely to be a frequent 
cause of CVI. For comparison, the most common cause of ID is Down syndrome, which ac-
counts for about 8% of the individuals with ID.372 Screening the whole initial cohort of 828 
CVI-patients on NR2F1 aberrations would be interesting in order to determine the prevalence 
of NR2F1 more accurately. There might be patients with Bosch-Boonstra-Schaaf optic atrophy 
syndrome in whom CVI had been addressed to perinatal problems. In addition, we excluded 
patients with West syndrome for the study in described in chapter 3, but West syndrome is 
now also associated with Bosch-Boonstra-Schaaf optic atrophy syndrome.373
Finally, in 19 patients (34%) a candidate genetic aberration for CVI was obtained, and recur-
rence is warranted to establish the relation with CVI, making a possible yield of ~50%.
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5.1 ChallenGes In VarIanT InTerPreTaTIon
There are considerable challenges in the assessment of the pathogenicity of single nucleo-
tide and copy number variants in human genomes. The use of prediction programs, variant 
databases, segregation, phenotypic analyses, functional assays, and animal models can help 
in this interpretation. However, one cannot always come to a clear conclusion, leaving the 
patient and parents with uncertainties. Below, the interpretation of single nucleotide variants 
identified by whole exome sequencing (WES) in patients with cerebral visual impairment 
(CVI) will be discussed.
Variant characteristics and gene function
The presence of a variant in healthy controls is an important reason to classify a variant as 
nonpathogenic. However, how healthy is a healthy control? One of the most recent and larg-
est databases (~60,000 individuals; http://exac.broadinstitute.org/) for healthy controls also 
includes individuals with schizophrenia and bipolar disorders. Moreover, there are disorders 
with a milder phenotype and/or a wide clinical spectrum. For example, the range of IQ of 
the individuals with a NR2F1 mutation, a recently identified gene for CVI, is between 48 and 
normal (chapter 3.3 and www.nr2f1gene.com). Based on the frequency of the investigated 
disorder, the severity of the disorder, and the inheritance pattern, the allele frequency can be 
estimated and used to define a frequency threshold, as was done in chapter 3.1 for CVI. In 
addition, it is important to investigate whether the variant segregates with the phenotype. In 
chapter 3.1 we could exclude two thirds of the predicted pathogenic X-linked variants based 
on segregation analyses in nonaffected second degree relatives.
In addition to databases with control individuals there are databases in which variants in 
disease genes are collected and assessed on pathogenicity, for example the HGMD or Leiden 
Open Variation Databases (LOVDs).374,375 When these databases and segregation analyses 
are not helpful, the variant can be judged on several aspects as pointed out in chapter 3.1. 
The conservation of the wild-type nucleotide and amino acid can be assessed, and it can be 
predicted whether the variant leads to an aberrantly functioning protein. There are many 
prediction programs, and the application of two or more programs yields more reliable 
results.376 We used SNPs&Go, Mutpred and Polyphen-2, because they asses different aspects 
of the variant and have a relatively high sensitivity and specificity according to the study of 
Thusberg et al.377 Other commonly used tools, which are also applicable for a large dataset, 
are SIFT, Condel and the more recently introduced program Combined Annotation Depen-
dent Depletion (CADD),378-380 but there is no consensus which tools should be used when 
assessing missense variants.
In addition, the gene function, and its possible involvement in neurological disorders, can 
be predicted based on gene ontology and mouse phenotype terms (http://www.informatics.
jax.org/).381,382 Moreover, sometimes a gene is guilty by association: the gene product can 
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have an interaction with a protein encoded by a gene known to be associated with the same 
or a similar disease (RERE binds NR2F1), belongs to the same protein family (DLG4 belongs 
to the same protein family as DLG3), or is involved in a pathway (PGAP1 in GPI-anchoring 
pathway) that is associated with a disease. All these aspects can be helpful in the interpreta-
tion of a variant, but there remain always false-positives and false-negatives. For example the 
method we used to interpret the variants was based on two previously published papers on 
WES and whole genome sequencing (WGS) in patients with intellectual disability (ID).182,256 
In four out of 100 patients the assignment of an identified variant to be causative turned out 
to be false-positive. However, more than two years after the publication of the first paper 
on 100 patients with ID already more than half of the proposed candidate genes have been 
confirmed through various methods to be ID-associated genes, supporting the validity of 
this method.182
Recurrence and phenotyping
An important aspect in assessing the pathogenicity is to compare the phenotype of individu-
als with an aberration in the same gene. In the patient in which we identified NGLY1 muta-
tions (chapter 3.1), the phenotype showed strong similarity with the previously reported 
patients, including the rare feature of ‘absence of tears’.259,261 In contrast, when a variant is 
identified in for example NR2F1, and the patient shows significant facial dysmorphisms and 
no visual impairment, the causality of the variant remains uncertain. Sometimes however, the 
phenotype is broader than previously thought, as variants in KCNQ3 illustrated. Mutations in 
KCNQ3 were associated with benign epilepsy, without CVI or ID, but subsequently, we and 
others identified variants in patients with CVI and ID.185,285-295
The use of WES not only broadens the spectrum of known disease-associated genes, but 
also many new associations between genes and phenotypes are being made. However, 
strong conclusions come from additional patients with a similar phenotype. In chapter 3.3 
we calculated that the chance of identifying three patients with de novo NR2F1 variants in 
the cohort was very small, p=1.40x10-10. Since this publication already more than 20 patients 
have been identified with an overlapping phenotype including CVI, corroborating the 
causality of NR2F1 mutations in Bosch-Boonstra-Schaaf optic atrophy syndrome. However, 
for other candidate genes identified in chapter 3.1 and chapter 4.1 additional data are 
needed to assess causality. If loss-of-function mutations have been identified, additional 
cases can be identified by searching for overlapping deletions. For a truncating variant the 
loss-of-function may be clear, but for missense variants only functional assays can confirm 
the loss-of-function. When there are overlapping deletions, comparing phenotypes is valu-
able. Databases like ECARUCA and DECIPHER contain many deletions with clinical data and 
it is possible to contact the clinician involved (http://umcecaruca01.extern.umcn.nl:8080/
ecaruca/ecaruca.jsp and https://decipher.sanger.ac.uk/).148,149,383 Other cases with mutations 
in the same gene can also be found by screening additional patient cohorts. For the NR2F1 
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gene the CVI cohort was screened by Sanger sequencing and this revealed an additional 
patient with a de novo NR2F1 variant. Cost-effective sequencing methods, such as a method 
based on molecular inversion probes (MIPs) opens the possibility to screen the identified 
candidate CVI genes on the entire initial CVI cohort (n = 828).280 Moreover, also other large 
cohorts can be screened, such as an ID patient cohort, since ID is a common finding in CVI 
patients and CVI is probably underreported and/or underdiagnosed. Additional cases can 
also be found through collaborations. In addition to presentation at congresses or publica-
tions, web based programs, such as gene matcher or human disease gene websites have 
been developed (https://genematcher.org/ and http://humandiseasegenes.com/). A lot of 
genetic data, however, are not published or shared in a public domain. Very likely, this will be 
overcome thanks to the efforts of the parents and patients. The RERE-facebooksite of a par-
ent initiated the collaboration between another research group and us. Also for other newly 
identified genes parents played an important role. Through the identification of the NGLY1 
associated disorder, parents not only recruited additional patients, they even suggested a 
functional assay.384,385
Functional investigations
Not always is the phenotype distinct enough or are there enough patients identified to assess 
the pathogenicity of the variant. Another way to obtain additional proof is by functional in-
vestigations. Depending on the function of the gene, assays are developed to test whether a 
specific variant influences its function. For example, we identified missense variants in NR2F1 
(chapter 3.3), and the transcriptional activity of the mutant construct was decreased in pa-
tients with Bosch-Boonstra-Schaaf optic atrophy syndrome. In contrast, the mutant construct 
based on the non-segregating missense variant in a patient with non-syndromal progressive 
optic atrophy showed normal transcriptional activity (data not shown). This indicates that 
an assay can be used to test newly identified missense variants on their pathogenicity for a 
specific syndrome. However, these types of assays investigate only one single function of a 
protein. Sometimes a protein is involved in multiple processes and different variants could 
affect different functions, which might lead to different disorders.
Another possibility to investigate the pathogenicity of a variant and to learn more about the 
function of the gene are animal models, for instance fruit flies, zebrafish, or mice.386-388 There 
are obvious differences, and not all genes are conserved between species.387 In addition, simi-
lar genetic defects can result in different or no phenotype at all. For instance, no significant 
photoreceptor disease is present in Myo7a null mice, whereas in human MYO7A deficiency 
leads to Usher syndrome type 1B.389,390 Nevertheless, when an orthologue is present and the 
phenotype of the genetically modified animal is reminiscent of the human disorder, animal 
models are important to investigate the pathophysiology and to test potential therapeutic 
interventions.391 Moreover, tools have been developed to generate ‘knock out’ and ’knock in’ 
animals, in which the mutated gene can be conditionally expressed at a specific life stage or 
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in a specific tissue.388 Subsequently, many phenotypic aspects can be investigated, including 
anatomy and behavioural features, which can reflect cognitive function.386,387,391 It is possible 
to assess vision in for example fruit flies, zebrafish and mice, making these animal models 
suitable to investigate CVI.392-394
5.2 CVI: a seParaTe enTITy?
More than 90% of the patients in this study were intellectually disabled (chapter 2.1 and 
chapter 4.1), and several of the genes we identified have been implicated in ID. This might 
raise the question whether CVI is an inherent feature of ID. CVI with a visual acuity of ≤0.1 is 
indeed much more prevalent in persons with cognitive and/or motor impairment compared to 
the prevalence in persons without ID, 60% vs 6% respectively.55 Vice versa, in individuals with 
ID CVI with low vision (visual acuity ≤0.3) is present in 5%-20% of the cases.225,395,396 In addition, 
it has been shown that in the more severe ID cases, the number of individuals with low vision 
increases (Table 1).225,397-399 This increase in prevalence of low vision is not due to uncorrected 
refraction errors, thus the reason remains to be elucidated.397
It would be interesting to plot the visual performance in patients with CVI, such as visual 
acuity, crowding and visual fields, against the developmental age. In our study this was not 
possible, because at the moment of the ophthalmological examination the developmental 
age was not recently measured. Nevertheless, an inverse relation between the cognitive level 
and the visual performance can be expected.
On the other hand, there is evidence that discrepancy in developmental level between 
various neurological functions (such as cognition and speech) can occur. For instance, in Wil-
liams syndrome some aspects of speech are relatively well preserved, whereas in Angelman 
syndrome the development of speech is relatively more affected compared to their cognitive 
development.401,402 Moreover, FOXP2 aberrations lead to a severe impairment of speech in 
patients, while their cognitive development is hardly affected.403,404 For CVI, the same might 
Table 1: Visual acuity in persons with ID
level of ID* Developmental level* Va > 0.5 Va ≤ 0.3†
Mild ID (IQ 50-70) 9-12 years ~90%225,397
~3-25%225,397-399
Moderate (IQ 35-49) 6-9 years ~75%397
Severe (IQ 20-34) 3-6 years ~45%397
~40-75%397-399
Profound (IQ <20) < 3 years ~25%397
*based on ICD-10 (http://apps.who.int/classifications/icd10/browse/2015/en). The individuals with ID are 
children and adults. †In the general Dutch population, age between 15 - 49 years, the prevalence of low 
vision is 0.3%.400 VA = visual acuity.
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apply: in some disorders the visual system functions relatively well, and in others relatively 
bad. When there is localized brain damage, e.g. ischaemia of the visual cortex, the explanation 
for this discrepancy is obvious. However, for more global (and possible genetically induced) 
brain malfunctioning, it is more challenging to unravel the underlying mechanism of the 
discrepancy in the degree of impairment between neurological functions.
5.3 an ouTlooK
Diagnosing CVI
As discussed in the introduction there is no consensus about the diagnostic criteria for 
CVI. Moreover, in clinical practice the differential diagnosis of primary optic atrophy and 
delayed visual maturation (DVM) can be difficult. There are measurable features of CVI, 
such as slow vision (saccade latency), crowding and visual fields defects, which have been 
investigated.42,60,72,76 In clinical practice, these assessments can provide additional support for 
the diagnosis of CVI. Besides the current practice of comprehensive ophthalmological, neu-
rological, and neuropsychological investigations, additional investigations such as genetic 
investigation and functional MRI (fMRI) are becoming helpful in the diagnosis of CVI.
Therapy in CVI
Stimulation, guidance and support are essential for CVI patients,52,405 but only limited research 
have been performed to measure the effect of stimulation programs in CVI.42,193 Especially in 
young patients with acquired brain damage, it was shown that spontaneous recovery oc-
curred and the visual processing was reorganised towards undamaged areas.406 In addition, in 
adults with a hemianopia due to stroke part of the visual field could be regained by visual field 
training.407-409 However, it is imaginable that a genetic disorder that affects the whole brain 
needs an approach, different from localized damage to the visual system. By knowing the 
aetiology it can be examined whether there is a specific ‘CVI-profile’ for different conditions. 
In chapter 2.1 we showed that there is a difference in ocular features between CVI due to an 
acquired cause compared to CVI in patients with a genetic disorder. In line with this, it is likely 
that there are differences in CVI features between different genetic disorders. For instance, 
that in some genetic disorders the fixation and visual fields are mainly affected, whereas in 
other genetic disorders crowding is a major feature. Subsequently, it can be investigated 
which stimulation programs can be best used for specific aetiologies and ‘CVI-profiles’. More-
over, as discussed in chapter 1.2, there is a critical period for the development of the visual 
system so the timing of the intervention is likely important.
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Unravelling the pathophysiology
Understanding the pathophysiology will help answering the raised questions and cope with 
challenges: is the variant in this specific gene causal, why is the visual system sometimes 
affected more severely, which part of the visual system is affected, what is the pathophysi-
ological difference between DVM and CVI, is there transsynaptic retrograde degeneration 
(secondary optic atrophy) or an endogenous defect of the optic nerve (primary optic atro-
phy), and from which therapy might the patient benefit most? The use of animal models 
and fMRI are different approaches for further investigating the disturbed development of the 
visual system and this is illustrated below.
Haploinsuffiency of NR2F1 leads to optic nerve abnormalities, CVI and ID (chapter 3.3). 
In mouse studies it was shown that the subplate neurons differentiation was compromised 
and that the thalamocortical axon projections were disturbed during visual development, 
which might lead to an impairment of the transport of visual stimuli towards the cortex.363 
It may be possible that other thalamocortical projections, e.g. hearing, would also be 
disturbed,410 but hearing loss is only present in a minority of cases.348,368 To investigate the 
effect of the disturbed thalamocortical projections on vision, conditional knock-out mice 
with tissue-specific deficiency of NR2F1 in, for example the thalamus or subplate, could be 
developed.388 This could help in the understanding of the origin of the visual deficits in NR2F1 
patients. Another approach to gain insight would be fMRI, that has been used to visualize 
the abnormal visual processing in individuals with acquired localized damage.406 In indi-
viduals with Neurofibromatosis Type 1 with higher visuospatial impairment (a higher visual 
deficit), deficient activation was seen in several visual areas.411 This deficient activation was 
not correlated with IQ. However, for many young children and patients with ID fMRI can be 
too demanding, because of the noise and the necessity to remain without motion for about 
4-8 minutes.412 Therefore, fMRI studies in sedated and natural sleeping children exposed to 
flashing lights have been performed, which results in activation of the visual cortex.412-418 In 
one report the flash induced activated brain volume increased with the increasing severity of 
the occipital periventricular leukomalacia (which is strongly correlated with CVI), but visual 
function was not investigated in this group.413 In contrast, in children with established visual 
function deficits due to perinatal damage, the area of activation was smaller.414,418 Further 
research is necessary to unravel whether different aetiologies of CVI lead to different patterns 
of activated brain areas. In addition, this fMRI pattern might correlate with the presence or 
absence of CVI-features (e.g. low visual acuity, visual field defects, prosopagnosia). Moreover, 
it can be investigated whether fMRI patterns are of predictive value for the visual outcome. 
For this research homogeneous study groups are required, which can be obtained by select-
ing patients with a similar gene defect.
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Patients without a genetic diagnosis
In more than half of the CVI patients in the cohort of the study described in chapter 3 and 
4 we did not identify any possible cause. Also in the patients for which we performed WES, 
some remain without a plausible genetic diagnosis. There are several possible explanations. 
The first explanation is the coverage of the exonic regions. For example, a frameshift muta-
tion in NR2F1 was missed in one of the patients due to low coverage. Although WES has 
improved considerably in the last years, the exome coverage of whole genome sequencing 
(WGS) still outperforms WES.419-421 Moreover, with WGS unbalanced structural variants can be 
detected more accurately, and (small) balanced structural pathogenic variants can be identi-
fied.256 In addition, WGS can also be used to assess non-coding variants, but interpretation 
of these variants remains difficult. At the moment, however, the costs of the analysis and the 
large amount of data per genome are the main limitations of the use of WGS in the routine 
diagnostic setting.419-421
In some of the unsolved patients, the variant might have been picked up by WES analysis, 
but subsequently not prioritized or wrongly classified. The variant might not have been 
prioritized when the disorder is caused by digenically inherited or polygenic variants, which 
can be detected by using a candidate gene based approach.422 If the variant is wrongly clas-
sified (e.g. due to the prediction programs, or the GO- and MP-term enrichment), this might 
be overcome when meta-analysis of large dataset is performed. When variants in a specific 
gene are enriched in a dataset of patients with CVI compared to controls, this gene is worth 
to reconsider.
Other causes of CVI that might have been missed in the current study are mutations in the 
mitochondrial DNA or methylation defects. In addition, environmental factors can also be the 
cause of unsolved cases of CVI; a subclinical prenatal infection, or unrecognized problems 
during birth. Even more difficult to unravel is a genetic predisposition to be vulnerable for 
environmental threats, a multifactorial aetiology.
5.4 fInal reMarK
In this thesis we investigated the genetic causes of CVI and have shown that genetic aberra-
tions play an important role in the aetiology. NR2F1 aberrations appeared to be a major cause 
of CVI, and are associated with Bosch-Boonstra-Schaaf optic atrophy syndrome. Knowledge 
about the aetiology will improve our understanding of the (mal)function of vision and is nec-
essary to allow subdivision of CVI. This will enable the development of CVI-subtype specific 
guidance and visual rehabilitation programs. This thesis shows the importance of genetic 
testing in CVI patients and comprehensive ophthalmological investigation patients with ID.
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Cerebral visual impairment (CVI) is a major cause of low vision in children due to impairment 
in projection and/or interpretation of the visual input in the brain. The impairment can affect 
many aspects of vision, and may consist of low visual acuity, visual field defects, motility 
disorders of the eye and/or higher visual perceptual disorders. The patients are often intel-
lectually disabled, and, vice versa, CVI is present in 5-20% of the patients with an intellectual 
disability (ID). Other co-morbidities, such as epilepsy, multiple congenital abnormalities or 
hearing loss, can be present.
CVI was first recognized as a consequence of acquired brain damage, mainly due to pre-
term birth. However, which genetic defects play a role in the aetiology was largely unknown.
In chapter 1 an overview of the anatomy and the pre- and postnatal development of the 
visual system is given, and the features and causes of CVI are described. Higher perceptual 
deficits with normal visual acuity have been systematically investigated in the past and are 
present in some genetic disorders. However, CVI with low vision is, in general, only sporadically 
mentioned in case reports concerning patients with a genetic syndrome. In the last hundred 
years the knowledge of genetics and the methods to investigate the genome have improved 
tremendously. Microarray and whole exome sequencing (WES), predominantly to detect 
copy number variants and single nucleotide variants respectively, are the main techniques to 
identify genetic aberrations nowadays. To investigate whether and which genetic causes are 
important in the pathogenesis of CVI, two file studies were performed, presented in chapter 
2. Patients with CVI, low vision (visual acuity ≤0.3 and/or visual field <30°), and no major ocular 
disease (e.g. retinopathy of prematurity) were included. First, 309 CVI patients were analysed 
for aetiology and ocular variables (chapter 2.1). Almost all, 96% (298/309), had ID. In 60% 
(184/309) a putative cause was present, such as periventricular leukomalacia or congenital 
disorder of glycosylation type 1a. In 9% of the individuals (28/309) a genetic disorder was 
present, and these persons had no other risk factors that could cause CVI (e.g. preterm birth). 
Moreover, CVI could be associated with ATR-X, Mowat-Wilson, and Pitt Hopkins syndrome for 
the first time. Comparing the ocular variables in patients with a genetic disorder strabismus 
(64% versus 88%), pale optic discs (27% versus 65%) and visual field defects (30% versus 72%) 
could be observed less frequent than in patients with an acquired cause.
In chapter 2.2 chromosomal aberrations identified in 607 patients were further classified 
for pathogenicity. In 7% (41/607) of the patients the chromosomal aberrations were associ-
ated with CVI. For four aberrations, present in 26 patients, the association with CVI had been 
reported before: trisomy 21, 1p36 deletion syndrome, 17p13.3 deletion syndrome (Miller-
Dieker syndrome) and 22q13.3 deletion syndrome (Phelan-McDermid syndrome), whereas 
chromosomal aberrations in another 15 patients had not been reported earlier.
In chapter 3 and chapter 4 56 patients without risk factors for CVI were included from 
828 persons with CVI and low vision. Of these patients the history was taken, and dysmor-
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phological, ophthalmological and genetic examinations, mainly microarray and WES, were 
performed. The results of WES investigations in 25 patients and their parents are reported 
in chapter 3.1. In addition to CVI, all 25 patients had ID. The WES-data were analysed for de 
novo, autosomal recessive and X-linked variants, and subsequently, classified into known, 
candidate or unlikely to be associated with CVI. This classification was based on the Online 
Mendelian Inheritance in Man database, literature reports, variant characteristics and func-
tional relevance of the gene. After classification, variants in four genes known to be associated 
with CVI were identified in five patients (20%), establishing a conclusive genetic diagnosis for 
CVI. In addition, in 11 patients (44%) with CVI, variants in one or more candidate genes were 
identified. In one patient we could associate compound heterozygous variants in PGAP1 for 
the first time with CVI, which is further discussed in chapter 3.2. PGAP1 is a member of the 
glycosylphosphatidylinositol-anchor biosynthesis and remodelling pathway and defects in 
this pathway form a subclass of congenital disorders of glycosylation. Until that moment two 
siblings with homozygous PGAP1 variants had been reported, and the only phenotypic fea-
ture in common was ID. Therefore, support was obtained for the pathogenicity of variants we 
identified by the use of PGAP1-deficient Chinese hamster ovary cell lines and lymphoblastoid 
cell lines of the affected individual. Recently, another patient with CVI and PGAP1 deficiency 
had been reported, which confirms our PGAP1 association with CVI.
In chapter 3.3 the identification of NR2F1 aberrations is described. In the CVI cohort (n=56) 
three persons had a de novo heterozygous mutation and one individual had a deletion of 
NR2F1. Moreover, we could recruit two additional patients with de novo NR2F1 aberrations, 
one of which also had CVI. In addition, all patients had mild to moderate intellectual impair-
ment and optic disc abnormalities, including enlarged excavation and pale and/or small optic 
discs. NR2F1 encodes a nuclear receptor protein that regulates transcription. A reporter assay 
showed that NR2F1 transcriptional activity was decreased for the constructs containing the 
identified missense mutations in the DNA-binding domain and the putative ligand-binding 
domain. These findings indicated that disruption of NR2F1 could lead to optic atrophy with 
ID.
All identified aberrant genes or chromosomal regions in the 56 persons with CVI are sum-
marized in chapter 4. In 11 (20%) of the 56 persons we could identify a genetic aberration 
that was previously associated with CVI and in 19 individuals (34%) a potential cause for the 
CVI was revealed. For the last group we need to identify additional patients with mutations in 
these genes to establish the causal relationship.
In the last chapter, chapter 5, the challenge of the interpretation of genetic variants is 
discussed. Variant characteristics, functional investigations and recurrence can be helpful 
in classifying these variants. Because several variants have been identified in genes known 
to cause ID and many CVI patients have ID, the question was addressed whether CVI is a 
separate entity. However, it seems that the development of the visual system is not always 
comparable to the cognitive developmental level: it sometimes is more severely affected and 
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sometimes relatively well preserved. To further unravel this and to gain more insight in the 
pathophysiology, animal models and functional MRI can be used. For these investigations a 
homogeneous study group is necessary, obtained by a similar underlying acquired or gene 
defect. Moreover, subdivision of CVI based on aetiology will enable the development of CVI-
subtype specific guidance and visual rehabilitation programs.
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Cerebrale visussstoornis (cerebral visual impairment, CVI) is een belangrijke oorzaak van 
slechtziendheid bij kinderen. CVI is het gevolg van een stoornis in projectie en/of inter-
pretatie van de visuele input in de hersenen. Verschillende aspecten van het zien kunnen 
hierdoor aangedaan zijn en dit kan leiden tot bijvoorbeeld een lage gezichtsscherpte, 
beperkt gezichtsveld, oogbewegingsstoornissen of problemen met de visuele perceptie. De 
patiënten zijn vaak verstandelijk beperkt en omgekeerd heeft 5-20% van de patiënten met 
een verstandelijk beperking (VB) een CVI. Andere co-morbiditeiten, zoals epilepsie, multipele 
aangeboren afwijkingen of gehoorsverlies kunnen aanwezig zijn.
CVI werd in eerste instantie herkend bij personen met verworven hersenschade, vaak 
ten gevolge van vroeggeboorte. Echter welke genetische afwijkingen een rol spelen in de 
etiologie was grotendeels onbekend.
In hoofdstuk 1 wordt een overzicht gegeven van de anatomie en de pre- en postnatale 
ontwikkeling van het visuele systeem. Daarnaast worden de kenmerken en oorzaken van 
CVI beschreven. In de literatuur is van sommige genetische aandoeningen systematisch 
onderzocht of hogere perceptuele stoornissen met een normale gezichtsscherpte aanwezig 
zijn. Echter, CVI met een lage gezichtscherpte ten gevolge van een genetische aandoening is 
over het algemeen slechts sporadisch genoemd in casuïstiek.
De kennis van de genetica en de technieken om genetisch onderzoek te verrichten zijn 
in de laatste eeuw sterk ontwikkeld. “Microarray” en “whole exome sequencing” (WES), met 
name om chromosoomafwijkingen en nucleotide varianten te detecteren, zijn tegenwoordig 
de voornaamste technieken om genetische afwijkingen vast te stellen. In dit onderzoek zijn 
met behulp van deze technieken de genetische oorzaken in CVI-cohort met lage gezichts-
scherpte in kaart gebracht.
In hoofdstuk 2 worden de twee dossier-onderzoeken beschreven die zijn verricht. Daarin 
is onderzocht of en welke genetische oorzaken belangrijk zijn in de pathogenese van CVI. 
Patiënten met CVI, slechtziendheid (gezichtsscherpte ≤0.3 of gezichtsveld <30°) en geen 
belangrijke oogziekte (bijv. prematuren retinopathie) werden geïncludeerd.
In het eerste dossier-onderzoek werden bij 309 CVI-patiënten de etiologie en de bevin-
dingen bij oogheelkundig onderzoek geanalyseerd (hoofdstuk 2.1). Bijna alle patiënten, 
96% (298/309), had een VB. In 60% van de patiënten (184/309) was een mogelijke oorzaak te 
identificeren, zoals periventriculaire leukomalacie of een congenitale glycosyleringsstoornis 
type 1a. In 9% van de personen (28/309) was een genetische aandoening vastgesteld zonder 
dat andere risicofactoren die CVI kunnen veroorzaken (zoals vroeggeboorte) aanwezig wa-
ren. Daarnaast konden we CVI voor de eerste keer associëren met ATR-X, Mowat-Wilson, en 
Pitt Hopkins-syndroom. Vervolgens werden de bevindingen bij oogheelkundig onderzoek 
vergeleken tussen de patiënten met een genetische aandoening en die met een verworven 
oorzaak. Strabismus (64% versus 88%), een bleke papil (27% versus 65%) en een beperkt 
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gezichtsveld (30% versus 72%) kwamen vaker voor bij de patiënten met een verworven 
oorzaak.
In het tweede dossier-onderzoek (hoofdstuk 2.2) werden de gevonden chromosoomaf-
wijkingen in 607 patiënten verder geclassificeerd op pathogeniciteit. Bij 7% (41/607) van de 
patiënten werd een chromosoomafwijking geassocieerd met CVI. Bij vier chromosoomafwij-
kingen, aanwezig in 26 patiënten, was de associatie met CVI eerder gepubliceerd: trisomie 
21, 1p36 deletie-syndroom, 17p13.3 deletie-syndroom (Miller-Dieker-syndroom) en 22q13.3 
deletie-syndroom (Phelan-McDermid-syndroom), terwijl de chromosoomafwijkingen in 15 
andere patiënten nog niet eerder beschreven waren in relatie tot CVI.
Voor hoofdstuk 3 en hoofdstuk 4 werden uit 828 personen met CVI en slechtziendheid 
56 patiënten zonder risicofactoren voor CVI geïncludeerd. Een uitgebreide anamnese werd 
afgenomen en dysmorfologisch, oogheelkundig en genetisch onderzoek werd verricht. Het 
genetische onderzoek bestond voornamelijk uit microarray en WES. De resultaten van het 
WES-onderzoek in 25 patiënten en hun ouders is beschreven in hoofdstuk 3.1. Naast CVI 
hadden alle 25 patiënten een VB. De WES-data is geanalyseerd voor varianten die een de 
novo, autosomaal recessief, en X-gebonden recessieve overerving volgen. Vervolgens zijn 
de varianten geclassificeerd in varianten met een bekende, kandidaat- of onwaarschijnlijke 
associatie met CVI. Deze classificatie is gebaseerd op de Online Mendelian Inheritance in Man 
database, literatuur, variant-karakteristieken en functionele relevantie van het gen. In vier 
verschillende genen die een bekende associatie met CVI hadden, werden in vijf personen 
(20%) varianten gevonden. Dit leidde tot een sluitende genetische diagnose voor CVI. Daar-
naast werden in 11 patiënten (44%) varianten in een of meerdere kandidaat-genen geïdenti-
ficeerd. In één patiënt konden we een nieuwe associatie leggen tussen CVI en de gevonden 
compound heterozygote varianten in PGAP1. Dit wordt verder besproken in hoofdstuk 3.2.
PGAP1 is een onderdeel van de glycosylphosphatidylinositol-anker-biosynthese en de 
remodelleringsroute. Defecten in deze biosynthese of route vormen een subklasse van 
congenitale glycosyleringsstoornissen. Destijds waren er twee families met kinderen met 
homozygote PGAP1-varianten gerapporteerd en het enige gezamenlijke kenmerk was VB. 
Daarom werd extra bewijs verkregen voor de pathogeniciteit van de door ons gevonden va-
rianten door middel van eicellijnen van de Chinese hamster en lymfoblastoïde cellijnen van 
de patiënt. Recentelijk werd een andere patiënt met CVI en PGAP1-deficiëntie beschreven 
hetgeen onze associatie met CVI bevestigt.
In hoofdstuk 3.3 wordt de ontdekking van NR2F1-afwijkingen beschreven. In het CVI-
cohort (n=56) hadden drie personen een de novo heterozygote mutatie en één patiënt een 
deletie van NR2F1. Er werden nog twee patiënten met de novo NR2F1-afwijkingen geïdentifi-
ceerd (buiten het CVI-cohort), van wie één ook CVI bleek te hebben. Alle 6 patiënten hadden 
milde tot matige VB en papil-afwijkingen, waaronder een vergrote excavatie en een bleke of 
kleine papil. NR2F1 codeert voor een nucleair receptor-eiwit dat de transcriptie reguleert. Een 
reporter-assay toonde aan dat de transcriptionele activiteit van NR2F1 was verminderd voor 
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de constructen die de gevonden missense mutatie bevatten, welke gelokaliseerd waren in 
het DNA-bindings domein en in het mogelijke ligand-bindings domein. Deze bevindingen 
wijzen erop dat een verstoring van NR2F1 kan leiden tot opticus atrofie met VB.
Alle gevonden afwijkende genen en chromosomale regio’s in de 56 personen met CVI zijn 
samengevat in hoofdstuk 4. In 11 (20%) van de 56 personen konden we een genetische 
afwijking vinden die eerder geassocieerd was met CVI en in 19 patiënten (34%) konden we 
een mogelijke oorzaak voor de CVI detecteren. Voor deze laatste groep zijn meer patiënten 
met mutaties in hetzelfde gen nodig om een oorzakelijk relatie vast te stellen.
In het laatste hoofdstuk, hoofdstuk 5, worden de genetische variant interpretatie en de 
bijbehorende uitdagingen bediscussieerd. Variant-karakteristieken, functionele onderzoe-
ken en meerdere personen met een variant in het hetzelfde gen kunnen behulpzaam zijn in 
het beoordelen van de varianten. Omdat verschillende varianten gevonden werden in genen 
die geassocieerd zijn met VB en vele CVI patiënten een VB hebben, wordt de vraag besproken 
of CVI een aparte aandoening is. Echter, het lijkt dat de ontwikkeling van het visuele functio-
neren niet altijd vergelijkbaar is met het cognitieve niveau; soms loopt de ontwikkeling van 
het visuele functioneren voor en soms achter ten opzichte van de cognitieve ontwikkeling. 
Om meer inzicht te krijgen in de onderliggende pathofysiologie kunnen diermodellen en 
functionele MRI worden gebruikt. Voor deze onderzoeken zijn homogene studiegroepen 
nodig, welke kunnen worden verkregen door patiënten te verzamelen met eenzelfde ver-
worven of genetische oorzaak. Bovendien opent het onderverdelen van CVI gebaseerd op 
etiologie de mogelijkheid om begeleiding en therapie te ontwikkelen die specifiek is voor 
het subtype CVI.
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